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A B S T R A C T
Background
Maintaining therapeutic concentrations of drugs with a narrow therapeutic window is a complex task. Several computer systems have
been designed to help doctors determine optimum drug dosage. Signi cant improvements in health care could be achieved if computer
advice improved health outcomes and could be implemented in routine practice in a cost-effective fashion. This is an updated version
of an earlier Cochrane systematic review, first published in 2001 and updated in 2008.
Objectives
To assess whether computerized advice on drug dosage has beneficial effects on patient outcomes compared with routine care (empiric
dosing without computer assistance).
Search methods
The following databases were searched from 1996 to January 2012: EPOC Group Specialized Register, Reference Manager; Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE, Ovid; EMBASE, Ovid; and CINAHL, EbscoHost. A “top up” search
was conducted for the period January 2012 to January 2013; these results were screened by the authors and potentially relevant studies
are listed in Studies Awaiting Classification. The review authors also searched reference lists of relevant studies and related reviews.
Selection criteria
We included randomized controlled trials, non-randomized controlled trials, controlled before-and-after studies and interrupted time
series analyses of computerized advice on drug dosage. The participants were healthcare professionals responsible for patient care. The
outcomes were any objectively measured change in the health of patients resulting from computerized advice (such as therapeutic drug
control, clinical improvement, adverse reactions).
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Data collection and analysis
Two review authors independently extracted data and assessed study quality. We grouped the results from the included studies by drug
used and the effect aimed at for aminoglycoside antibiotics, amitriptyline, anaesthetics, insulin, anticoagulants, ovarian stimulation,
anti-rejection drugs and theophylline. We combined the effect sizes to give an overall effect for each subgroup of studies, using a
random-effects model. We further grouped studies by type of outcome when appropriate (i.e. no evidence of heterogeneity).
Main results
Forty-six comparisons (from 42 trials) were included (as compared with 26 comparisons in the last update) including a wide range
of drugs in inpatient and outpatient settings. All were randomized controlled trials except two studies. Interventions usually targeted
doctors, although some studies attempted to influence prescriptions by pharmacists and nurses. Drugs evaluated were anticoagulants,
insulin, aminoglycoside antibiotics, theophylline, anti-rejection drugs, anaesthetic agents, antidepressants and gonadotropins. Although
all studies used reliable outcome measures, their quality was generally low.
This update found similar results to the previous update and managed to identify specific therapeutic areas where the computerized
advice on drug dosage was beneficial compared with routine care:
1. it increased target peak serum concentrations (standardized mean difference (SMD) 0.79, 95% CI 0.46 to 1.13) and the proportion
of people with plasma drug concentrations within the therapeutic range after two days (pooled risk ratio (RR) 4.44, 95% CI 1.94 to
10.13) for aminoglycoside antibiotics;
2. it led to a physiological parameter more often within the desired range for oral anticoagulants (SMD for percentage of time spent
in target international normalized ratio +0.19, 95% CI 0.06 to 0.33) and insulin (SMD for percentage of time in target glucose range:
+1.27, 95% CI 0.56 to 1.98);
3. it decreased the time to achieve stabilization for oral anticoagulants (SMD -0.56, 95% CI -1.07 to -0.04);
4. it decreased the thromboembolism events (rate ratio 0.68, 95% CI 0.49 to 0.94) and tended to decrease bleeding events for
anticoagulants although the difference was not significant (rate ratio 0.81, 95% CI 0.60 to 1.08). It tended to decrease unwanted effects
for aminoglycoside antibiotics (nephrotoxicity: RR 0.67, 95% CI 0.42 to 1.06) and anti-rejection drugs (cytomegalovirus infections:
RR 0.90, 95% CI 0.58 to 1.40);
5. it tended to reduce the length of time spent in the hospital although the difference was not significant (SMD -0.15, 95% CI -0.33
to 0.02) and to achieve comparable or better cost-effectiveness ratios than usual care;
6. there was no evidence of differences in mortality or other clinical adverse events for insulin (hypoglycaemia), anaesthetic agents, anti-
rejection drugs and antidepressants.
For all outcomes, statistical heterogeneity quantified by I2 statistics was moderate to high.
Authors’ conclusions
This review update suggests that computerized advice for drug dosage has some benefits: it increases the serum concentrations for
aminoglycoside antibiotics and improves the proportion of people for which the plasma drug is within the therapeutic range for
aminoglycoside antibiotics.
It leads to a physiological parameter more often within the desired range for oral anticoagulants and insulin. It decreases the time to
achieve stabilization for oral anticoagulants. It tends to decrease unwanted effects for aminoglycoside antibiotics and anti-rejection
drugs, and it significantly decreases thromboembolism events for anticoagulants. It tends to reduce the length of hospital stay compared
with routine care while comparable or better cost-effectiveness ratios were achieved.
However, there was no evidence that decision support had an effect on mortality or other clinical adverse events for insulin (hypogly-
caemia), anaesthetic agents, anti-rejection drugs and antidepressants. In addition, there was no evidence to suggest that some decision
support technical features (such as its integration into a computer physician order entry system) or aspects of organization of care (such
as the setting) could optimize the effect of computerized advice.
Taking into account the high risk of bias of, and high heterogeneity between, studies, these results must be interpreted with caution.
P L A I N L A N G U A G E S U M M A R Y
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Computerized advice on drug dosage to improve prescribing practice
Background
Physicians and other healthcare professionals often prescribe drugs that will only work at certain concentrations. These drugs are said to
have a narrow therapeutic window. This means that if the concentration of the drug is too high or too low, they may cause serious side
effects or not provide the benefits they should. For example, blood thinners (anticoagulants) are prescribed to thin the blood to prevent
clots. If the concentration is too high, people may experience excessive bleeding and even death. In contrast, if the concentration is too
low, a clot could form and cause a stroke. For these types of drugs, it is important that the correct amount of the drug be prescribed.
Calculating and prescribing the correct amount can be complicated and time-consuming for healthcare professionals. Sometimes
determining the correct dose can take a long time since healthcare professionals may not want to prescribe high doses of the drugs
initially because they make mistakes in calculations. Several computer systems have been designed to do these calculations and assist
healthcare professionals in prescribing these types of drugs.
Study characteristics
We sought clinical trial evidence from scientific databases to evaluate the effectiveness of these computer systems. The evidence is
current to January 2012. We found data from 42 trials (40 randomized controlled trials (trials that allocate people at random to receive
one of a number of drugs or procedures) and two non-randomized controlled trials).
Key results
Computerized advice for drug dosage can benefit people taking certain drugs compared with empiric dosing (where a dose is chosen
based on a doctor’s observations and experience) without computer assistance.When using the computer system, healthcare professionals
prescribed appropriately higher doses of the drugs initially for aminoglycoside antibiotics and the correct drug dose was reached more
quickly for oral anticoagulants. It significantly decreased thromboembolism (blood clotting) events for anticoagulants and tended to
reduce unwanted effects for aminoglycoside antibiotics and anti-rejection drugs (although not an important difference). It tended to
reduce the length of hospital stay compared with routine care with comparable or better cost-effectiveness. There was no evidence of
effects on death or clinical side events for insulin (low blood sugar (hypoglycaemia)), anaesthetic agents, anti-rejection drugs (drugs
taken to prevent rejection of a transplanted organ) and antidepressants.
Quality of evidence
The quality of the studies was low so these results must be interpreted with caution.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Computerized advice on drug dosage for leading serum concentrations within therapeutic range
Patient or population: patients with leading serum concentrations within therapeutic range
Settings: outpatient/inpatient
Intervention: computerized advice on drug dosage
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Computerized advice on
drug dosage
Serum concentrations -
aminoglycoside antibi-
otics: peak concentra-
tion
Follow-up: 2 days
- The mean serum concen-
trations - aminoglycoside
antibiotics: peak concen-
tration in the intervention
groups was
0.79 standard deviations
higher
(0.46 to 1.13 higher)
- 372
(4 studies)
⊕⊕©©
low1,2,3
SMD 0.79 (95% CI 0.46
to 1.13)
Serum concentrations -
theophylline
- The mean serum con-
centrations - theophylline
in the intervention groups
was
0.41 standard deviations
higher
(0.2 lower to 1.02 higher)
- 201
(4 studies)
⊕⊕©©
low3,4,5
SMD 0.41 (95% CI -0.2
to 1.02)
Proportion of partici-
pants within therapeutic
range - aminoglycoside
antibiotics: % of partici-
pants with peak concen-
Study population RR 4.44
(1.94 to 10.13)
72
(2 studies)
⊕⊕⊕©
moderate3,6
-
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trations adequate after 2
days
Follow-up: 2 days
135 per 1000 600 per 1000
(262 to 1000)
Moderate
151 per 1000 670 per 1000
(293 to 1000)
Proportion of partici-
pants with toxic drug lev-
els - theophylline
Study population RR 0.53
(0.25 to 1.13)
109
(2 studies)
⊕⊕⊕©
moderate3,7
-
273 per 1000 145 per 1000
(68 to 308)
Moderate
217 per 1000 115 per 1000
(54 to 245)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; SMD: standardized mean difference.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Lack of blinding of participants and personnel in all studies. Incomplete outcome data in three studies. Random sequence generation
and allocation concealment unclear in one study.
2 I2 = 51%.
3 No funnel plot was performed since the validity conditions were not met.
4 No blinding of participants and personnel in the two studies. Random sequence generation and allocation concealment unclear in one
study.
5 I2 = 76%5
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6 Lack of blinding of participants and personnel, incomplete outcome data in all studies. Participants were not similar at baseline in one
study.
7 No blinding of participants and personnel in the two studies. Random sequence generation and allocation concealment unclear in one
study.
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B A C K G R O U N D
Medication mistakes still represent 20% of all medical errors al-
though many efforts have focused in recent years on reducing the
risk of drug errors (Brennan 1991). Maintaining therapeutic con-
centrations of drugs is a complex task requiring knowledge of ev-
idence-based clinical guidelines, clinical pharmacology and skills
in dose calculation. The potential for error is great since many of
the drugs commonly used have a narrow ’window’ within which
therapeutic benefits can be obtained with a low risk of unwanted
effects.
Description of the condition
Monitoring drug therapy to optimize effects and minimize dan-
gers can be very time consuming. Practitioners may need access
to a large amount of information to make an appropriate dose
adjustment in situations such as prevention of deep vein throm-
bosis or management of people with renal insufficiency (Durieux
2005). Under these conditions, healthcare professionals make er-
rors of judgement because their ability to process information is
finite (McDonald 1976a).
For example, in ambulatory settings, general practitioners (GP) re-
ported difficulties with drug dosing, especially for children, elderly
people and people with renal impairment (Franke 2000). More-
over, physicians’ computational abilities are often insufficient to
perform calculations for drug dosage (Baldwin 1995). For exam-
ple, 82 out of 150 hospital doctors were unable to calculate how
many milligrams of lidocaine were in a 10 mL ampoule of 1%
solution (Rolfe 1995).
Description of the intervention
Clinical decision support systems (CDSS), either computerized or
not, have been proposed to improve clinical practice (Kawamoto
2005). Ideally, decision support, integrated in the electronic med-
ical record as the platform, can provide physicians with tools mak-
ing it possible to improve practice and patient safety (Bates 2003).
An effective decision support system would anticipate needs and
deliver informationquickly in real time, adapted to the user’swork-
flow (Bates 2003).
How the intervention might work
Computers are very good at collecting information and perform-
ing repetitive calculations.Moreover, the drugs that cause themost
problems have often been in use for many years. The pharmacol-
ogy of the drugs is, therefore, well understood and thus computer
models can be used to generate advice on dosage. Several types
of computer systems have been designed to help doctors in the
task of determining the optimum dosage of drugs. Significant im-
provements in health could be achieved if computer advice was
shown to be beneficial and was provided by the computers that
clinicians now use for their everyday work.
In addition, the logistics by which the advice on drug dosage is
delivered to the healthcare professional is critical to its effectiveness
and to the transferability of this effectiveness in other settings.
Computer physician order entry (CPOE) systems, which allow
physicians to enter orders directly into a computer rather than
hand writing them, have the potential to incorporate CDSS into
daily practice (Kuperman 2003). According to three systematic
reviews (Garg 2005; Kawamoto 2005; Nieuwlaat 2011a), CDSSs
are more often associated with improvement of practice when the
decision aid is automatically prompted, integrated in clinicians’
workflow, and provided at time and location of decision making.
This review focuses on advice with a personalized dosage for a
specific participant. Two other Cochrane systematic reviews were
interested in computer-generated reminders: one evaluated the
effects of on-screen computer reminders delivered to clinicians at
the point of care (Shojania 2009), and one considered reminders
delivered on paper to healthcare professionals (Arditi 2012).
Why it is important to do this review
This is an updated version of two earlier Cochrane systematic re-
views (Walton 2001; Durieux 2008).Those earlier reviews pro-
vided some evidence to support the use of computer assistance in
determining drug dosage but concluded that further clinical trials
were necessary to confirm those results.
O B J E C T I V E S
The primary objective of this systematic review was to examine
whether computerized advice on drug dosage given to healthcare
professionals is beneficial when compared with routine care (em-
piric dosing without computer assistance). The secondary objec-
tive was to determine whether any technical features of comput-
erized systems or organizational aspects concerning their imple-
mentation influence their effectiveness.
Hypothesis tested
In previous versions of this review, we tested the benefit in terms
of effects on process of care (healthcare professional oriented) and
on outcome of care (patient oriented). The effect on process of
care was any change in drug dose as a process measure. However,
there are problems with this approach since a higher dose may,
in some circumstances, be beneficial and, in others, be disadvan-
tageous. Thus, in this review we have removed this outcome and
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only reported effects on dosage where we judged the changes to
be meaningful. We examined six hypotheses on patient-oriented
outcomes (most of them measuring surrogate outcomes).
Effect on outcome of care (patient-oriented
outcomes)
1. Decisions on drug dosage based on computer advice lead
more often to drug levels within the therapeutic range.
2. Decisions on drug dosage based on computer advice lead
more often to a physiological parameter being maintained within
the desired range (e.g. blood pressure or prothrombin (PT) time).
3. Decisions on drug dosage based on computer advice lead to
more rapid therapeutic control, assessed by a physiological
parameter.
4. Decisions on drug dosage based on computer advice lead to
greater clinical effectiveness, assessed by clinical improvement.
5. Decisions on drug dosage based on computer advice lead to
fewer unwanted effects than conventional dose adjustment.
6. Computer advice reduces the cost of health care or the use
of resources (e.g. length of hospital stay).
Unlike the previous update of this review, we decided to analyze
the results individually for each drug because of a high clinical and
statistical heterogeneity between drugs (each drug has its specific
outcomes).
Other hypotheses address our secondary objectives and reflect a
series of subgroup analyses.
Effect of decision support logistics and
organization of care
1. Computer advice given in real time is more effective than
that given by delayed feedback.
2. Computer advice integrated in CPOE system is more
effective than other systems.
3. System-initiated computer advice is more effective than
user-initiated computer advice.
4. Direct intervention (system delivers advice directly to the
provider) is more effective than indirect intervention (advice is
made available to the provider by the intermediate of a third
party actor, i.e. system is not directly used by the provider).
5. The impact of computer advice depends on the setting
where it is implemented (inpatient versus outpatient care).
6. Computer advice given as a recommendation is more
effective than a calculated dose proposed without possibility of
change and which does not take into account the healthcare
professional’s experience).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered for inclusion all types of study designs that met
Effective Practice and Organization of Care Group (EPOC) in-
clusion criteria:
• Randomized controlled trials (RCTs) where the unit of
randomization was:
1. the participant or
2. the cluster: healthcare professionals (doctors, nurses or
pharmacists) or groups of professionals (practices or hospitals);
• Non-randomized controlled trials (NRCTs);
• Controlled before-and-after (CBA) studies with:
1. the same pre- and postintervention periods for study and
control sites;
2. comparable study and control sites with respect to level of
care, setting of care and baseline characteristics;
3. two intervention sites and two control sites;
• Interrupted time series (ITS) studies with:
1. a clearly defined point in time when the intervention
occurred;
2. at least three data points before and three after the
intervention.
See the EPOC checklist for definition of designs (EPOC 2012).
Types of participants
The participants were healthcare professionals with responsibility
for patient care.
Types of interventions
We sought to identify all comparative studies comparing comput-
erized advice on drug dosage given to routine care (empiric dosing
without computer assistance). We defined computerized advice
on drug dosage as a recommendation provided to the healthcare
professional on the drug dosage needed for a specific participant
and a specific drug and calculated by a computer.
Computer program
The computer program was a software model or an application
integrated into a laptop, a smartphone, a tablet computer, the
CPOE, or a website (online calculator). We did not consider in-
terventions where the recommended drug dose was not calculated
by a computer, for example an equation or a nomogram not im-
plemented in a computer device.
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Nature of advice
The advice included a dosage personalized for a specific partici-
pant. We did not include studies reporting a popup with general
advice on the dosage required for a specific condition (most fre-
quently dose of medication, dose interval, maximum total daily
dose).
Content of recommendation and calculation of drug dose
The recommendation could be evidence-based, a clinical practice
guideline developed by expert bodies (government, professional)
or local clinicians, or population pharmacokinetic/pharmacody-
namic models. The participant’s drug dose was computed using an
equation including participant’s characteristics (participant’s age,
weight, previous drug levels…). Alternatively, a more complex
mathematical model was used, which was generally a pharmacoki-
netic model of the relationship between administered doses of the
drug and observed concentrations in the participant’s body.
Advice delivery and timing
The computerized advice could be delivered to clinicians when
they are writing their prescription (point of care delivery) or it
could be delivered at a later time. In addition, the computerized
advice could be delivered to another healthcare professional (e.g.
a pharmacist or a pharmacokinetic unit) and passed to the clin-
ician. Unlike the review on the effect of point-of-care computer
reminders on physician behaviour (Shojania 2009), we included
systems that were not encountered during routine performance of
the activities of interest, for example a dedicated computer used
only for performing dose calculation for anticoagulants. These
systems require clinicians to depart from their usual workflow in
order to avail themselves of the reminder or decision support.
Control of the healthcare professional
We included studies where advice was given as a recommendation
so that the healthcare professional was able to accept or refuse it.
We did not include studies reporting non-specific advice given
to a healthcare professional to adjust drug dosage or when the
healthcare professional was not in charge of every adjustment of
the drug, for example studies reporting the direct administration of
a drug to the participant bymeans of a computer supervised device
(closed-loop system) or through self dosing devices (one Cochrane
review addresses the evaluation of anticoagulant self management
(Garcia-Alamino 2010)).
Starter
The advice could be system-initiated (advice appears without user
intervention) or user-initiated (the computer program must be
started by the user to obtain an advice).
Control group
The control group included empiric dosing without computer
assistance, in general routine care.
Types of outcome measures
All outcome measures included were patient-oriented outcomes.
1. Proportion of participants or time for which the plasma
drug concentrations was within the therapeutic range.
2. Proportion of participants or time for which the studied
physiological parameter was maintained within the target range.
3. Time to achieve therapeutic control.
4. Proportion of participants with toxic drug levels.
5. Proportion of participants with clinical improvement.
6. Proportion of participants with adverse effects of drug
therapy.
7. Proportion of deaths.
8. Length of hospital stay.
9. Total cost per participant.
We excluded the outcomes for which reporting was incomplete
(e.g. no numerical values reported, no measure of dispersion) and
excluded studies whose only relevant outcomes were death or ad-
verse effects requiring monitoring and which did not explicitly
report such outcomes as primary.
For serum concentrations, we also considered peak, trough and
steady-state concentrations. The measurement of drug levels in
the blood, called therapeutic drug monitoring (TDM), is required
for some drugs to ensure that the participants maintain the con-
centration of drug within the established therapeutic range (drug
effective without toxicity). Blood for peak level is collected at the
drug’s highest concentration within the dosing period. Trough
levels (occasionally called residual levels) are measured just prior
to administration of the next dose, and are the lowest concentra-
tion in the dosing interval. Most therapeutic drugs have a narrow
trough to peak difference (therapeutic range), and, therefore, only
trough levels are needed to detect blood levels that are too low or
too high. Peak levels are needed for some drugs, especially amino-
glycoside antibiotics: a concentration below the therapeutic range
will not resolve the bacterial infection so high peak concentrations
are necessary for optimal efficacy; however, too high a level can
cause damage such as nephrotoxicity so it is important that the
trough concentration be allowed to fall in order to avoid accu-
mulation. The steady-state concentration is defined as the point
at which the amount of drug administered (drug intake) and the
amount of drug excreted (drug elimination) reach an equilibrium.
The goal of TDM is to optimize the drug dose so that the partic-
ipant’s drug concentrations remain within the therapeutic range.
Search methods for identification of studies
Updates to Cochrane systematic reviews usually entail executing
previously used search strategies for the update period or, in other
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words, from the date of the last search, to present. In some cases,
however, search strategies must be assessed and revised in order
to optimize the identification of evidence. When this occurs, it is
advisable to search retrospectively--that is, to re-search previously
searched time periods, in order to discover whether or not studies
have been missed. This update represents a review where search
strategies have been revised significantly (by M. Fiander, Infor-
mation Scientist, and Trials Search Co-ordinator for the EPOC
Group) and where, consequently, searching has been conducted
not only from the date of last search in 2006, but retrospectively
from 1996 to January 2012, where 1996 to 2006 represents a pre-
viously searched time period.
The revised search strategies had an impact on the review since the
strategies identified a number of studies which should have been
found during previous searches: Ageno 2000, Claes 2005, Claes
2006, Mitra 2005, Plank 2006, Poller 2002, Poller 2003.
For the initial review, the databases listed below were searched
from database start date to 1996; for the first update, the search
period was 1996 to 2006; for this, the second, update, searches
were run from 1996 to January 2012. Two methodological search
filters were used to limit retrieval to appropriate study designs: the
Cochrane Highly Sensitive Search Strategy (sensitivity- and pre-
cision-maximizing version, 2008 revision) to identify randomized
trials; and an EPOC methodology filter (Appendix 1) to identify
non-RCT designs. Related reviews were identified by searching
the Database of Abstracts of Reviews (DARE). All databases were
searched from their start date forward; start date represents the date
the database began to index journals. Note that database start dates
vary by database (Medline, EMBASE, etc.) and provider (OVID,
Ebsco, etc.). Start dates are provided in the list of databases, below.
A top-up search was conducted for the period January 2012 to
January 2013; the authors screened the titles and abstracts of these
results and added potentially relevant studies to Studies awaiting
classification.
The original MEDLINE search strategies used until 2006 are in
Appendix 2.The revised search strategies used for this update are in
Appendices 2 to 6 as follows: MEDLINE, Appendix 3; EMBASE,
Appendix 4; CINAHL, Appendix 5; Cochrane Central Register
of Controlled Trials, Appendix 6; EPOC Specialised Register, Ap-
pendix 7.
Databases searched
• Cochrane Central Register of Controlled Trials
(CENTRAL), Issue 12, 2012, OvidSP EBM Reviews
• MEDLINE, including In-Process & Other Non-Indexed
Citations, OvidSP, 1946-January 2013
• EMBASE, 1947 to January 2013, OvidSP
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature), 1980-January 2013, EbscoHost
• EPOC Group, Specialised Register
Searching other resources
The review authors handsearched reference lists from primary ar-
ticles and relevant reviews identified, and conference proceedings.
We contacted experts in the field.
We also:
• Screened (hand searched) the following journals:
◦ Therapeutic Drug Monitoring journal (1979 to
December 2006).
◦ Journal of the American Medical Informatics Association
(January 1996 to March 2007).
• Reviewed reference lists of all included studies, relevant
systematic reviews and primary studies.
• Contacted authors of relevant studies/ reviews to clarify
reported published information and to seek unpublished results/
data.
• Contacted researchers with expertise relevant to the review
topic/ EPOC interventions.
Data collection and analysis
Selection of studies
Wemerged the search results using ReferenceManager 5 (RevMan
2011), and removed duplicate records. We examined all titles and
abstracts.
Two review authors (FG, PD) examined independently each title
and abstract to exclude obviously irrelevant reports (mainly ther-
apeutic trials and genetic research). We retrieved full texts, which
were independently screened. We then randomly allocated each
selected study to two pairs of review authors (IC and FG, MR
and PD) who reviewed it and extracted data independently. We
resolved disagreements by group discussion with the four review
authors. We reported reasons for excluding full papers.
Data extraction and management
We reviewed the data abstraction form for the previous update of
the review. We adapted a checklist to the specific subject to extract
the decision support technical features by which the advice on
drug dosage was delivered to the healthcare professional.
• Was the computerized advice delivered in real time (at the
moment of the practitioners decision making) or by delayed
feedback?
• Was the computerized advice integrated in a CPOE?
• Was the computerized advice user-initiated or system-
initiated?
• Was the intervention direct or indirect (a third party
brought advice from computer and transfers it to user)?
An additional feature was added:
• Was the information of the calculated dose given as a
recommendation to the healthcare professional who prescribed
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through the computer or through another healthcare
professional (the healthcare professional had the possibility to
accept or refuse the advice)?
The review authors abstracted the data independently and resolved
disagreements by discussion. A statistician (FG) reviewed all data
and contacted authors of included studies for additional informa-
tion.
Assessment of risk of bias in included studies
We assessed the risk of bias of the studies using the ’Risk of bias’
criteria described by the EPOC group and extracted data using the
EPOC checklist (EPOC2009; Higgins 2011).We used nine stan-
dard criteria for RCTs, NRCTs and CBAs: allocation sequence ad-
equately generated; allocation adequately concealed; baseline out-
come measurements similar; baseline characteristics similar; in-
complete outcome data adequately addressed; knowledge of the al-
located interventions adequately prevented during the study; study
adequately protected against contamination; study free from se-
lective outcome reporting; study free from other risks of bias. We
scored studies using cluster randomization to be adequate on con-
cealment of allocation (if the sequence generation was adequate)
and on protection against contamination. Baseline characteristics
were considered for similarity at the unit of analysis level. Risk
of bias on baseline outcome measurements was only evaluated for
insulin. For the other drugs, the baseline measurement was not
relevant since there was no drug intake before the intervention.
Therefore, we considered risk of bias on baseline outcome mea-
surements to be ’low risk’ for these drugs.
The risk of bias for ITS studies can be evaluated using seven stan-
dard criteria but we found no ITS studies.
We included all the ’Risk of bias’ criteria in the data abstraction
form and independently scored criteria as ’yes’ (adequate), ’no’
(inadequate) or ’unclear’.We resolved disagreements by discussion
and, where necessary, with a third review author. The risk of bias
of included studies is summarized in the text and presented in the
’Risk of bias’ section within the Characteristics of included studies
table.
Two review authors (EC, PD) assessed the quality of evidence
for each main outcome - that is the extent of confidence in the
estimate of effect across studies (high, moderate, low or very low)
- using the GRADE approach (Guyatt 2008).
Measures of treatment effect
For dichotomous variables, we used the risk ratio (RR).
When the outcomeswere continuous variables, we calculated stan-
dardized mean differences (SMD) with 95% confidence intervals
(CI). The SMD is a statistical measure of the impact of the inter-
vention, which is independent of the units used to measure study
outcomes. This measure allows studies of the same intervention
using different outcomes to be compared. For example, measure-
ment of drug concentrations in blood in different studies may use
different assays in several laboratories and results may be reported
in different units. The SMD compares differences between ex-
perimental and control groups to the standard deviation of the
outcome for each study. Hence, a quantitative approximation can
be made of the overall effect of decision support on plasma lev-
els. Because SMD can be difficult to interpret (as it is reported
in units of standard deviation), we also presented mean difference
(MD), that is the absolute difference between the mean value in
two groups, in relevant cases (when measurements were made on
the same scale).
Clinical adverse events were expressed as RRs or rate ratios. In a
randomized trial, rate ratios may often be very similar to RRs ob-
tained after dichotomizing the participants, since the mean period
of follow-up should be similar in all intervention groups. Rate
ratios and RRs will differ, however, if an intervention affects the
likelihood of some participants experiencing multiple events.
The effect sizes were combined to give an overall effect for each
subgroup of studies, using a random-effects model. The random-
effects model was chosen because it does not assume that all in-
terventions have the same underlying effect.
Unit of analysis issues
Analyses of studies using cluster randomization that do not ac-
count for the design effect risk inflating the type 1 error-rate re-
sulting in artificially narrow CIs (Ukoumunne 1999). We have
reported potential errors and did not attempt to reanalyze data
unless standard errors were correctly stated with number of clus-
ters allowing the calculation of appropriate CIs.
Dealing with missing data
When the mean and standard deviation were missing, we esti-
mated the mean from the median and standard deviation from
the interquartile range or range (Hozo 2005). Missing data on
outcomes or estimated data are explicitly indicated in the tables
and text. We did not attempt to impute or model other missing
data.
Assessment of heterogeneity
We explored heterogeneity using tests of heterogeneity and exami-
nations of direction, magnitude and variability of effects. The sta-
tistical test for heterogeneity (Chi2 test) tests the null hypothesis
that all studies in a meta-analysis have the same underlying mag-
nitude of effects. The I2 statistic quantifies the proportion of the
variation in point estimates due to among-study differences but is
influenced by sample size. An I2 statistic greater than 50%may be
considered as substantial heterogeneity and I2 statistic greater than
75% as considerable heterogeneity (Deeks 2011). High P value
for the test of heterogeneity (P value > 0.1) and low I2 values do
not necessarily indicate low heterogeneity (Guyatt 2011). Thus,
we alsomanually examined the variability in point estimates across
studies and the overlap of CIs.
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Assessment of reporting biases
To be meaningful and appropriate, funnel-plot asymmetry tests
must be performed when four criteria are met: no significant het-
erogeneity (P value for the Chi2 test of heterogeneity > 0.10), low
I2 statistic (< 50%), 10 or more studies with at least one with
significant results, and a ratio of the maximal to minimal variance
across studies greater than four (Ioannidis 2007). We could not
assess publication bias because these conditions were not met.
Data synthesis
We grouped the results from the included studies by drug used and
the effect aimed at for aminoglycoside antibiotics, amitriptyline,
anaesthetics, insulin, anticoagulants, ovarian stimulation, anti-re-
jectiondrugs and theophylline.We further grouped studies by type
of outcome when appropriate (i.e. no evidence of heterogeneity).
We constructed Forest plots for the main outcomes without po-
tential unit of analysis error for which data were available for more
than one comparison.
The doses of drugs administered to participants and the number
of dose changes per participant were described but not compared.
Subgroup analysis and investigation of heterogeneity
We considered the following potential sources of heterogeneity to
explain variation in the results of the included studies:
• time of delivery of advice (real time/delayed feedback);
• location of advice (integrated in CPOE systems/other);
• initiation of the computer advice (system-initiated/user-
initiated);
• advice given directly to the provider (direct intervention)
versus the intermediate of a third party actor (indirect
intervention);
• type of hospital (outpatient/inpatient);
• type of advice (recommendation/calculated dose proposed
without possibility of change).
Sensitivity analysis
We had planned to perform a sensitivity analysis, excluding high
risk of bias studies, but, since most of the identified studies had
high risk of bias, we were unable to perform this analysis.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The initial review identified 15 comparisons (14 articles) (Walton
2001), whereas the previous update of this review identified 26
comparisons (23 articles) that met inclusion criteria (Durieux
2008).
Figure 1 shows the study PRISMA flow chart (Moher 2009). We
screened 5328 non-duplicate records, of which 64 were identi-
fied through other sources than database searches (references from
previous versions of this review and published before 1996, ref-
erences from bibliography or website of screened articles or sys-
tematic reviews). We assessed 199 articles for potential inclusion:
136 articles identified from the new updated search strategy (from
January 1996) (including eight from the previous version of the
review) and 48 additional relevant articles from handsearches and
reference lists of trials and systematic reviews, leading to 176 po-
tential ’new’ inclusions as compared with the previous version of
the review; and 15 articles from the previous review and published
before 1996.
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Figure 1. Study flow diagram.
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Since the search strategy missed studies we will search pre-1996
for the next update of this review.
Included studies
This update identified 20 new trials with 21 comparisons, for a
total of 42 trials and 46 comparisons and are included as follows:
25 comparisons (22 trials) from the previous update of this review
(Durieux 2008), and 21 comparisons (20 trials) from this update.
These 42 trials were reported in 53 references (many reports for
some trials). Three articles were separate cost-effectiveness analy-
ses: Jowett 2009 (main results in Poller 2008 PARMA 5; Poller
2009 DAWN AC), Rousseau 2010 (main results in Le Meur
2007), and Claes 2006 (main results in Claes 2005). One article
was a separate safety analysis: Mihajlovic 2010 (main results in
Mihajlovic 2003).
In four trials, two different comparisons were analyzed in one ar-
ticle, midazolam and fentanyl continuous infusion anaesthesia for
cardiac surgery were independently titrated to maintain haemo-
dynamic stability infusions but analyzed in the same population
(Theil 1993 fentanyl; Theil 1993 midazolam). Therefore, these
two drugs were reviewed separately. In one article, Vadher 1997
pop1 considered people starting warfarin with a targeted interna-
tional normalized ratio (INR) between 2 and 3; Vadher 1997 pop2
considered people on long-term treatment with a targeted INR
between 3 and 4.5. Poller 1998 pop1 considered inpatients need-
ing anticoagulant therapy (stabilized patients); Poller 1998 pop2
considered outpatients needing anticoagulant therapy (in the sta-
bilization period). The results from two computer-assisted dosage
programs (DAWNAC and PARMA 5) were first published in one
clinical endpoint report from the European Action on Anticoagu-
lation (EAA), which gave the combined results (Poller 2008) and
secondly published in two separate reports (Poller 2008 PARMA
5; Poller 2009 DAWN AC), because the computer-assistance dif-
fered considerably between the participant centres in the study
using the two alternative programs. We decided to include the two
computer-assisted dosage programs as two subgroup analyses.
All studies were RCTs, except two (Chertow 2001;Manotti 2001),
which we classified as NRCTs.
In one publication concerning warfarin dosage adjustment (Carter
1987), three groups were studied: we reviewed only the compari-
son between the group using an analogue-computer method and
the group using empiric dosing (control). The third group, using
a linear regression model, was excluded because it did not involve
any computer assistance.
In one publication (Manotti 2001), two different groups of people
were studied: one group starting oral anticoagulants (induction)
and one group on long-term treatment (maintenance). The main-
tenance study was not reviewed because of the absence of relevant
data for the primary outcome.
In one publication, two different studies were reported: the first
study considered people starting warfarin with a targeted INR
between 2 and 3 (Vadher 1997 pop1); the second study considered
people on long-term treatment with a targeted INR between 3
and 4.5 (Vadher 1997 pop2).
In one publication (Fitzmaurice 2000), there were two levels of
randomization. Practices were randomized to intervention or con-
trol. The study used two control populations: people individually
randomly allocated to control in the intervention practices (in-
trapractice controls) and all participants in the control practices
(interpractice controls). We did not analyze interpractice controls
to avoid a possible unit of analysis error.
In one publication concerning oral anticoagulation therapy at
steady state where randomization was at the GP practice level (re-
ported in Claes 2005; Claes 2006), four groups were studied: we
reviewed only the comparison between group A (Grol’s multi-
faceted education: summary of the guidelines printed on the cover
of a folder containing the anticoagulation files; information book-
lets on anticoagulation for their patients; website with guidelines,
study design, and general information; newsletter sent every two
months to inform the GPs on the study progress and requested
them to send the anticoagulation files for checking) and group D
(Grol’s multifaceted education + DAWN AC computer-assisted
advice that generated a recommended dosing scheme and the time
to next visit). Group A did not correspond to standard practice
but it was considered as a control group because GPs in group D
also received the multifaceted education. Groups B and C were
excluded because the interventions were not computerized advice
on drug dosage.
In one publication concerning insulin in cardiac surgery patients
(Blaha 2009), three groups were studied: we reviewed only the
comparison between the group using the Matias protocol based
on the absolute glucose value and the group using computer-
based model predictive control algorithm with variable sampling
rate (Enhanced software Model Predictive Control (eMPC)). The
third group, using the Bath protocol based on the relative glu-
cose change was excluded since most standard protocols in blood
glucose management use the absolute glucose value and the Bath
protocol had not been used in the hospital before the study.
Four comparisons/three trials included (Poller 1998 pop1;
Anderson 2007; Poller 2008 PARMA 5; Poller 2009 DAWN AC)
had duplicate publications (Poller 2002; Anderson 2008; Poller
2008), and three comparisons/two trials included (Le Meur 2007;
Poller 2008 PARMA 5; Poller 2009 DAWN AC) were mentioned
earlier in abstracts (Poller 2003; Le Meur 2007 extract).
Excluded studies
We excluded 143 of the 199 full-text articles assessed for eligi-
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bility: 72 because the intervention was not a computerized drug
dosage, 38 for an inappropriate design, 12 for absence of relevant
data for primary outcome, seven because the patient aid was not
under physician control, five because the dose advice was not indi-
vidualized, three discussions, two conferences publications where
contact to author failed (Ghazal-Aswad 1997; Tomek 2011), one
abstract published elsewhere (van Leeuwen 2005), one because
some participants were already included in another publication
(Jankovic 1999) and one comment (Ligtenberg 2006).
One study included in the previous update of the review was ex-
cluded because the intervention corresponded to a closed-loop sys-
tem (automatic optimization of the infusion rate of sodium nitro-
prusside achieved by an integrated hardware-software closed-loop
controller implemented as a small bedside device) (Ruiz 1993).
Ongoing studies
A total of 17 studies are awaiting classification (possibly relevant
ongoing studies published between January 2012 and January
2013). Three references corresponding to conference publications
not published at the time of the search for this update (Overgaard
2010; Anderson 2011; Nieuwlaat 2011), have been published
since then (Anderson 2012; Nieuwlaat 2012; Rasmussen 2012).
Characteristics of the providers
The providerswere primarily doctors, although 14 studies (33.3%)
targeted several categories of healthcare professionals including
pharmacists (Carter 1987; White 1987; Destache 1990; Leehey
1993; Mungall 1994; Anderson 2007), nurses (Vadher 1997;
Vadher 1997 pop2; Vadher 1997 pop1; Ageno 1998; Ageno 2000;
Fitzmaurice 2000; Blaha 2009), or other healthcare professionals
(Claes 2005; Claes 2006; Saager 2008). Three studies addressed
only nurses’ behaviour (White 1991; Pachler 2008; Cordingley
2009).
Twenty studies (47.6%) were conducted in North America (17 in
the US, three in Canada) and 15 (35.7%) in Europe (three studies
with numerous countries Poller 1998 pop1; Poller 1998 pop2;
Plank 2006; Cordingley 2009). Two studies took place in New
Zealand (Begg 1989; Hickling 1989), one in Australia (Hurley
1986), one in Israel (Verner 1992), one in Norway (Asberg 2010),
and one in Serbia (Mihajlovic 2003;Mihajlovic 2010). One study
was conducted in 13 countries from Europe, Israel and Australia
(Poller 2008 PARMA 5; Poller 2009 DAWN AC).
Thirty-one studies (73.8%) were conducted in one centre, and
seven studies (16.7%) in two to five centres. One study took place
in 11 centres (Le Meur 2007); one study included 12 practices
(Fitzmaurice 2000); one study was conducted in 32 centres from
Europe (29 centres), Israel (two centres), and Australia (one cen-
tre) (Poller 2008 PARMA 5; Poller 2009 DAWN AC); one study
included 96 GPs regrouped in 66 GP practices (Claes 2005; Claes
2006).
Twenty-seven comparisons (58.7%) included fewer than 100 par-
ticipants in the analyses (median: 80 participants, mean: 779 par-
ticipants).
Target behaviour
The target behaviour of the healthcare provider was the prescrip-
tion and the dosing of drugs.
Characteristics of the interventions
Most of the studies provided advice about appropriate drug
dosages to healthcare professionals who then decided whether to
follow this or not. Fifteen studies (35.7%) (18 comparisons) eval-
uated anticoagulants, 10 studies (23.8%) evaluated the adminis-
tration of insulin, five studies (11.9%) evaluated the administra-
tion of aminoglycoside antibiotics, four studies (9.5%) evaluated
theophylline, four studies (9.5%) evaluated anti-rejection drugs
requiring adjustments for renal impairment, two studies (4.8%)
(three comparisons) evaluated computer-controlled infusions of
anaesthetic agents, one study (2.4%) evaluated amitriptyline in
the treatment of major depressive episodes and one study (2.4%)
evaluated ovarian stimulation by gonadotropins.
Most of the computer support systems used a mathematical model
of the pharmacokinetics of the drug to predict the required dose.
These models represent the compartments in the body in which
the drug is distributed, with rate constants determining the move-
ment of the drug between different compartments. These systems
allowed the operator to specify a target serum drug level, which the
computer attempted to achieve using Bayesian forecasting meth-
ods. Where the effect of the drug was more important than the
serum level, pharmacodynamic parameters based on population
data could be added to the model (White 1987).
Anticoagulants (fifteen studies, eighteen comparisons)
Fourteen studies evaluated oral anticoagulant and one study eval-
uated heparin (Mungall 1994). Five studies analyzed initiation
of warfarin (Carter 1987; White 1987; Ageno 2000; Manotti
2001; Anderson 2007), with varying target INR ranges (see
Characteristics of included studies). Four studies (five compar-
isons) analyzed long-term warfarin therapy (White 1991; Vadher
1997 pop1; Ageno 2000; Fitzmaurice 2000; Claes 2005; Claes
2006), with varying target INR ranges (see Characteristics of
included studies). One study analyzed heparin therapy (Mungall
1994). Six studies (five comparisons) analyzed both initiation and
long-termwarfarin therapywith at least threemonths of follow-up
(Vadher 1997; Vadher 1997 pop2; Poller 1998 pop1; Poller 1998
pop2; Mitra 2005; Poller 2008 PARMA 5; Poller 2009 DAWN
AC).
The settingwas outpatient care for six studies (White 1991;Vadher
1997 pop1; Vadher 1997 pop2; Ageno 1998; Poller 1998 pop1;
Poller 1998 pop2; Manotti 2001; Poller 2008), community-based
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care in two studies (Fitzmaurice 2000; Claes 2005; Claes 2006),
and inpatient care for six studies (Carter 1987: White 1987;
Mungall 1994; Ageno 2000; Mitra 2005; Anderson 2007); it was
mixed in one study (Vadher 1997).
The computer support systems were programs that were not inte-
grated into a CPOE. The computer-generated program DAWN
AC (4S Information Systems Ltd.) was used in five studies (Poller
1998 pop1; Poller 1998 pop2; Ageno 2000; Claes 2005; Mitra
2005; Claes 2006; Poller 2009 DAWNAC). Two modules existed
in the DAWN AC program (induction and maintenance). Four
studies used a (Bayesian) computer pharmacokinetic or a phar-
macodynamic model (Carter 1987; White 1987; White 1991;
Mungall 1994), or both, whereas one used a pharmacogenetics
model (Anderson 2007). One study used the PARMA (Program
for Archive, Refertation, and Monitoring of Anticoagulated pa-
tients) software program developed in Italy (Manotti 2001), and
one comparison used PARMA 5, a new version of the program
(Poller 2008 PARMA 5). Other studies used dosage algorithms or
prediction rules.
The advice was given in real time to the healthcare professional in
all studies except three, where it was unclear (Vadher 1997; Poller
1998 pop1; Poller 1998 pop2; Claes 2005; Claes 2006). The com-
puterized advice was user-initiated in seven studies (White 1987;
White 1991; Vadher 1997 pop1; Vadher 1997 pop2; Ageno 1998;
Fitzmaurice 2000; Claes 2005; Claes 2006; Anderson 2007), sys-
tem-initiated in two studies (Manotti 2001; Poller 2008 PARMA
5; Poller 2009 DAWN AC), and it was unclear in six studies
(Carter 1987; Mungall 1994; Vadher 1997; Poller 1998 pop1;
Poller 1998 pop2; Ageno 1998; Mitra 2005). The intervention
was direct in seven studies (White 1991; Vadher 1997 pop1;
Vadher 1997 pop2; Ageno 1998; Fitzmaurice 2000; Ageno 2000;
Manotti 2001; Anderson 2007), indirect in three studies (dosage
determined by pharmacy in Carter 1987 and Mungall 1994, and
the pathologist reviewed the computer-generated advice in Claes
2005) and it was unclear in five studies (White 1987; Vadher 1997;
Poller 1998 pop1; Poller 1998 pop2; Mitra 2005; Poller 2008).
Three comparisons provided the warfarin maintenance doses per
participant (Carter 1987; Vadher 1997 pop1; Vadher 1997 pop2),
and there was no significant difference between groups (MD -
0.33 mg/day, 95% CI -1.18 to 0.53). One study reported signif-
icantly larger amounts of drug prescribed for people with high
INR target both of warfarin (computer group = 33.3 mg/week
versus manual = 31.3 mg/week; P value < 0.001), and aceno-
coumarol (computer group = 19.2 mg/week versus manual = 17.8
mg/week; P value < 0.01), whereas there was no significant dif-
ference between the doses prescribed for people with low INR
target (Manotti 2001). One study analyzed the number of dose
adjustments (Anderson 2007): pharmacogenetic guidance signif-
icantly decreased the number of required dose adjustments (by
0.62 dose adjustments per participant; 95% CI 0.04 to 1.19; P
value = 0.035).
There were two eligible comparisons with potential unit of analy-
sis error that analyzed the proportion of dose adjustments. In one
comparison (Ageno 1998), the percentage of dose adjustments
performed by the healthcare professionals was 47.4%, whereas the
computer needed 31.3% dose adjustments, a statistically signifi-
cant 34.0% relative reduction (95%CI -41.9% to -24.7%). In the
other comparison (Ageno 2000), the proportion of dose adjust-
ments was 48% in the computer group and 45% in the manual
group, a non-significant relative increase of 7% (95% CI -10% to
27%).
In Claes 2005, there was no significant difference among the
groups in number of tests per participant per month and per cent
of participants with treatment changes.
For heparin (Mungall 1994), the mean dose was not significantly
different between the computer and the standard groups (MD100
units/hour, 95% CI -96 to 296).
Insulin (ten studies)
Eight studies (80%) evaluated insulin in people admitted into
the intensive care unit with hyperglycaemia: six studies in car-
diac surgery patients (Plank 2006; Hovorka 2007; Kremen 2007;
Saager 2008; Blaha 2009; Sato 2011) and two studies in critically
ill patients (Pachler 2008; Cordingley 2009). One study was con-
ducted in general medical inpatients with type 2 diabetes (Wexler
2010) and one study in diabetic outpatients (Augstein 2007).
The computer support system was integrated into a CPOE in
one study (Wexler 2010), whereas other systems were software
developed by companies. The software Model Predictive Control
(MPC) was used in two studies (Plank 2006; Kremen 2007). The
laptop-based algorithmMPC is amodel representing the glucoreg-
ulatory system. Glucose concentration, insulin dosage and carbo-
hydrate intake are the input variables for the MPC. The insulin
infusion rate is the output parameter based on hourly glucose sam-
pling. eMPC was used in four studies (Hovorka 2007; Pachler
2008; Blaha 2009; Cordingley 2009). The eMPC is an enhanced
version of the model predictive control algorithm (MPC), which
additionally generates the time of the next glucose measurement
with an interval between samples varying from 0.5 to 4 hours. All
six studies were part of the CLINICIP (Closed Loop Insulin In-
fusion for Critically Ill Patients; www.clinicip.org), an integrated
project funded by the European Community working towards the
development of a closed-loop system to achieve safe tight glucose
control in intensive care patients. Three studies used other soft-
ware that take account of the characteristics of glucose dynam-
ics (KArlsburg Diabetes Management System (KADIS): Augstein
2007, EndoTool Glucose Management System (MD Scienti c):
Saager 2008, GINComputer Software (GINCS): Sato 2011), and
one study used a weight-based insulin dose calculator (Wexler
2010).
The advice was given in real time to the healthcare professional in
all studies except one, where it was unclear (Augstein 2007). The
computerized advice was user-initiated in six studies (Plank 2006;
16Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hovorka 2007;Kremen2007; Augstein 2007; Pachler 2008; Blaha
2009), system-initiated in two studies (Saager 2008;Wexler 2010),
and it was unclear in two studies (Cordingley 2009; Sato 2011).
The intervention was direct in seven studies (Hovorka 2007;
Pachler 2008; Saager 2008; Cordingley 2009; Blaha 2009; Wexler
2010; Sato 2011), indirect in one study (eMPC algorithmwas run
by study personnel (input glucose and change of Insulin infusion
rate) under the supervision of the healthcare professional in Plank
2006) and it was unclear in two studies (Kremen 2007; Augstein
2007).
Seven comparisons provided the insulin doses. The statistical het-
erogeneity was moderate. In one study (Hovorka 2007), the mean
insulin infusion rate was significantly higher in the computer-
ized glucose management group than standard management pro-
tocol group (MD +2.10 insulin units/hour, 95%CI 0.77 to 3.43),
whereas there were no significant differences in the others (four
comparisons with higher doses in the computer group, two com-
parisons with higher doses in the standard group). Overall, the
insulin doses were higher in the computer groups, but this was not
significantly different (pooled SMD 0.23, 95% CI -0.04 to 0.50).
One study reported no differences in the amount of glucose ad-
ministered between the computer group (79.4 ± 24 g) and the
manual group (81.6 ± 28 g) during the study period (before, dur-
ing and after cardiopulmonary bypass) (MD -2.2 g, 95% CI -19.2
to 14.8) (Sato 2011).
One study analyzed the number of times the insulin rate was
changed in 72 hours: the insulin infusion rate was altered a mean
of 23.5 times more (95% CI 19.0 to 28.0) in the computer group
than in the control group (35.5, 95% CI 31.1 to 39.9 versus 12.0,
95% CI 10.3 to 13.7) (Pachler 2008).
Aminoglycoside antibiotics (five studies)
Five studies (Begg 1989; Hickling 1989; Destache 1990; Burton
1991; Leehey 1993) evaluated the administration of aminogly-
coside in inpatient care. All computer support systems used a
(Bayesian) pharmacokinetic model with the advice given in real
time to the healthcare professional, not integrated into a CPOE,
and it was not clear if the computerized advice was user-initiated.
The intervention was indirect in two studies (Destache 1990: a
clinical pharmacokinetic service reviewed the initial aminoglyco-
side dose and dosing interval and made an oral recommendation
to the attending physician or resident; Leehey 1993: the orders for
aminoglycoside dosing were written by a pharmacist with coun-
tersignature by a physician and the duration of antibiotic therapy
as well as other aspects of clinical care were determined by the
primary physicians).
One comparison provided outcomes for the analysis on initial
and maintenance doses (Burton 1991). There was no statistical
difference between groups for initial doses (MD +8 mg/day, 95%
CI -11 to 27) or for maintenance doses (MD +11 mg/day, 95%
CI -16 to 38).
Two studies reported data on total administered dose with differ-
ent magnitude of effects. In one study (Begg 1989), the amino-
glycoside dose per day was significantly higher in the pharmacoki-
netic group than in the standard group (+109 g, 95% CI 67 to
151). In the other study (Leehey 1993), the milligrams per dose
were higher and number of doses per day was lower in the phar-
macist-directed dosing group compared with the standard group
(milligrams/dose: 107 ± 21 versus 91 ± 26; doses/day: 2.0 ± 0.6
versus 2.3 ± 0.5) but the mean total doses of aminoglycoside were
not significantly different between groups (pooled MD 141 mg,
95% CI -342 to 624).
One study analyzed the number of dosage changes and indicated
higher dosage changes in the group with pharmacokinetic service
recommendation than in the control group (MD +0.50 dosage
change, 95% CI 0.21 to 0.79) (Destache 1990).
Theophylline (four studies)
Four studies evaluated theophylline (Hurley 1986;Gonzalez 1989;
Verner 1992; Casner 1993), a drug that is not considered as the
first choice of treatment of asthma at present. However, moni-
toring serum concentrations of theophylline is essential to ensure
that non-toxic doses are achieved (National Asthma 2002). There
were no studies on recently introduced drugs where it is consid-
ered important to monitor drug levels such as for glycopeptides,
antifungal (fluconazole) and antiretroviral drugs.
The setting was inpatient care for all four studies.
All computer support systems used a Bayesian compartmental
pharmacokinetic model. The advice was given in real time to the
healthcare professional in three studies, whereas it was unclear in
one study (Verner 1992). The computer support system was inte-
grated into aCPOEwith a direct intervention in one study (Casner
1993), whereas it was unclear for the others. The computerized
advice was user-initiated in two studies and it was unclear in two
studies.
Three comparisons provided data on initial dose with substantial
heterogeneity (Hurley 1986; Gonzalez 1989; Verner 1992). The
theophylline initial dose was significantly higher in the computer
group (SMD 1.7, 95% CI 0.7 to 2.6), whereas the difference did
not reach significance in the two other studies (SMD 0.2, 95%
CI -0.1 to 0.6). Two comparisons provided data on maintenance
dose and indicated higher doses in the computer group (SMD0.8,
95% CI 0.5 to 1.1) (Hurley 1986; Gonzalez 1989).
Anti-rejection drugs (four studies)
Four studies evaluated anti-rejection drugs requiring adjustments
for renal impairment (Chertow 2001; Le Meur 2007; Asberg
2010; Terrell 2010). Two studies evaluated high-use medications
that required adjustments for renal impairment (Chertow 2001;
Terrell 2010), one study evaluated cyclosporine A (CsA) in the
early post-transplant phase (Asberg 2010), andone study evaluated
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mycophenolate mofetil (MMF) dosing in renal transplant patients
(Le Meur 2007).
The studies evaluating medications that required adjustments for
renal impairment took place in inpatient care, with the computer
support system integrated into a CPOE, and the advice system
initiated and given in real time. In the study evaluating CsA in
early post-transplant phase (Asberg 2010), the individual com-
puter dosing of CsA doses were calculated by a population phar-
macokinetic model and suggested to the physician (patients were
admitted in nephrology and had a standard clinical follow-up).
In the study evaluating MMF dosing in renal transplant patients
(Le Meur 2007), the MMF dose adjustments in the concentra-
tion-controlled regimen were calculated by a computer program
to reach a mycophenolic acid (MPA) area under the curve (AUC)
target of 40 mg.h/L and were proposed to the physician.
No study reported data on drug dosages. One eligible study with
potential unit of analysis error showed that a computerized de-
cision support system for prescribing drugs in people with renal
insufficiency improved the proportion of appropriate orders (RR
1.71, 95% CI 1.64 to 1.78) (Chertow 2001).
Anaesthetic agents (two studies, three comparisons)
Two studies (three comparisons) evaluated computer-controlled
infusions of anaesthetic agents (Rodman 1984; Theil 1993
fentanyl; Theil 1993 midazolam). One study evaluated the lido-
caine therapy (Rodman 1984), whereas one study evaluated fen-
tanyl and midazolam infusions (Theil 1993 fentanyl; Theil 1993
midazolam).
The setting was inpatient care for the two studies. The computer
support system for initial therapy of lidocaine was an individu-
alized linear two-compartment pharmacokinetic model not inte-
grated into a CPOE, and the advice was user-initiated and given
at real time. The computer-controlled pump for fentanyl and mi-
dazolam infusions used a pharmacokinetic model integrated into
a CPOE, and the advice was system-initiated.
Rodman 1984 provided outcomes for the initial, maintenance
and total doses. Computerized advice had no significant effect on
lidocaine dosage (SMD 2.5, 95% CI 1.3 to 3.8 for initial dose; -
0.2, 95% CI -1.0 to 0.7 for maintenance dose; 0.2, 95% CI -0.7
to 1.1 for total dose).
Theil 1993 fentanyl and Theil 1993 midazolam provided out-
comes for the initial, maintenance and total doses for both fen-
tanyl and midazolam infusions. Computerized advice had no sig-
nificant effect on fentanyl drug dosage (SMD 0.5, 95% CI -0.3 to
1.3 for initial dose; 0.0, 95% CI -0.8 to 0.8 for maintenance dose;
0.5, 95% CI -0.3 to 1.3 for total dose), but reduced significantly
midazolam initial, maintenance and total drug doses (SMD -1.9,
95% CI -2.9 to -0.9 for initial dose; -1.2, 95% CI -2.1 to -0.3 for
maintenance dose; -1.1, 95%CI -1.9 to -0.2 for total dose). There
was no significant difference in the number of infusion changes
during the cardio-pulmonary bypass (MD -0.2, 95% CI -1.0 to
0.6 for fentanyl; 0.5, 95% CI -0.3 to 1.3 for midazolam).
Antidepressants (one study)
One study evaluated amitriptyline in the treatment of major de-
pressive episodes (Mihajlovic 2003; Mihajlovic 2010). The study
took place in one psychiatric clinic of a clinical hospital centre.
The computer-aided dose of amitriptyline was calculated using
the modified Bayesian method. It was not clear if the computer
support system was integrated into a CPOE, if the intervention
was direct or if the advice was user-initiated and given at real time.
The drug daily doses of amitriptyline plus nortriptyline at day 14
were significantly lower when they were individualized compared
with empiric doses (133.3 mg, 95% CI 126.7 to 140.0 versus
148.3 mg, 95% CI 140.2 to 156.4).
Gonadotropins (one study)
One study evaluated ovarian stimulation by gonadotropins (
Lesourd 2002). The study included women from three centres
who were undergoing ovarian stimulation to treat infertility. The
software (GonaSoft) was created by the author to help clinicians to
monitor ovarian stimulation and to provide a tool for evaluation
of efficiency and complications. The software was not integrated
into a CPOE. The intervention was direct with the advice given
at real time.
There was no significant difference between groups in the num-
ber of follicle-stimulating hormone units administered (860 units,
95% CI 776 to 944 in the intervention group versus 938 units,
95% CI 825 to 1051 in the control group).
Risk of bias in included studies
See Figure 2; Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Four studies were not assessed for the risk of bias, since they were
cost-effectiveness or safety analyses conducted as a part of previ-
ous included studies (same trial): Claes 2006 (see Claes 2005);
Jowett 2009 (see Poller 2008 PARMA 5; Poller 2009 DAWNAC);
Mihajlovic 2010 (see Mihajlovic 2003); and Rousseau 2010 (see
Le Meur 2007).
Random sequence generation (selection bias)
The sequence generation process used a random component in
21 studies (50%). A non-random method was used in two studies
(5%): in one study the study periods were four alternating eight-
week blocks of intervention and control subperiods (Chertow
2001); and in one study, the randomization was based on the final
digit in the patient’s identification card number (odds versus even)
(Verner 1992). The sequence generation process was not specified
in 19 studies (45%).
Allocation concealment (selection bias)
The allocation was adequately concealed in 16 studies (38%). The
unit of allocation was institution, team or provider in five studies
(Burton 1991; Fitzmaurice 2000;Claes 2005;Terrell 2010;Wexler
2010), but cluster effect was not taken into account in statistical
analysis for Burton 1991 and Wexler 2010. The unit of allocation
was by participant or episode of care and there was some form of
centralized randomization scheme in 11 studies (on-site computer
system: eight studies, sealed opaque envelopes: three studies). The
allocation was not considered adequately concealed in the two
studies (5%) where a non-randommethodwas used (Verner 1992;
Chertow 2001). The allocation concealment was not specified in
24 studies (57%).
Baseline outcome measurements similar
The mean blood glucose was measured prior to the intervention
and no important differences were present across study groups
in eight (80%) of the 10 studies on insulin drug administration.
One study reported the blood glucose at entry for each centre but
not across study group (Plank 2006), and in one study there were
many data reported on blood glucose but it was unclear if results
given were baseline measurements (Wexler 2010).
Other studies were considered at ’low risk’ because baseline out-
come measurements were not relevant (baseline data realized be-
fore medication intake).
Baseline characteristics similar
Of the five studies where the unit of allocation was by institu-
tion, team or professional, only one reported the characteristics
of providers (Terrell 2010). Baseline characteristics of participants
were reported and similar in 26 studies (62%). Seven studies
(17%) reported differences between participants in control and
intervention groups, one study reported the participants’ char-
acteristics only in a subgroup of participants (Carter 1987), one
study reported the participants’ characteristics by centres (Plank
2006), and three studies did not report participants’ characteristics
(Hickling 1989; Poller 1998 pop1; Poller 1998 pop2; Claes 2005).
Four studies mentioned participants’ characteristics in text but no
data were presented (Gonzalez 1989; Ageno 2000; Chertow 2001;
Asberg 2010).
Incomplete outcome data (attrition bias)
In 18 studies (43%), the missing outcome measures were unlikely
to bias the results (e.g. the proportions of missing data were sim-
ilar in the intervention and control groups or the proportions of
missing data were unlikely to overturn the study result). In 13
studies (31%), missing outcome measures were not specified in
the paper or it was unclear if missing data could overturn the study
result. In 11 studies, the missing outcome data were likely to bias
the results (Carter 1987; Begg 1989; Gonzalez 1989; Hickling
1989; Destache 1990; Burton 1991; Casner 1993; Vadher 1997;
Fitzmaurice 2000; Augstein 2007; Terrell 2010).
Blinding of outcome assessment (detection bias)
In 36 studies (86%), the assessment of primary outcome was ob-
jective or blinded. In six studies (14%), there was a risk of de-
tection bias: five studies used clinical events as main outcomes
and they were not clearly defined (Gonzalez 1989; Ageno 2000;
Fitzmaurice 2000; Mitra 2005; Le Meur 2007); and one study
used a hetero-questionnaire as main outcome (Mihajlovic 2003).
Blinding of participants and personnel (performance
bias)
When studies were randomized by participant, the same health-
care professional may have given treatment both to intervention
and control groups: it is possible that computerized advice in-
fluenced the treatment of the control groups. Protection against
contamination was considered to be done only in three studies
(Theil 1993 fentanyl; Theil 1993 midazolam; Claes 2005; Claes
2006; Anderson 2007), and it was unclear for three studies were it
was possible that communication between intervention and con-
trol professionals could have occurred (Fitzmaurice 2000; Terrell
2010; Wexler 2010).
Thirty-seven studies (88%) randomized the participants, but in
two of them the participants were blinded (Theil 1993 fentanyl;
Theil 1993 midazolam; Anderson 2007). Two studies randomized
the GP practices (Fitzmaurice 2000; Claes 2005; Claes 2006), one
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study randomized 42 emergency medicine faculty and resident
physicians from one urban public hospital (Terrell 2010), and one
study randomized seven teams of providers (42 internal medicine
residents) in general medical acute care units of one medical centre
(Wexler 2010). There was a risk of performance bias in one study
where the house staff teams were randomized (17 house staff teams
in one Veterans Administration medical centre) and at the end
of each four months during the study, intervention groups were
changed to control and vice versa (Burton 1991).
Selective reporting (reporting bias)
The relevant outcomes were reported in the results section in 39
studies (93%). In three studies, the outcomeswere not presented in
themethods section (Rodman 1984;White 1991; Kremen 2007).
Other bias
There was no evidence of other risk of biases in 34 studies (81%),
an evidence of other risk of bias in three studies (7%) and it was
unclear in five studies (12%).
In one study, an erratum had been published because there were
some inconsistencies in the text and tables; we found other incon-
sistencies in tables, full text, and abstract; the author was contacted
but had not replied (Cordingley 2009, by January 2012). There is
a risk of selection bias for one study (Mihajlovic 2003; Mihajlovic
2010): there was a first publication in 1999 including 15 partic-
ipants during 1997 (Jankovic 1999, study excluded because the
author confirmed that the participants were included in the Mi-
hajlovic study), a second publication in 2003 on main outcomes
including 60 participants during 1997 (Mihajlovic 2003), and a
third publication in 2010 on clinical adverse events (Mihajlovic
2010). In one study, there was a risk of contamination due to
logistical problems (“it was difficult to shield the clinicians from
the CDSS suggestions”) and the nurse practitioners used the com-
puter-decision support system and were compared with the clini-
cian group of three junior doctors undergoing general professional
training in general medicine (Vadher 1997 pop1; Vadher 1997
pop2).
There was potential other risk of bias in five studies: in one study,
the Cockcroft-Gault formula might overestimate renal function
when the serum creatinine was increasing, and underestimate re-
nal function when the serum creatinine was decreasing (Chertow
2001); one study was described as a pilot study (10 participants
in each group), the article was in Czech language so it was diffi-
cult to understand all details (authors were contacted in Febru-
ary 2012 but queries remained unanswered) (Kremen 2007); in
one study, few results were reported (one sentence in the results)
so there was not enough information to evaluate the bias of the
study (Lesourd 2002); in one study, only 20 participants were in-
cluded (Rodman 1984); and in one study, 46% participant visits
were excluded (only prescription that required dosage adjustment
were analyzed), there was no adjustment for within-patient corre-
lation, and providers in the intervention group initially prescribed
targeted medications more often than control physicians did and
consequently had substantially more opportunities to adjust dos-
ing (Terrell 2010).
Protection against bias
No study met the nine previous criteria for protection against bias.
Two studies met eight criteria (Anderson 2007; Sato 2011), nine
studies met seven criteria (Begg 1989; Destache 1990; Burton
1991; Casner 1993; Theil 1993 fentanyl; Theil 1993 midazolam;
Claes 2005; Claes 2006; Pachler 2008; Wexler 2010), 16 studies
met six criteria (Hurley 1986;White 1987; Hickling 1989;White
1991; Mungall 1994; Vadher 1997; Poller 1998 pop1; Poller
1998 pop2; Fitzmaurice 2000; Augstein 2007; Hovorka 2007;
Le Meur 2007; Poller 2008 PARMA 5; Blaha 2009; Poller 2009
DAWNAC; Terrell 2010), nine studies met five criteria (Gonzalez
1989; Verner 1992; Leehey 1993; Vadher 1997 pop1; Vadher
1997 pop2;Manotti 2001; Saager 2008; Cordingley 2009; Asberg
2010), seven studies met four criteria (Carter 1987; Ageno 1998;
Ageno 2000; Chertow 2001;Mihajlovic 2003; Mitra 2005; Plank
2006; Mihajlovic 2010), and three studies met three criteria (
Rodman 1984; Lesourd 2002; Kremen 2007).
Power calculation
Fifteen studies (36%) reported a sample size calculation, among
them, one study was presented as a non-inferiority trial but no
margin was addressed (Pachler 2008). The power calculation was
not reported in 22 studies (53%) and in five studies (12%) the
authors specifically reported that the studymight be underpowered
(White 1987; Gonzalez 1989; Casner 1993; Mitra 2005; Asberg
2010).
Effects of interventions
See: Summary of findings for the main comparison
Computerized advice on drug dosage for leading serum
concentrations within therapeutic range; Summary of findings
2 Computerized advice on drug dosage for leading physiological
parameters within therapeutic range; Summary of findings 3
Computerized advice on drug dosage for reducing time to achieve
therapeutic control;Summary of findings 4Computerized advice
on drug dosage for leading to fewer clinical adverse events;
Summary of findings 5 Saving healthcare resources for saving
healthcare resources
See: Summary of findings for the main comparison; Summary
of findings 2, Summary of findings 3; Summary of findings 4;
Summary of findings 5.
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Hypothesis 1. Decisions on drug dosage based on
computer advice lead more often to drug levels
within the therapeutic range
For this comparison, the outcomes analyzed were: the serum con-
centrations (Analysis 1.1; Analysis 1.2; Figure 4; Figure 5), the
proportion of time for which the plasma drug concentrations was
within the therapeutic range (Analysis 1.3; Figure 6), the propor-
tion of participants with plasma drug concentrations within the
therapeutic range (at fixed time) and the proportion of partici-
pants with toxic drug levels (Analysis 1.4; Figure 7).
Figure 4. Forest plot of comparison: 1 Serum concentrations and therapeutic range, outcome: 1.1 Serum
concentrations (mg/L) - part A (SMD > 0 in favour of the intervention).
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Figure 5. Forest plot of comparison: 1 Serum concentrations and therapeutic range, outcome: 1.2 Serum
concentrations (ng/L) - part B (SMD < 0 in favour of the intervention).
Figure 6. Forest plot of comparison: 1 Serum concentrations and therapeutic range, outcome: 1.3
Proportion of participants within therapeutic range.
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Figure 7. Forest plot of comparison: 1 Serum concentrations and therapeutic range, outcome: 1.4
Proportion of participants with toxic drug levels.
Serum concentrations
There was a high clinical and statistical heterogeneity between
drugs so we did not pool the results. Since the interpretation of the
direction of change in serum concentration varied according to the
drug, we grouped the drugs in two Forest plots (part A and part
B). Part A (Analysis 1.1; Figure 4) includes the drugs for which an
SMD greater than 0 corresponds to a difference in favour of the
intervention; Part B (Analysis 1.2; Figure 5) includes the drugs for
which an SMD less than 0 corresponds to a difference in favour
of the intervention.
Anticoagulants (fifteen studies, eighteen comparisons)
No data available.
Insulin (ten studies)
No data available.
Aminoglycoside antibiotics (five studies)
Four comparisons (Begg 1989; Hickling 1989; Burton 1991;
Leehey 1993) analyzed the aminoglycoside target peak concentra-
tion and the objective was to obtain a higher target peak concen-
tration since target peak concentrations are often not met. Hetero-
geneity was moderate (inconsistency I2 = 51%, P value from the
Chi2 = 0.11) but the CIs for the results of individual studies over-
lapped and all studies resulted in a significant higher aminogly-
coside peak concentration in the computer group (pooled SMD
0.79, 95% CI 0.46 to 1.13), which was in favour of the interven-
tion.
In Burton 1991, the proportion of participants with maximum
peak serum aminoglycoside concentrations greater than 4 mg/L
was greater in the Bayesian pharmacokinetic dosing group (RR
1.37, 95% CI 1.11 to 1.70; odds ratio (OR) 3.19, 95% CI 1.46
to 6.94).
One study analyzed the aminoglycoside trough concentration
(residual) and the objective was to obtain a lower trough concen-
tration (Leehey 1993): themean serum trough drug concentration
was lower in the pharmacist-directed dosing group compared with
the control group (SMD -0.42, 95% CI -0.74 to -0.09).
Theophylline (four studies)
Four comparisons analyzed the theophylline concentration:
Hurley 1986 compared the mean serum concentration at day two,
Gonzalez 1989 compared the concentration four hours post load,
Verner 1992 compared the serum concentration 20 minutes af-
ter completion of loading dose infusion and Casner 1993 com-
pared the serum level just before discontinuation of the infusion.
The Forest plot and heterogeneity statistics showed high statistical
heterogeneity (inconsistency I2 = 76%, P value from the Chi2 =
0.005). The theophylline concentration was significantly higher
in the computer group in one comparison (Gonzalez 1989), which
was in favour of the intervention; tended to be higher in the com-
puter group (although it did not reach statistical significance) in
two comparisons (Verner 1992; Casner 1993); and tended to be
lower in one comparison (Hurley 1986). The pooled difference
was not significant (SMD 0.41, 95% CI -0.20 to 1.02).
Anti-rejection drugs (four studies)
No data available.
Anaesthetic agents (two studies, three comparisons)
Rodman 1984 showed that computer-assisted initial lidocaine
therapy significantly increased the lidocaine concentration (SMD
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1.32, 95% CI 0.33 to 2.32), which is in favour of the intervention
(Analysis part A).
In two comparisons dealing with anaesthesiology (Theil 1993
fentanyl; Theil 1993 midazolam), the objective was to obtain a
lower administered drug dose in order to provide a reduction in
time for extubation. Computerized advice had no effect on fen-
tanyl serum concentrations but significantly reduced midazolam
serum concentrations (SMD-1.43, 95%CI -2.34 to -0.51), which
was in favour of the intervention (Analysis part B).
Antidepressants (one study)
The steady-state plasma concentrations of amitriptyline plus nor-
triptyline during the treatment course (day 14) was significantly
lower in the individualized regimen compared with the empiric
dose regimen (SMD -0.68, 95% CI -41.20 to -0.16), which was
in favour of the intervention.
Gonadotropins (one study)
No data available.
Proportion of time for which the plasma drug
concentrations were within the therapeutic
range/proportion of participants with plasma drug
concentrations within the therapeutic range (at a fixed
time) (Analysis 1.3)
Anticoagulants (fifteen studies, eighteen comparisons)
No data available.
Insulin (ten studies)
No data available.
Aminoglycoside antibiotics (five studies)
Several studies have suggested that the mortality in people with
severe infections treatedwith aminoglycosidesmay be substantially
reduced if adequate peak plasma concentrations are achieved early
in the course of treatment (Moore 1984a, Moore 1984b, Moore
1987). Thus, accurate dose prescription is important, not only to
avoid toxicity associated with overdosage, but more important to
avoid the highermortality associated with underdosage during the
first one or two days of treatment.
Three studies analyzed the proportion of participants with amino-
glycoside peak concentration adequate: one study (Destache 1990)
considered the first peak aminoglycoside serum ’adequate’ 30min-
utes after infusionwhereas two studies (Hickling 1989; Begg1989)
considered the peak plasma concentrations within 6 to 10 mg/
L after two days, so we pooled only the results of these two last
studies. There was no evidence of difference in Destache 1990
(RR 1.02, 95% CI 0.63 to 1.64), whereas there were significantly
more participants within the therapeutic range after two days in
the computer group for the two other studies (pooled RR 4.44,
95% CI 1.94 to 10.13).
Hickling 1989 and Begg 1989 also analyzed the proportion of
participants with aminoglycoside peak and trough concentrations
adequate: Hickling 1989 considered the peak trough concentra-
tions lower than 2 mg/L after two days whereas Begg 1989 consid-
ered the peak trough concentrations within 1 to 2 mg/L after two
days. Both comparisons tended to have more participants with
aminoglycoside peak and trough concentrations adequate in the
computer group and the pooled effect showed a significant differ-
ence between groups (pooled RR 3.88, 95% CI 1.04 to 14.44).
Theophylline (four studies)
Hurley 1986 reported that during oral therapy more monitored
than control participants had trough concentrations in the thera-
peutic range (RR 1.60, 95% CI 1.00 to 2.55).
One study reported that serum theophylline concentrations dur-
ing maintenance therapy in the computer group were maintained
within the therapeutic range (10 to 20 µg/mL) longer than in the
control group (77% versus 51%, P versus < 0.05), but the study
included a small number of participants (n = 25) (Verner 1992).
Anti-rejection drugs (four studies)
In Le Meur 2007, there was no significant difference between
concentration-controlled doses and xed-dose MMF on the pro-
portion of participants within therapeutic range at day 14 (MPA
AUC > 30 mg.h/L). The AUC is a model for determining MPA
exposure. MPA is the active metabolite of the inactive prodrug
MMF. However, by day 14, median MPA exposure was signifi-
cantly higher in the concentration-controlled group than in the
fixed-dose group (with a majority of participants in the concen-
tration-controlled group, but not in the fixed-dose group, having
met targeted levels), and at one month, the concentration-con-
trolled group again had significantly higher median MPA AUC,
with more than 90% of participants achieving target levels.
In Asberg 2010, the overall percentage of whole-blood concen-
trations of cyclosporine within the therapeutic window was not
different between groups (SMD 0.23, 95% CI -0.39 to 0.85; MD
3.80%, 95% CI -6.25% to 13.85%).
Anaesthetic agents (two studies, three comparisons)
No data available.
Antidepressants (one study)
No data available.
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Gonadotropins (one study)
No data available.
Proportion of participants with toxic drug levels (Analysis
1.4)
Anticoagulants (fifteen studies, eighteen comparisons)
No data available.
Insulin (ten studies)
No data available.
Aminoglycosides (five studies)
No data available.
Theophylline (four studies)
Two studies analyzed the proportion of participants with toxic
drug levels. In Hurley 1986, fewer monitored participants in
whom infusion rates were based on pharmacokinetic analysis had
serum concentrations in the toxic range but the difference was not
significant (RR 0.50, 95% CI 0.23 to 1.10; OR 0.38, 95% CI
0.13 to 1.09). Casner 1993 found no statistical difference between
the empiric and kinetic groups in the number of toxic (> 20 mg/
L) levels (one in each group).
Anti-rejection drugs (four studies)
In Terrell 2010, where the physicians were randomized to decision
support intervention group or control group, usual care physicians
were more likely to dose medications excessively than intervention
physicians were (OR3.9, 95%CI 1.7 to 9.0, according to amixed-
effects logistic regression to adjust for within-physician correla-
tion). After adjusting for participant age, sex, race and physician
status, this difference remains significant in favour of intervention
(OR usual care versus intervention 4.3, 95% CI 1.4 to 12.8).
Anaesthetic agents (two studies, three comparisons)
No data available.
Antidepressants (one study)
No data available.
Gonadotropins (one study)
No data available.
Summary
The results differed according to drugs. In summary, in spite of
high heterogeneity and small number of studies, comparisons on
serum concentrations were in favour of the computer group for
aminoglycoside antibiotics (higher target peak and lower trough
concentrations) and antidepressants (one study). Results were con-
trasted for theophylline and anaesthetic agents.
Computerized advice improved the proportion of participants for
aminoglycoside antibiotics and theophylline (one study), and the
proportion of time for theophylline (one study) for which the
plasma drug concentrations were within the therapeutic range, but
not for anti-rejection drugs before day 14.
There were three comparisons on toxic drug levels: there was no
evidence of difference for theophylline (two studies) whereas the
CPOE with decision support significantly reduced excessive dos-
ing of targeted medications in one study on people with renal im-
pairment where physicians were randomized.
Hypothesis 2. Decisions on drug dosage based on
computer advice lead more often to a physiological
parameter being maintained within the desired range
(e.g. blood pressure or prothrombin time)
For this comparison, the outcomes analyzed was the proportion of
time forwhich the studied physiological parameterwasmaintained
within the target range (Analysis 2.1; Analysis 2.2; Analysis 2.3;
Figure 8; Figure 9; Figure 10).
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Figure 8. Forest plot of comparison: 2 Physiological parameters, outcome: 2.1 Oral anticoagulants: % time
in target INR range.
Figure 9. Forest plot of comparison: 2 Physiological parameters, outcome: 2.2 Insulin: % time in target
glucose range.
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Figure 10. Forest plot of comparison: 2 Physiological parameters, outcome: 2.3 Insulin: mean blood glucose
(mg/dL).
Oral anticoagulants (fifteen studies, eighteen comparisons):
proportion of time in target international normalized ratio
range
The main outcome reported was the percentage of time spent in
target INR range calculated for each participant as a mean time in
range using interpolation methods between INR values. Six com-
parisons analyzed the mean % of TIR using various INR ranges
(see Description of the intervention) (White 1987; Poller 1998
pop1; Poller 1998 pop2; Anderson 2007; Poller 2008 PARMA
5; Poller 2009 DAWN AC). The magnitude of effects differed
between studies and the statistical heterogeneity was high (I2 =
79%) but all studies were in favour of the computer groups: the
difference was significant in four studies (White 1987; Poller 1998
pop1; Poller 2008 PARMA 5; Poller 2009 DAWN AC), and did
not reach significance in two studies (Poller 1998 pop2 considering
outpatients in the stabilization period; and Anderson 2007 con-
sidering people starting oral anticoagulation). The pooled SMD
favoured the computer group (SMD 0.19, 95% CI 0.06 to 0.33;
MD 3.68%, 95% CI 0.90% to 6.45%) (Analysis 2.1; Figure 8).
In one study where GP practices were randomized, there was a
significant increase in percentage of time within 0.5 INR from
target, from 49.5% at baseline to 60% after implementing the
different interventions, but therewas no evidence that the increases
from baseline were different between the four intervention groups
(P value = 0.8) (Claes 2005). The increase was +8% (95% CI
2.0% to 13.5%) in the group with multifaceted education and
+11% (95% CI 5.5% to 16.5%) in the group with multifaceted
education plus DAWN AC computer-assisted advice.
Another comparison on people within target final PT time showed
no evidence of difference in anticoagulant control in people whose
dose was determined by computer, compared with those who were
treated by a nurse specialist (RR 0.87, 95% CI 0.47 to 1.61)
(White 1991). Finally, one comparison analyzed the proportion of
participants reaching a stable state of anticoagulation (three INR
measurements within therapeutic range) and was in favour of the
computer group compared with the control group (RR 1.46, 95%
CI 1.07 to 2.00) (Manotti 2001).
Five comparisons reported the number of days per 100 patient-
days of treatment spent in the INR therapeutic range but the
inconsistency across studies was very high (combined incidence
rate ratio 1.10, 95% CI 1.00 to 1.20, inconsistency I2 = 91%)
(Vadher 1997; Vadher 1997 pop1; Vadher 1997 pop2; Ageno
1998;Mitra 2005): in two studies, participants in the intervention
group spent significantly more time in the therapeutic range (
Vadher 1997 pop1; Mitra 2005), whereas there was no evidence
of difference in three studies.
Two comparisons analyzed the proportion of INRs measurements
within therapeutic range and were in favour of computerized ad-
vice of drug dosage (RR 1.10, 95% CI 1.02 to 1.19) (Ageno 1998;
Fitzmaurice 2000). Ageno 1998 and Ageno 2000 compared the
proportions of INRs above 5: there was no evidence of difference
between the computer and standard groups. In Claes 2005, dur-
ing the intervention period there was a significant difference in
per cent of participants with a least one INR above 5 between
the four intervention groups (P value = 0.009), but there was no
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evidence that the decreases from baseline were different between
the four intervention groups (P = 0.28) and group A (multifaceted
education) and group D (multifaceted education plus DAWNAC
computer-assisted advice) had the closest results. In Ageno 1998,
the INRs below 2 (underanticoagulated patients) were more in the
computer-controlled group than in the manual group (RR 1.55,
95% CI 1.11 to 2.16) whereas in Claes 2005 there was no statis-
tically significant difference from baseline in the decrease of per
cent of participants with at least one INR less than 2 (P = 0.67).
Insulin (ten studies): percentage of time in target glucose
range (four studies), hyperglycaemia index (nine studies)
Four studies of the CLINICIP project analyzed the percentage of
time in target glucose range (Plank 2006; Hovorka 2007; Blaha
2009; Cordingley 2009). The magnitude of effects differed be-
tween studies and the statistical heterogeneity was high (I2 = 83%)
but all studies were in favour of the computer groups: the differ-
ence was significant in three studies (Plank 2006; Hovorka 2007;
Cordingley 2009), and did not reach significance in one study
(Blaha 2009). The pooled SMD was in favour of the computer
group (SMD 1.27, 95% CI 0.56 to 1.98; MD 22.18%, 95% CI
9.94% to 34.43%) (Analysis 2.2; Figure 9).
In one study with a potential unit of analysis error, the percent-
age of time in target range was significantly higher with the com-
puter software program (SMD 1.91, 95% CI 1.70 to 2.11; MD
21.70%, 95% CI 20.02% to 23.38%) (Sato 2011). In the same
study, participants in the computer group were significantly more
likely to have all measurements within the target glycaemic range
than participants in the manual group (RR 9.00, 95% CI 1.27 to
63.89).
In aCBA study, the change inA1C (primary outcome)was -0.34%
± 0.49% in the group with the diabetes management system-based
decision support compared with +0.27% ± 0.67% in the group
without the system (MD -0.60%, 95% CI -0.96% to -0.25%)
(Augstein 2007).
Two studies analyzed the hyperglycaemic index (HGI) for the
assessment of glucose control (Pachler 2008; Cordingley 2009).
In Pachler 2008, the HGI was defined as the AUC above the
upper limit of normal (glucose level 6.1 mmol/L, modified from
the original 6.0 mmol/L) divided by the total length of stay (time
in study). The advantage of this measure of glucose control is the
independence of the number of measurements, and it is not falsely
lowered by hypoglycaemic values. In theory, the best HGI of 0.0
mM indicates that all glucose values were below the upper target
limit. An HGI around 2.0 mM shows that the person was exposed
on average to glucose values of 8.1mM (exceeding the upper target
limit of 6.1 mM) during the observed period. In general, a low
HGI and a low number of hypoglycaemic events indicate tight
and safe blood glucose control. In Cordingley 2009, there were
some inconsistencies in the text and tables so conclusions should
be made with caution: in one centre (n = 20) the HGI was not
significantly different between groups whereas in the other (n =
14) the HGI was significantly greater in the standard care group.
In Pachler 2008, the HGI was significantly lower in the computer
group (MD -1.20 mmol/L, 95% CI -1.63 to -0.77).
The time in blood glucose range was higher in the computer-
guided glucose management during surgery (Saager 2008: MD
57.00 minutes, 95% CI 9.57 to 104.43), and after surgery in
the intensive care unit (Kremen 2007; Saager 2008: pooled MD
257.92 minutes, 95% CI 60.96 to 454.87).
Nine studies reported the mean blood glucose with high hetero-
geneity (I2 = 86%, one study with opposite direction): the mean
blood glucose was significantly lower with the computer advice
(pooled SMD -0.72, 95% CI -1.03 to -0.42; pooled MD -14.81
mg/dL, 95% CI -22.06 to -7.56) (Analysis 2.3) (Plank 2006;
Augstein 2007; Hovorka 2007; Kremen 2007; Pachler 2008;
Saager 2008; Blaha 2009; Wexler 2010; Sato 2011). Excluding
two studies with potential unit of analysis error did not change the
conclusions (pooled SMD -0.55, 95% CI -0.83 to -0.27; pooled
MD -10.48 mg/dL, 95% CI -17.10 to -3.86) (Hovorka 2007;
Pachler 2008).
Aminoglycoside antibiotics (five studies)
No data available.
Theophylline (four studies)
No data available.
Anti-rejection drugs (four studies)
No data available.
Anaesthetic agents (two studies, three comparisons)
No data available.
Antidepressants (one study)
No data available.
Gonadotropins (one study)
No data available.
Summary
In summary, in spite of difference in magnitude effects, comput-
erized advice led more often to a physiological parameter within
the desired range for oral anticoagulants (significantly higher per-
centages of time in target INR range) and for insulin (significantly
higher percentages of time in target glucose, lower levels of mean
blood glucose).
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This result may be explained by the fact that computer advice
improved the sampling time and intervals for warfarin or insulin.
These two drugs have a narrow therapeutic window. They have
variable effects depending on the plasma concentration: a lower
dose is ineffective and a higher dose is hazardous. For these drugs,
sampling time is critical, since the drug concentration varies over
the entire dosing interval and with the duration of dosing in re-
lation to achieving a steady state. Sampling interval, the number
of sampling, is also important. For insulin, in three studies, this
interval was significantly lower in the computer groups (Hovorka
2007; Pachler 2008; Cordingley 2009), in one study, there was
no significant difference between groups (Blaha 2009), whereas in
one study, mean sampling intervals were significantly longer in the
computer-assisted group compared with the manual group (Sato
2011).
Hypothesis 3. Decisions on drug dosage based on
computer advice led to more rapid therapeutic
control, assessed by a physiological parameter
For this comparison, the outcomes analyzed were the time to
achieve therapeutic range and the time to stabilization (Analysis
3.1; Analysis 3.2; Figure 11; Figure 12).
Figure 11. Forest plot of comparison: 3 Time to achieve therapeutic control, outcome: 3.1 Time to achieve
therapeutic range.
Figure 12. Forest plot of comparison: 3 Time to achieve therapeutic control, outcome: 3.2 Time to
stabilization.
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Oral anticoagulants (fifteen studies, eighteen comparisons)
Two comparisons analyzed the “time to achieve” therapeutic PT
ratio (White 1987; Vadher 1997). There was no evidence of dif-
ference between groups (SMD -0.22, 95% CI -0.69 to 0.26; MD
-0.58 days, 95% CI -1.84 to 0.6).
Three comparisons analyzed the “time to stabilization” (Carter
1987; White 1987; Vadher 1997). In Carter 1987, the outcome
was reported for participants who achieved stable PT ratios before
discharge. The pooled effect showed a significant reduction in
time to achieve stabilization (SMD -0.56, 95% CI -1.07 to -0.04;
MD -2.49 days, 95% CI -3.93 to -1.05) even if there was an high
inconsistency (I2 = 71%).
Insulin (ten studies)
The “time to target” (time to establish blood glucose control)
for insulin was reported in three studies. In one study, the com-
puter advice led to less rapid control of glycaemia (Kremen 2007),
whereas there was no significant difference in Blaha 2009 and
Cordingley 2009. There was no evidence of difference between
groups (SMD 0.22, 95% CI -0.52 to 0.95; MD 0.53 hour, 95%
CI -1.22 to 2.27).
Aminoglycoside antibiotics (five studies)
No data available.
Theophylline (four studies)
No data available.
Anti-rejection drugs (four studies)
No data available.
Anaesthetic agents (two studies, three comparisons)
No data available.
Antidepressants (one study)
No data available.
Gonadotropins (one study)
No data available.
Summary
The pooled effect showed a significant reduction in time to achieve
stabilization for oral anticoagulants (three comparisons) whereas
there was no evidence of difference for insulin.
Hypothesis 4. Decisions on drug dosage based on
computer advice lead to more effectiveness, assessed
by clinical improvement
For this comparison, the outcomes analyzed was the proportion
of participants with clinical improvement (Analysis 4.1; Analysis
4.2; Figure 13; Figure 14). Forest plots are only presented for
aminoglycoside antibiotics and anti-rejection drugs (no study or
only one for other drugs).
Figure 13. Forest plot of comparison: 4 Clinical improvement, outcome: 4.1 Aminoglycoside antibiotics.
32Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 14. Forest plot of comparison: 4 Clinical improvement, outcome: 4.2 Anti-rejection drugs.
Anticoagulants (fifteen studies, eighteen comparisons)
No data available.
Insulin (ten studies)
No data available.
Aminoglycoside antibiotics (five studies)
Two studies reported efficacy outcomes. In Burton 1991, there
were no statistical differences in the number of participants cured
(RR 0.95, 95% CI 0.55 to 1.64), whereas in Leehey 1993, there
was more success to respond to treatment in the pharmacist-direct
dosing based on a Bayesian pharmacokinetic dosing program (RR
1.12, 95% CI to 1.03 to 1.23).
Theophylline (four studies)
No data available.
Anti-rejection drugs (four studies)
Two studies reported efficacy outcomes on biopsy-confirmed acute
rejections. In Asberg 2010, there were no statistical differences
in the number of participants without acute rejections (RR 0.94,
95% CI 0.71 to 1.25), whereas in Le Meur 2007, there were more
participants with clinical improvement (no acute rejections) in the
individualized MMF dosing group (RR 1.22, 95% CI 1.05 to
1.43).
Anaesthetic agents (two studies, three comparisons)
No data available.
Antidepressants (one study)
In Mihajlovic 2003, the participants from individualized or em-
piric doses of amitriptyline were evaluated clinically using the
Hamilton Depression Rating Scale (HAM-D; 21 items) and Clin-
ical Global Impression Scale (CGI). Total HAM-D scores were
significantly lower in the experimental group after day 28 (MD -
2.80, 95% CI -4.93 to -0.67). CGI scores had a statistically signif-
icant difference between the groups after day 28 for the three items
(in favour of the intervention for Severity of illness and Therapeu-
tic effect, and in favour of the control for Global improvement).
Gonadotropins (one study)
In the study on the effectiveness of a computerized decision sup-
port system for ovarian stimulation with gonadotropins (Lesourd
2002), there were no statistical differences in the number of partic-
ipants with clinical pregnancies (RR 1.15, 95% CI 0.59 to 2.27).
Summary
For each drug, there were, at most, two comparisons. Some com-
parisons showed significant improvement with computer advice
whereas there was no evidence of differences in others.
Hypothesis 5. Decisions on drug dosage based on
computer advice lead to fewer unwanted effects
For this comparison, we considered two outcomes: death and ad-
verse reactions.
Death
Ten comparisons analyzed death rates (Analysis 5.1; Figure 15).
Globally, there was no significant difference observed between the
computer and control groups (RR 1.08, 95% CI 0.80 to 1.45).
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Figure 15. Forest plot of comparison: 5 Clinical adverse events, outcome: 5.1 Death.
Clinical adverse events
Nineteen comparisons assessed the proportion of participants with
clinical adverse events. Since there was a great diversity of drugs
and of type of clinical adverse events, we did not pool the results
that were presented by drug.
Anticoagulants (fifteen studies, eighteen comparisons)
Bleeding events
The proportion of participants with bleeding events was available
in five comparisons (nine events in computer group, 15 events in
control group). In Ageno 2000, the minor bleeding events were
observed until discharge or until the seventh day of treatment,
in Vadher 1997; Vadher 1997 pop1; Vadher 1997 pop2, haem-
orrhagic events were collected during the follow-up (maximum
length of follow-up: 3 to 13months) and inWhite 1987, the bleed-
ing complicationswere collected duringhospitalization.Therewas
a trend towards fewer people with bleeding events although it did
not reach statistical significance (pooled RR 0.65, 95% CI 0.30
to 1.41) (Analysis 5.2; Figure 16).
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Figure 16. Forest plot of comparison: 5 Clinical adverse events, outcome: 5.2 Anticoagulants: events.
The participant exposure time was reported in four comparisons
but the bleeding incidence rate could be calculated only in three
comparisons (in Fitzmaurice 2000, there was no serious bleeding
in the control group). In two studies, there was significantly less
bleeding events in the computer group (Claes 2005; Poller 2008
PARMA 5), whereas the difference was not statistically significant
in one study (Poller 2009 DAWN AC). The pooled effect showed
a non-significant reduction in bleeding events with an estimated
rate ratio of 0.81 (95% CI 0.60 to 1.08) (Analysis 5.3; Figure 17).
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Figure 17. Forest plot of comparison: 5 Clinical adverse events, outcome: 5.3 Anticoagulants: event rates.
For heparin, there was no statistical difference in bleeding events
between the computer-assisted and the nomogram-directed ther-
apy (Mungall 1994).
Thromboembolism
In two studies, there was no thromboembolism due to undertreat-
ment in both computer and standard dosing groups (Vadher 1997
pop2;Mitra 2005). In two studies, the number of participantswith
thromboembolism tended to be higher in the computer group but
the pooled effect showed no statistical difference between groups
(pooled RR 3.25, 95% CI 0.66 to 16.03) (Vadher 1997; Vadher
1997 pop1) (Analysis 5.2; Figure 16).
For the incidence rate, in two studies, there was significantly less
thromboembolism events in the computer group (Fitzmaurice
2000; Claes 2005), whereas the difference was not significant in
two studies (Poller 2008 PARMA5; Poller 2009DAWNAC). The
pooled effect showed a significant reduction in thromboembolism
events with an estimated rate ratio of 0.68 (95% CI 0.49 to 0.94)
but the inconsistency was high (I2 = 65%) (Analysis 5.3; Figure
17).
Total clinical adverse events
In Anderson 2007, total clinical adverse events (clinical events plus
INR 4 or greater) were numerically fewer in the pharmacogenetic
than standard arm (34 versus 42), although the difference was not
significant (P value = 0.26) and the serious clinical events were
infrequent (pharmacogenetic 4, standard 5) and were unrelated to
out-of-range INRs.
In Mungall 1994 (heparin), there was a trend towards less clinical
adverse events in the computer-assisted heparin therapy compared
with nomogram-directed therapy (RR0.08, 95%CI 0.00 to 1.35).
Insulin (ten studies)
Hypoglycaemia
The proportion of participants with hypoglycaemia was available
in seven comparisons (11 events in computer group, 17 events
in control group). Hypoglycaemia was defined as blood glucose
less than 60 mg/dL (< 3.3 mmol/L) in three studies (Saager 2008;
Cordingley 2009; Wexler 2010), less than less 54 mg/dL (< 3.0
mmol/L) in one study (Plank 2006), and less than 52 mg/dL
(< 2.9 mmol/L) in three studies (Hovorka 2007; Kremen 2007;
Sato 2011). No significant difference was observed between the
computer and control groups (pooled RR 0.71, 95% CI 0.35 to
1.48) (Analysis 5.4; Figure 18).
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Figure 18. Forest plot of comparison: 5 Clinical adverse events, outcome: 5.4 Insulin.
Severe hypoglycaemia
The proportion of participants with severe hypoglycaemia was
available in four comparisons (one event in computer group, two
events in control group). Severe hypoglycaemia was defined as
blood glucose less than 40 mg/dL (< 2.2 mmol/L) in three studies
(Pachler 2008; Cordingley 2009; Wexler 2010), and less than less
41 mg/dL (< 2.3 mmol/L) in one study (Blaha 2009), and less
than 42 mg/dL (<2.9 mmol/L) in three studies (Hovorka 2007;
Kremen 2007; Sato 2011). No significant difference was observed
between the computer and control groups (pooled RR 0.69, 95%
CI 0.11 to 4.31).
Aminoglycoside antibiotics (five studies)
Nephrotoxicity
Four studies reported outcomes on nephrotoxicity (Begg 1989;
Destache 1990; Burton 1991; Leehey 1993). There was a trend
towards lower nephrotoxicity in computer group although the
difference was not significant (pooled RR 0.67, 95% CI 0.42 to
1.06) (Analysis 5.5; Figure 19).
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Figure 19. Forest plot of comparison: 5 Clinical adverse events, outcome: 5.5 Aminoglycoside antibiotics.
Need for dialysis
Leehey 1993 compared people who needed dialysis. No differ-
ence was observed between the pharmacist-directed dosing using a
Bayesian pharmacokinetic dosing program and the control group
(RR 0.30, 95% CI 0.03 to 2.86).
Theophylline (four studies)
Tachycardia
Casner 1993 analyzed the theophylline toxicity (including nausea,
vomiting, tremor, tachycardia and seizures): one participant had a
tachycardia in the kinetic group whereas there was no episode of
toxicity in the empiric group (RR 3.17, 95% CI 0.14 to 72.80).
Total clinical adverse events
InGonzalez 1989, adverse reactions occurred in 7%of participants
with population-based emergency department guidelines dosing,
and 10% of participants with Bayesian-derived pharmacokinetic
dosing (RR 1.62, 95% CI 0.32 to 8.26).
Anti-rejection drugs (four studies)
Cytomegalovirus infections
Two comparisons reported outcomes on cytomegalovirus infec-
tions (Le Meur 2007; Asberg 2010). No significant difference was
observed between the computer and control groups (pooled RR
0.90, 95% CI 0.58 to 1.40) (Analysis 5.6; Figure 20).
Figure 20. Forest plot of comparison: 5 Clinical adverse events, outcome: 5.6 Anti-rejection drugs.
38Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Total clinical adverse events
LeMeur 2007 analyzed clinical adverse events including anaemia,
leukopenia, gastrointestinal adverse events and infections. There
was no statistical difference between individualized doses based on
therapeutic monitoring of MPA and fixed-dose MMF (RR 1.07,
95% CI 0.98 to 1.17).
Anaesthetic agents (two studies, three comparisons)
Total clinical adverse events
In Rodman 1984, there was no clinical adverse event in the people
monitored clinically (monitoring of rhythm, intermittent hard-
copy rhythm strips, serial ECGs, dailymeasurements of electrolyte
and cardiac enzyme levels, liver function tests).
Antidepressants (one study)
Total clinical adverse events
The comparison of safety between individualized and empiric
dose regimen of amitriptyline in the treatment of major depres-
sive episode (Mihajlovic 2003) was studied in Mihajlovic 2010.
The CGI scale and originally designed questionnaire were used for
clinical adverse events assessment. In the experimental group, 69
complaints on nine different types of adverse effects were recorded
during the eight-week treatment period and in control group, 111
complaints on 12 different types of adverse effects were recorded.
Mihajlovic 2010 indicated that “significantly higher number of
patients complaining on adverse effects were in the control group”.
Nevertheless, none of the comparisons during the eight-week treat-
ment period was significant (RR: day 14 0.63, 95% CI 0.34 to
1.15; day 28 0.71, 95% CI 0.41 to 1.21; day 42 0.75, 95% CI
0.30 to 1.90; day 56 0.75, 95% CI 0.30 to 1.90).
Gonadotropins (one study)
No data available.
Summary
No significant difference on death was observed between the com-
puter and control groups. For clinical adverse events, we did not
pool the results because of the diversity of outcomes. There was
a trend for less nephrotoxicity for aminoglycoside antibiotics, for
less bleeding and thromboembolism events for anticoagulants with
the computer group.When considering the incidence rates for an-
ticoagulants, which is a more precise outcome measure taking into
account the exposure time, this difference was significant in favour
of the computer group for thromboembolism despite a high het-
erogeneity. There was no evidence of difference for insulin, theo-
phylline, anaesthetic agents, anti-rejection drugs and antidepres-
sants.
Hypothesis 6. Computer advice reduces the cost of
health care or the use of resources (length of stay)
For this comparison, the outcomes analyzed were the length of
stay (Analysis 6.1; Figure 21) and the cost per participant.
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Figure 21. Forest plot of comparison: 6 Healthcare resources, outcome: 6.1 Length of stay (days).
Length of stay
Nine comparisons analyzed the length of stay (oral anticoagulants:
White 1987; Mitra 2005; insulin: Wexler 2010; aminoglycoside:
Destache 1990; Burton 1991; theophylline: Hurley 1986; Verner
1992; Casner 1993; cyclosporine: Chertow 2001). There was a
significant reduction of the length of stay in the computer group
in four comparisons (Hurley 1986; White 1987; Burton 1991;
Chertow 2001), whereas the difference was not significant in five
comparisons. The pooled effect tended to be in favour of the
computer group (SMD -0.15, 95% CI -0.33 to 0.02).
Costs per participant and incremental cost-effectiveness ratio
Five studies analyzed the costs of interventions using computer
advice on drug dosage.
In Destache 1990, clinical pharmacokinetic service direct costs
were significantly lower than usual care (without clinical phar-
macokinetic service monitoring) for aminoglycoside antibiotics:
USD7102.56 ± 8898.18 compared with USD13,758.64 ±
22,874.31 (P value < 0.02).
In Chertow 2001, there were no significant differences between
intervention and control periods in estimated hospital and phar-
macy costs for cyclosporine.
In Claes 2006 (main results in Claes 2005), the total cost per
participant per month was EUR53.79 for usual care, EUR50.62
for intervention A (multifaceted intervention) and EUR53.20 for
intervention D (multifaceted intervention plus DAWN AC com-
puter advice) for anticoagulants.
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Jowett 2009 reported the cost-effectiveness for anticoagulants
of the randomized multicentre study of two computer-assisted
dosage programs (DAWN AC or PARMA 5) versus manual dos-
ing conducted by Poller et al. (Poller 2008 PARMA 5; Poller 2009
DAWN AC). Dosing time and costs were available in 28 of the 32
clinics participating. Total overall costs per participant were sig-
nificantly lower in the computer-dosing arm (EUR -50.5, boot-
strapped 95% CI -76.8 to -24.1), mainly driven by the differ-
ence in dosing costs. The authors concluded that computer-as-
sisted dosage with the two programs (DAWN AC and PARMA 5)
was not less effective clinically but was lower in cost than manual
dosage.
In Rousseau 2010 (main results in Le Meur 2007), the mean total
yearly cost per participant was EUR47,477 (95% CI 43,933 to
51,020) in the concentration-controlled group and EUR46,783
(95% CI 44,152 to 49,414) in the fixed-dose group (P value =
0.7) for mycophenolate.
In three studies (Claes 2006; Jowett 2009; Rousseau 2010), the in-
cremental cost-effectiveness ratio (ICER) was reported. The ICER
represents the additional cost required to provide one unit of addi-
tional effect. In Jowett 2009, as the costs were lower and the inter-
vention more favourable, calculation of an ICER in this case was
not appropriate. In Rousseau 2010, the incremental 12-month
cost was EUR3757 per treatment failure (Purchasing Power Par-
ities United States/France: USD4129). In Claes 2006, the ICER
for intervention A (multifaceted intervention) was EUR5.2 per
day within range (DWR) and for intervention D (multifaceted in-
tervention plus DAWNAC computer advice) EUR4.9 per DWR.
Intervention A was less effective but also slightly less costly com-
pared with D resulting in comparable cost-effectiveness ratios.
Summary
There was a trend to a reduction of the length of stay in the
computer groups. In most of trials, the computer-assisted dosage
was not less effective but was lower in cost than manual dosage
resulting in a comparable or better cost-effectiveness ratio than
usual care.
Subgroup analyses
No study compared the effect of decision support logistics or or-
ganizations of care. We found no studies where the computerized
advice was delivered by delayed feedback.
Since fewer than 10 studies were available for each characteristic
to model, we did not investigate heterogeneity.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Computerized advice on drug dosage for leading physiological parameters within therapeutic range
Patient or population: patients with leading physiological parameters within therapeutic range
Settings: outpatient/inpatient
Intervention: computerized advice on drug dosage
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Computerized advice on
drug dosage
Oral anticoagulants:
time in target INR range
(%)
- The mean oral anticoag-
ulants: time in target INR
range (%) in the interven-
tion groups was
0.19 standard deviations
higher
(0.06 to 0.33 higher)
- 13,581
(6 studies)
⊕©©©
very low1,2,3
SMD 0.19 (95% CI 0.06
to 0.33)
Insulin: time in target
glucose range (%)
- The mean insulin: time in
target glucose range (%)
in the intervention groups
was
1.27 standard deviations
higher
(0.56 to 1.98 higher)
- 234
(4 studies)
⊕⊕©©
low3,4,5
SMD 1.27 (95% CI 0.56
to 1.98)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; INR: international normalized ratio; SMD: standardized mean difference.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No information given on random sequence generation and allocation concealment in half of the studies.
2 I2 = 79%.
3 No funnel plot was performed since the validity conditions were not met.
4 No blinding of participants and personnel in all studies.
5 I2 = 83%.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
4
3
C
o
m
p
u
te
riz
e
d
a
d
v
ic
e
o
n
d
ru
g
d
o
sa
g
e
to
im
p
ro
v
e
p
re
sc
rib
in
g
p
ra
c
tic
e
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
3
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Computerized advice on drug dosage for reducing time to achieve therapeutic control
Patient or population: patients with reducing time to achieve therapeutic control
Settings: outpatient/inpatient
Intervention: computerized advice on drug dosage
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Computerized advice on
drug dosage
Time to achieve ther-
apeutic range - oral
anticoagulants: time to
achieve therapeutic pro-
thrombin ratio (days)
- The mean time to achieve
therapeutic range - oral
anticoagulants: time to
achieve therapeutic pro-
thrombin ratio (days) in
the intervention groups
was
0.22 standard deviations
lower
(0.69 lower to 0.26
higher)
- 223
(2 studies)
⊕⊕©©
low1,2,3
SMD -0.22 (95% CI -0.69
to 0.26)
Time to achieve thera-
peutic range - insulin:
time to achieve thera-
peutic control (hours)
- The mean time to
achieve therapeutic range
- insulin: time to
achieve therapeutic con-
trol (hours) in the inter-
vention groups was
0.14 standard deviations
lower
(0.98 lower to 0.7 higher)
- 194
(4 studies)
⊕©©©
very low3,4,5
SMD -0.14 (95% CI -0.98
to 0.7)
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Time to stabilization
- oral anticoagulants:
time to stabilization
(days)
- The mean time to stabi-
lization - oral anticoagu-
lants: time to stabilization
(days) in the intervention
groups was
0.56 standard deviations
lower
(1.07 to 0.04 lower)
- 255
(3 studies)
⊕©©©
very low3,6,7
SMD -0.56 (95% CI -1.07
to -0.04)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; SMD: standardized mean difference.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Allocation concealment was unclear, and there was no blinding of participants and personnel in both studies.
2 I2 = 66%.
3 No funnel plot performed but very small studies in favour of the intervention.
4 In all studies: the random sequence generation and the allocation concealment were unclear, and there was no blinding of participants
and personnel.
5 I2 = 86%. Meta-analysis should be interpreted with caution.
6 Sequence generation and/or allocation concealment were unclear in all studies. There was no blinding of participants and personnel in
all studies. Data were incomplete in two studies.
7 I2 = 71%.
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Computerized advice on drug dosage for leading to fewer clinical adverse events
Patient or population: patients with leading to fewer clinical adverse events
Settings: outpatient/inpatient
Intervention: computerized advice on drug dosage
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Computerized advice on
drug dosage
Death Study population RR 1.08
(0.8 to 1.45)
14,046
(10 studies)
⊕⊕©©
low1,2
-
12 per 1000 13 per 1000
(10 to 18)
Moderate
28 per 1000 30 per 1000
(22 to 41)
Anticoagulants: events -
bleeding
Study population RR 0.65
(0.3 to 1.41)
552
(6 studies)
⊕⊕©©
low2,3
-
61 per 1000 40 per 1000
(18 to 86)
Moderate
65 per 1000 42 per 1000
(20 to 92)
Anticoagulants: events -
thromboembolism
Study population RR 3.25
(0.66 to 16.03)
355
(4 studies)
⊕©©©
very low2,4,5
-
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11 per 1000 36 per 1000
(7 to 176)
Moderate
7 per 1000 23 per 1000
(5 to 112)
Insulin - hypoglycaemia
(<60 mg/dL)
Study population RR 0.71
(0.35 to 1.48)
378
(7 studies)
⊕⊕©©
low2,6
-
90 per 1000 64 per 1000
(31 to 133)
Moderate
67 per 1000 48 per 1000
(23 to 99)
Insulin - severe hypogly-
caemia (<40 mg/dL)
Study population RR 0.69
(0.11 to 4.31)
292
(4 studies)
⊕©©©
very low2,7,8
-
14 per 1000 9 per 1000
(2 to 59)
Moderate
8 per 1000 6 per 1000
(1 to 34)
Aminoglycoside antibi-
otics - nephrotoxicity
Study population RR 0.67
(0.42 to 1.06)
493
(4 studies)
⊕⊕©©
low2,9
-
162 per 1000 108 per 1000
(68 to 172)
Moderate
154 per 1000 103 per 1000
(65 to 163)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No (or unclear) blinding of participants and personnel in all studies. In half of the studies: sequence generation and/or allocation
concealment were unclear, and the data were incomplete.
2 No funnel plot was performed since the validity criteria were not met.
3 In all studies: sequence generation or allocation concealment, or both were unclear, and there was no blinding of participants or
personnel. Data were incomplete or unclear in four studies.
4 Allocation concealment was unclear in all studies. There was no blinding of participants and personnel in all studies and the blinding of
outcome assessment was unclear in one study. Data were incomplete or unclear in all studies.
5 Large confidence intervaI due to very small studies (n = 335 for four studies) and a few events (n = 8).
6 No (or unclear) sequence generation or allocation concealment, or both in all studies. No (or unclear) blinding of participants or
personnel in all studies. Selective reporting in one study.
7 Random sequence generation and allocation concealment were unclear in half of the studies. No (or unclear) blinding of participants
or personnel in all studies.
8 Large confidence interval due to only three events for 292 participants.
9 No blinding of participants and personnel in all studies. Incomplete outcome data in three studies. Baseline characteristics not
comparable in one study.
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Saving healthcare resources for saving healthcare resources
Patient or population: saving healthcare resources
Settings:
Intervention: saving healthcare resources
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Saving healthcare re-
sources
Length of stay (days) - The mean length of stay
(days) in the intervention
groups was
0.15 standard deviations
lower
(0.33 lower to 0.02
higher)
- 18,507
(9 studies)
⊕©©©
very low1,2
SMD -0.15 (95% CI -0.33
to 0.02)
Length of stay (days) -
oral anticoagulants
- The mean length of stay
(days) - oral anticoagu-
lants in the intervention
groups was
0.12 standard deviations
lower
(1.1 lower to 0.86 higher)
- 105
(2 studies)
⊕©©©
very low2,3,4,5
SMD -0.12 (95% CI -1.1
to 0.86)
Length of stay (days) -
insulin
- The mean length of stay
(days) - insulin in the in-
tervention groups was
0.18 standard deviations
higher
(0.17 lower to 0.53
higher)
- 128
(1 study)
⊕⊕⊕⊕
high6
SMD 0.18 (95% CI -0.17
to 0.53)
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Length of stay (days) -
theophylline
- The mean length of stay
(days) - theophylline in
the intervention groups
was
0.2 standard deviations
lower
(0.56 lower to 0.16
higher)
- 151
(3 studies)
⊕⊕©©
low2,7,8
SMD -0.2 (95% CI -0.56
to 0.16)
Length of stay (days)
- aminoglycoside antibi-
otics
- The mean length of stay
(days) - aminoglycoside
antibiotics in the interven-
tion groups was
0.35 standard deviations
lower
(0.58 to 0.12 lower)
- 295
(2 studies)
⊕⊕⊕©
moderate2,9
SMD -0.35 (95% CI -0.58
to -0.12)
Length of stay (days) -
anti-rejection drugs
- The mean length of stay
(days) - anti-rejection
drugs in the intervention
groups was
0.04 standard deviations
lower
(0.07 to 0.01 lower)
- 17,828
(1 study)
⊕⊕⊕©
moderate2,10
SMD -0.04 (95% CI -0.07
to -0.01)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; SMD: standardized mean difference.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 I2 = 57%.
2 No funnel plot was performed since the validity criteria were not met.5
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3 No blinding of participants and personnel in all studies, and blinding of outcome assessment unclear in half of the studies. Random
sequence generation or allocation concealment, or both unclear in all studies.
4 I2 = 81%. Meta-analysis should be interpreted with caution.
5 Although small studies (n = 105 for all the studies).
6 To be interpreted with caution since based on only one monocentric study of 128 participants.
7 No blinding of participants and personnel in the three studies. No or unclear random sequence generation and allocation concealment
in two studies.
8 Although small studies (n = 151 for all studies).
9 No blinding of participants and personnel in all studies.
10 Alternating time series design with four consecutive two-month period.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
This update found similar results to the previous review (Durieux
2008), and, in addition, specific therapeutic areas where the in-
tervention is beneficial (the level of evidence was based upon the
’Summary of findings’ tables):
1. For oral anticoagulants, CDSS ledmore often to an INR within
the desired range and reduced the time to achieve stabilization of
PT and the incidence rates of thromboembolism, in a statistical
significant manner.
2. For insulin, it significantly improved the percentage of time in
target glucose and reduced the mean blood glucose. For clinical
outcomes, there was no efficacy outcome assessed and the differ-
ence for safety outcomes was not statistically significant.
3. For aminoglycoside antibiotics, it was significantly more ef-
ficient for reaching appropriate drug serum concentrations. For
clinical outcomes, positive treatment response was inconsistent in
the two studies.
For all these drugs, the quality of evidence was very low due to the
high heterogeneity, the low quality and small sample size in most
of studies.
4. For the other drugs (theophylline, anti-rejection drugs, anaes-
thetic agents, antidepressants and gonadotropins), the level of ev-
idence was too low (small number and sample size of studies) to
conclude.
5. Overall, CDSS tended to reduce the length of stay but the
difference did not reach statistical significance.Quality of evidence
by drugs was low or moderate since there were generally only one
or two trials studying this outcome. In most trials, the computer-
assisted dosage had lower or equivalent costs than manual dosage.
Overall completeness and applicability of
evidence
This review included 46 comparisons, of which 18 (39%) con-
cerned anticoagulants and 10 (22%) insulin dosage, providing
more consistent results for these drugs than for others (fewer than
five comparisons). Five comparisons (10%) concerned aminogly-
coside antibiotics but all studieswere published before 1993.Three
comparisons concerned theophylline, a drug that is not consid-
ered as the first-choice treatment of asthma at present. However,
monitoring serum concentrations of theophylline is essential to
ensure that non-toxic doses are achieved (National Asthma 2002).
Compared with the last version of this review, our update included
new drugs such as insulin and anti-rejection drugs. We found no
studies concerning some new drugs for which it is considered im-
portant to monitor drug levels such as glycopeptides, antifungal
(fluconazole) and antiretroviral drugs. CDSS may be more effi-
cient in sampling time and intervals for drugs with a narrow ther-
apeutic window such as insulin or oral anticoagulants. However,
we found no studies for other drugs with narrow therapeutic in-
dexes (such as lithium, vancomycin, levothyroxine, digoxin, car-
bamazepine and phenytoin).
Quality of the evidence
However, the findings need to be read with caution.
First, the quality of studies was generally low (see ’Summary of
findings’ tables). There was no blinding of participants and per-
sonnel in all studies. The random sequence generation or the al-
location concealment, or both were unclear in half of the studies.
In most comparisons, sample size was small.
Second, even when grouping the studies by drug, heterogeneity
remained high because of the widely different outcome defini-
tions, clinical contexts or organizations of care. This issue limits
the comparability between studies and the interpretation of the
clinical significance of the results presented with the SMDs. Be-
sides, the intervention type varied between studies. For example,
Anderson 2007 used a pharmacogenetic guidance program for
warfarin initiation. This differs totally with all the other studies
on oral anticoagulants.
Third, for some indicators (length of stay, mortality), crude results
can be affected by unknown confounding factors.
Last, the results are significant for relevant physiological outcomes
(assessed for oral anticoagulants and insulin). However, efficacy
clinical outcomes were assessed only for four drugs (aminogly-
coside antibiotics, anti-rejection drugs, antidepressants and go-
nadotropins) and there were at most two comparisons for each
drug. For aminoglycoside antibiotics and anti-rejection drugs (two
comparisons), the studies showed contradictory results.
For safety clinical events, no significant difference on death was
observed between the computer and control groups. For clinical
adverse events, there was a trend for less nephrotoxicity for amino-
glycoside antibiotics, for fewer bleeding and thromboembolism
events for anticoagulants with the computer group. When consid-
ering the incidence rates for thromboembolism, this difference was
significantly in favour of the computer group for anticoagulants
despite a high heterogeneity. There was no significant difference
in clinical adverse events for the other drugs.
Potential biases in the review process
We identified no potential biases. We considered congress reports
and other sources of unpublished studies.
Agreements and disagreements with other
studies or reviews
Nine reviews assessed the effect of computer advice ondrugdosage.
All found a low methodological quality and a high heterogeneity
52Computerized advice on drug dosage to improve prescribing practice (Review)
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of studies included. Most presented a publication bias or no eval-
uation of the methodological quality of the studies included. We
could not compare our results with seven reviews that reported
their quantitative results as the percentage of studies that showed
a significant improvement with computer advice (Garg 2005 up-
dated by Nieuwlaat 2011a; Yourman 2008; Eslami 2009; Mollon
2009; Pearson 2009; Robertson 2010).
Two old reviews (Chatellier 1998; Fitzmaurice 1998a) suggested
that computer advice may improve therapeutic INR control for
oral anticoagulants, but no meta-analysis was performed and the
evaluation of the quality of studies included was not clear or ade-
quate.
Eslami 2009 performed a systematic review on tight glycaemic
control with insulin in intensive care units, but performed no
meta-analysis because of the high heterogeneity. The results were
expressed as the percentage of studies that showed a significant
improvement with computer advice on the blood glucose regu-
latory process. Although most studies reported a positive effect,
the evidence was very low: the review only searched for published
studies in MEDLINE, there was no evaluation of the method-
ological quality of studies, which were mostly before-after designs.
Causality was difficult to determine because of the simultaneous
implementation of a new tight glycaemic control protocol with
computer advice.
Three other reviews assessed the effect of computer advice more
generally on all drugs, focusing on drug dosage, but their results
were expressed as the percentage of studies that showed a significant
improvement with computer advice (Mollon 2009; Pearson 2009;
Robertson 2010). Mollon 2009 excluded all RCTs that focused
only on dose adjustment.
Two reviews assessed the general benefits of computer advice:
Yourman 2008 for improving medication prescribing in older
adults and Garg 2005, updated by Nieuwlaat 2011a, for drug
monitoring and dosing. Unlike us, their results were the percent-
age of studies that showed a significant improvement with com-
puter advice. A study was considered to have a positive effect (i.e.
CDSS showed improvement) if at least 50% of the relevant study
outcomes were statistically significantly positive. This approach
does not give insight in the magnitude of effects and may have
underestimated the overall efficacy. In contrast, there is a risk for
publication bias of positive RCTs, which could cause overestima-
tion of CDSS efficacy. Yourman 2008 found that computer ad-
vice was effective in improving medication prescribing in older
adults, and Nieuwlaat 2011a in improving the process of care. In
Yourman 2008, there was no evaluation of the methodological
quality of included studies, a likely publication bias and a high
heterogeneity. In Nieuwlaat 2011a, the studies were small and of
low quality when using a 10-point-scale extended from the Jadad
scale.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. Analysis of trials suggests that computerized advice for drug
dosage has some benefits over routine care. It increases the serum
concentrations for aminoglycoside antibiotics. It improves the pro-
portion of time for which the plasma drug is within the therapeu-
tic range for aminoglycoside antibiotics and theophylline. It leads
to a physiological parameter more often within the desired range
for oral anticoagulants and insulin. It decreases the time to achieve
stabilization for oral anticoagulants. It also reduces the length of
hospital stay, and tends to decrease unwanted effects of anti-re-
jection drugs and aminoglycoside antibiotics. It significantly de-
creases unwanted effects for anticoagulants.
2. The results are based on studies mainly of low quality, concern-
ing a small number of drugs. Even when analyzing by drugs, the
heterogeneity was important for half of the outcomes.
3. No conclusion could be drawn concerning the logistics of the
computerized support and organization of care aspects. It is not
certain that these benefits could be achieved with different com-
puter systems in different clinical situations.
Implications for research
1.More studies are needed to demonstrate that the use of comput-
ers improves the quality of care. Well-designed trials randomized
by clusters are mandatory for assessment of the effect of comput-
erized support systems on drug dosage.
2. These studies should address the identification of the factors that
predict a successful and acceptable system: the decision support
logistics, the organizations of care and the healthcare professionals’
characteristics.
3. Studies evaluating other drugs with a narrow therapeutic
window or complicated pharmacokinetics (e.g. antibiotics) are
needed. These studies should address the identification of the fac-
tors that predict a successful and acceptable system: the decision
support logistics, the organizations of care and the healthcare pro-
fessionals’ characteristics.
4. Since the last update in 2008, we have found 22 additional trials,
which indicate that this field is in rapid extension, especially with
the advent of computer physician order entry (CPOE) systems.
Future research should look at other directions than only drug
dosage.
A C K N OW L E D G E M E N T S
The authors thank: Michelle Fiander, Effective Practice and Or-
ganisation of Care (EPOC) Trials Search Co-ordinator for re-
designing and optimizing search strategies for this review and for
53Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
writing the searchmethods for us; her revisions to the search strate-
gies identified previously unidentified studies; Elske Ammenwerth
for her review of an article in German; and Lucienne Boujon who
provided English corrections. We would also like to thank Jessie
McGowan and Doug Salzwedel for their assistance with search-
ing for previous versions of this review; and Alan Forster and Jim
Wright for their helpful comments on earlier versions of this re-
view.
R E F E R E N C E S
References to studies included in this review
Ageno 1998 {published data only}
Ageno W, Turpie AG. A randomized comparison of a
computer-based dosing program with a manual system to
monitor oral anticoagulant therapy. Thrombosis Research
1998;91(5):237–40.
Ageno 2000 {published data only}
Ageno W, Johnson J, Nowacki B, Turpie AG. A computer
generated induction system for hospitalized patients starting
on oral anticoagulant therapy. Thrombosis & Haemostasis
2000;83(6):849–52. [: 0340–6245]
Anderson 2007 {published data only}
Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S,
et al.Randomized trial of genotype-guided versus standard
warfarin dosing in patients initiating oral anticoagulation.
Circulation 2007;116(22):2563–70.
Anderson 2008 {published data only}
Anderson JL. A double blind randomised trial of genotype
guided versus standard warfarin dosing in patients initiated
on oral anticoagulation: the COUMAGEN study. Clinical
Research in Cardiology 2008;97:8.
Asberg 2010 {published data only}
Asberg A, Falck P, Undset LH, Dorje C, Holdaas H,
Hartmann A, et al.Computer-assisted cyclosporine dosing
performs better than traditional dosing in renal transplant
recipients: results of a pilot study. Therapeutic Drug
Monitoring 2010;32(2):152–8.
Augstein 2007 {published data only}
Augstein P, Vogt L, Kohnert KD, Freyse EJ, Heinke P,
Salzsieder E. Outpatient assessment of Karlsburg Diabetes
Management System-based decision support. Diabetes Care
2007;30(7):1704–8.
Begg 1989 {published data only}
Begg EJ, Atkinson HC, Jeffery GM, Taylor NW.
Individualised aminoglycoside dosage based on
pharmacokinetic analysis is superior to dosage based
on physician intuition at achieving target plasma drug
concentrations. British Journal of Clinical Pharmacology
1989;28(2):137–41.
Blaha 2009 {published data only}
Blaha J, Kopecky P, Matias M, Hovorka R, Kunstyr J,
Kotulak T, et al.Comparison of three protocols for tight
glycemic control in cardiac surgery patients. Diabetes Care
2009;32:757–61.
Burton 1991 {published data only}
Burton ME, Ash CL, Hill DPJ, Handy T, Shepherd
MD, Vasko MR. A controlled trial of the cost benefit of
computerized Bayesian aminoglycoside administration.
Clinical Pharmacology and Therapeutics 1991;49(6):685–94.
Carter 1987 {published data only}
Carter BL, Taylor JW, Becker A. Evaluation of three dosage-
prediction methods for initial in-hospital stabilization of
warfarin therapy. Clinical Pharmacy 1987;6(1):37–45.
Casner 1993 {published data only}
Casner PR, Reilly R, Ho H. A randomized controlled trial
of computerized pharmacokinetic theophylline dosing
versus empiric physician dosing. Clinical Pharmacology and
Therapeutics 1993;53(6):684–90.
Chertow 2001 {published data only}
Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J,
Seger DL, et al.Guided medication dosing for inpatients
with renal insufficiency. JAMA 2001;286(22):2839–44.
Claes 2005 {published data only}
Claes N, Buntinx F, Vijgen J, Arnout J, Vermylen J,
Fieuws S, et al.The Belgian Improvement Study on Oral
Anticoagulation Therapy: a randomized clinical trial.
European Heart Journal 2005;26:2159–65.
Claes 2006 {published data only}
Claes N, Moeremans K, Frank B, Jef A, Jos V, Herman VL,
et al.Estimating the cost-effectiveness of quality-improving
interventions in oral anticoagulation management within
general practice. Value in Health 2006;9:369–76.
Cordingley 2009 {published data only}
Cordingley JJ, Vlasselaers D, Dormand NC, Wouters PJ,
Squire SD, Chassin LJ, et al.Intensive insulin therapy:
enhanced Model Predictive Control algorithm versus
standard care. Intensive Care Medicine 2009;35(1):123–8.
Destache 1990 {published data only}
Destache CJ, Meyer SK, Bittner MJ, Hermann KG. Impact
of a clinical pharmacokinetic service on patients treated
with aminoglycosides: a cost-benefit analysis. Therapeutic
Drug Monitoring 1990;12(5):419–26.
54Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fitzmaurice 2000 {published data only}
Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan
TF, Rose PE. Oral anticoagulation management in primary
care with the use of computerized decision support and
near-patient testing: a randomized, controlled trial. Archives
of Internal Medicine 2000;160(15):2343–8.
Gonzalez 1989 {published data only}
Gonzalez ER, Vanderheyden BA, Ornato JP, Comstock
TG. Computer-assisted optimization of aminophylline
therapy in the emergency department. American Journal of
Emergency Medicine 1989;7(4):395–401.
Hickling 1989 {published data only}
Hickling K, Begg E, Moore ML. A prospective randomised
trial comparing individualised pharmacokinetic dosage
prediction for aminoglycosides with prediction based on
estimated creatinine clearance in critically ill patients.
Intensive Care Medicine 1989;15(4):233–7.
Hovorka 2007 {published data only}
Hovorka R, Kremen J, Blaha J, Matias M, Anderlova
K, Bosanska L, et al.Blood glucose control by a model
predictive control algorithm with variable sampling rate
versus a routine glucose management protocol in cardiac
surgery patients: a randomized controlled trial. Journal of
Clinical Endocrinology & Metabolism 2007;92:2960–4.
Hurley 1986 {published data only}
Hurley SF, Dziukas LJ, McNeil JJ, Brignell MJ. A
randomized controlled clinical trial of pharmacokinetic
theophylline dosing. American Review of Respiratory Disease
1986;134(6):1219–24.
Jowett 2009 {published data only}
Jowett S, Bryan S, Poller L, Van Den Besselaar AMHP, Van
Der Meer FJM, Palareti G, et al.The cost-effectiveness of
computer-assisted anticoagulant dosage: results from the
European Action on Anticoagulation (EAA) multicentre
study. Journal of Thrombosis & Haemostasis 2009; Vol. 7,
issue 9:1482–90.
Kremen 2007 {published data only}
Kremen J, Blaha J, Kopecky P, Bosansk L, Kotrlikova
E, Roubicek T, et al.The treatment of hyperglycaemia in
critically ill patients: comparison of standard protocol and
computer algorithm [In Czech]. Vnitrni Lekarstvi 2007;53
(12):1269–73.
Leehey 1993 {published data only}
Leehey DJ, Braun BI, Tholl DA, Chung LS, Gross CA,
Roback JA, et al.Can pharmacokinetic dosing decrease
nephrotoxicity associated with aminoglycoside therapy.
Journal of the American Society of Nephrology 1993;4:81–90.
Le Meur 2007 {published data only}
Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F,
Lavaud S, et al.Individualized mycophenolate mofetil dosing
based on drug exposure significantly improves patient
outcomes after renal transplantation. American Journal of
Transplantation 2007;7(11):2496–503. [: 1600–6135]
Le Meur 2007 extract {published data only}
Individualized dosing of MMF is superior to fixed dosing
in renal transplant patients. Nature Clinical Practice
Nephrology 2008; Vol. 4, issue 1:9. [: 1745–8323]
Lesourd 2002 {published data only}
Lesourd F, Avril C, Boujennah A, Parinaud J. A
computerized decision support system for ovarian
stimulation by gonadotropins. Fertility and Sterility 2002;
77(3):456–60.
Manotti 2001 {published data only}
Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori
AG. Effect of computer-aided management on the quality
of treatment in anticoagulated patients: a prospective,
randomized, multicenter trial of APROAT (Automated
Program for Oral Anticoagulant Treatment). Haematologica
2001;86(10):1060–70.
Mihajlovic 2003 {published data only}
Mihajlovic GS, Milovanovic DR, Jankovic SM. Comparison
of efficacy and safety between individualized and empiric
dose regimen of amitriptyline in the treatment of major
depressive episode. Psychiatry & Clinical Neurosciences 2003;
57(6):580–5. [: 1323–1316]
Mihajlovic 2010 {published data only}
Mihajlovic G, Djukic-Dejanovic S, Jovanovic-Mihajlovic
N, Jankovic S, Janjic V, Jovanovic M, et al.Comparison of
safety between individualized and empiric dose regimen of
amitriptyline in the treatment of major depressive episode.
Psychiatria Danubina 2010; Vol. 22, issue 2:354–7. [:
0353–5053]
Mitra 2005 {published data only}
Mitra R, Marciello MA, Brain C, Ahangar B, Burke DT.
Efficacy of computer-aided dosing of warfarin among
patients in a rehabilitation hospital. American Journal of
Physical Medicine & Rehabilitation 2005;84(6):423–7. [:
0894–9115]
Mungall 1994 {published data only}
Mungall DR, Anbe D, Forrester PL, Luoma T, Genovese R,
Mahan J, et al.A prospective randomized comparison of the
accuracy of computer-assisted versus GUSTO nomogram-
-directed heparin therapy. Clinical Pharmacology and
Therapeutics 1994;55(5):591–6.
Pachler 2008 {published data only}
Pachler C, Plank J, Weinhandl H, Chassin LJ, Wilinska ME,
Kulnik R, et al.Tight glycaemic control by an automated
algorithm with time-variant sampling in medical ICU
patients. Intensive Care Medicine 2008;34(7):1224–30. [:
0342–4642]
Plank 2006 {published data only}
Plank J, Blaha J, Cordingley J, Wilinska ME, Chassin LJ,
Morgan C, et al.Multicentric, randomized, controlled trial
to evaluate blood glucose control by the model predictive
control algorithm versus routine glucose management
protocols in intensive care unit patients. Diabetes Care
2006;29(2):271–6. [: 0149–5992]
55Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Poller 1998 pop1 {published data only}
Poller L, Shiach CR, MacCallum PK, Johansen AM,
Munster AM, Magalhaes A, et al.Multicentre randomised
study of computerised anticoagulant dosage. European
Concerted Action on Anticoagulation. Lancet 1998;352
(9139):1505–9.
Poller 1998 pop2 {published data only}
Poller L, Shiach CR, MacCallum PK, Johansen AM,
Munster AM, Magalhaes A, et al.Multicentre randomised
study of computerised anticoagulant dosage. European
Concerted Action on Anticoagulation. Lancet 1998;352
(9139):1505–9.
Poller 2002 {published data only}
Poller L. European Concerted Action on Anticoagulation
(ECAA): studies on computer-assisted anticoagulant dosage.
Turkish Journal of Haematology 2002;19(2):179–84. [:
1300–7777]
Poller 2003 {published data only}
Poller L, Jespersen J, Tripodi A, Van Den Besselaar AMHP,
Van der Mer FJM, Shiac C, et al.European Action on Anti-
coagulation - cost effectiveness of computer assisted anti-
coagulant dosage. Journal of Thrombosis & Haemostasis
2003;1(Suppl 1):Abstract.
Poller 2008 {published data only}
Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie
AG, et al.An international multicenter randomized study
of computer-assisted oral anticoagulant dosage vs. medical
staff dosage. Journal of Thrombosis & Haemostasis 2008;
Vol. 6, issue 6:935–43.
Poller 2008 PARMA 5 {published data only}
Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie
AG, et al.A multicentre randomised clinical endpoint study
of PARMA 5 computer-assisted oral anticoagulant dosage.
British Journal of Haematology 2008; Vol. 143, issue 2:
274–83.
Poller 2009 DAWN AC {published data only}
Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie
AG, et al.A multicentre randomised assessment of the
DAWN AC computer-assisted oral anticoagulant dosage
program. Thrombosis & Haemostasis 2009;101(3):487–94.
[: 0340–6245]
Poller 2009 erratum {published data only}
Poller. Erratum: A multicentre randomised assessment of
the DAWN AC computer-assisted oral anticoagulant dosage
program (Thrombosis and Haemostasis (2009) 101 (487-
494)). Thrombosis and Haemostasis 2009;101(4):794. [:
0340–6245]
Rodman 1984 {published data only}
Rodman JH, Jelliffe RW, Kolb E, Tuey DB, de Guzman MF,
Wagers PW, et al.Clinical studies with computer-assisted
initial lidocaine therapy. Archives of Internal Medicine 1984;
144(4):703–9.
Rousseau 2010 {published data only}
Rousseau A, Laroche M-L, Venisse N, Loichot-Roselmac
C, Turcant A, Hoizey G, et al.Cost-effectiveness analysis
of individualized mycophenolate mofetil dosing in
kidney transplant patients in the APOMYGRE trial.
Transplantation 2010; Vol. 89, issue 10:1255–62.
Saager 2008 {published data only}
Saager L, Collins GL, Burnside B, Tymkew H, Zhang L,
Jacobsohn E, et al.A randomized study in diabetic patients
undergoing cardiac surgery comparing computer-guided
glucose management with a standard sliding scale protocol.
Journal of Cardiothoracic & Vascular Anesthesia 2008; Vol.
22, issue 3:377–82.
Sato 2011 {published data only}
Sato T, Carvalho G, Sato H, Lattermann R, Schricker T.
Glucose and insulin administration while maintaining
normoglycemia during cardiac surgery using a computer-
assisted algorithm. Diabetes Technology & Therapeutics
2011;13:79–84.
Terrell 2010 {published data only}
Terrell KM, Perkins AJ, Hui SL, Callahan CM, Dexter PR,
Miller DK. Computerized decision support for medication
dosing in renal insufficiency: a randomized, controlled trial.
Annals of Emergency Medicine 2010; Vol. 56, issue 6:
623–9.
Theil 1993 fentanyl {published data only}
Theil DR, Stanley TE 3rd, White WD, Goodman DK,
Glass PS, Bai SA, et al.Midazolam and fentanyl continuous
infusion anesthesia for cardiac surgery: a comparison of
computer-assisted versus manual infusion systems. Journal
of Cardiothoracic and Vascular Anesthesia 1993;7(3):300–6.
Theil 1993 midazolam {published data only}
Theil DR, Stanley TE 3rd, White WD, Goodman DK,
Glass PS, Bai SA, et al.Midazolam and fentanyl continuous
infusion anesthesia for cardiac surgery: a comparison of
computer-assisted versus manual infusion systems. Journal
of Cardiothoracic and Vascular Anesthesia 1993;7(3):300–6.
Vadher 1997 {published data only}
Vadher B, Patterson DL, Leaning M. Evaluation of a
decision support system for initiation and control of oral
anticoagulation in a randomised trial. BMJ 1997;314
(7089):1252–6.
Vadher 1997 pop1 {published data only}
Vadher BD, Patterson DL, Leaning M. Comparison of
oral anticoagulant control by a nurse-practitioner using a
computer decision-support system with that by clinicians.
Clinical and Laboratory Haematology 1997;19(3):203–7.
Vadher 1997 pop2 {published data only}
Vadher BD, Patterson DL, Leaning M. Comparison of
oral anticoagulant control by a nurse-practitioner using a
computer decision-support system with that by clinicians.
Clinical and Laboratory Haematology 1997;19(3):203–7.
Verner 1992 {published data only}
Verner D, Seligmann H, Platt S, Dany S, Almog S, Zulty
L, et al.Computer assisted design of a theophylline dosing
regimen in acute bronchospasm: serum concentrations and
clinical outcome. European Journal of Clinical Pharmacology
1992;43(1):29–33.
56Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wexler 2010 {published data only}
Wexler DJ, Shrader P, Burns SM, Cagliero E. Effectiveness
of a computerized insulin order template in general medical
inpatients with type 2 diabetes: a cluster randomized trial.
Diabetes Care 2010; Vol. 33, issue 10:2181–3.
White 1987 {published data only}
White RH, Hong R, Venook AP, Daschbach MM, Murray
W, Mungall DR, et al.Initiation of warfarin therapy:
comparison of physician dosing with computer-assisted
dosing. Journal of General Internal Medicine 1987;2(3):
141–8.
White 1991 {published data only}
White RH, Mungall D. Outpatient management of
warfarin therapy: comparison of computer-predicted dosage
adjustment to skilled professional care. Therapeutic Drug
Monitoring 1991;13(1):46–50.
References to studies excluded from this review
Abbrecht 1982 {published data only}
Abbrecht PH, O’Leary TJ, Behrendt DM. Evaluation
of a computer-assisted method for individualized
anticoagulation: retrospective and prospective studies with
a pharmacodynamic model. Clinical Pharmacology and
Therapeutics 1982;32(1):129–36.
Absalom 2003 {published data only}
Absalom AR, Kenny GNC. Closed-loop control of propofol
anaesthesia using bispectral index: performance assessment
in patients receiving computer-controlled propofol and
manually controlled remifentanil infusions for minor
surgery. British Journal of Anaesthesia 2003;90(6):737–41.
[: 0007–0912]
Albisser 2007 {published data only}
Albisser AM, Wright CE, Sakkal S. Averting iatrogenic
hypoglycemia through glucose prediction in clinical
practice: progress towards a new procedure in diabetes.
Diabetes Research and Clinical Practice 2007;76:207–14.
Alvis 1985 {published data only}
Alvis JM, Reves JG, Govier AV, Menkhaus PG, Henling
CE, Spain JA, et al.Computer-assisted continuous infusions
of fentanyl during cardiac anesthesia: comparison with a
manual method. Anesthesiology 1985;63(1):41-9.
Barletta 2009 {published data only}
Barletta J, McAllen K, Eriksson E, Thayer S, Deines G, Blau
S, et al.The effect of a computer-assisted insulin infusion
protocol on glucose control and variability in a surgical
intensive care unit. Critical Care Medicine 2009:A25. [:
0090–3493]
Barras 2008 {published data only}
Barras MA, Duffull SB, Atherton JJ, Green B. Individualized
compared with conventional dosing of enoxaparin. Clinical
Pharmacology & Therapeutics 2008;83(6):882–8.
Barras 2010 {published data only}
Barras MA, Duffull SB, Atherton JJ, Green B. Individualized
dosing of enoxaparin for subjects with renal impairment is
superior to conventional dosing at achieving therapeutic
concentrations. Therapeutic Drug Monitoring 2010;32(4):
482–8.
Bartal 2003 {published data only}
Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan
M, Smoliakov R, et al.Pharmacokinetic dosing of
aminoglycosides: a controlled trial. American Journal of
Medicine 2003;114:194–8.
Berg 2009 {published data only}
Berg T, Weich V, Teuber G, Klinker H, Moller B, Rasenack
J, et al.Individualized treatment strategy according to early
viral kinetics in hepatitis C virus type 1-infected patients.
Hepatology 2009;50(2):369–77.
Burger 2003 {published data only}
Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon
F, et al.Therapeutic drug monitoring of nelfinavir and
indinavir in treatment-naive HIV-1-infected individuals.
AIDS 2003;17(8):1157–65. [: 0269–9370]
Bury 2005 {published data only}
Bury J, Hurt C, Roy A, Cheesman L, Bradburn M, Cross
S, et al.LISA: a web-based decision-support system for trial
management of childhood acute lymphoblastic leukaemia.
British Journal of Haematology 2005;129(6):746–54.
Caraballo 2008 {published data only}
Caraballo PJ, North F, Peters S, Puffer M, Nyman M, Epps
S, et al.Use of decision support to prevent errors when
documenting height and weight in the hospital electronic
medical record. AMIA 2008; Vol. Annual Symposium
Proceedings/AMIA Symposium:890.
Carter 1987a {published data only}
Carter BL, Taylor JW, Becker A. Evaluation of three dosage-
prediction methods for initial in-hospital stabilization of
warfarin therapy. Clinical Pharmacy 1987;6(1):37–45.
Cavalcanti 2009 {published data only}
Cavalcanti AB, Silva E, Pereira AJ, Caldeira-Filho M,
Almeida FP, Westphal GA, et al.A randomized controlled
trial comparing a computer-assisted insulin infusion
protocol with a strict and a conventional protocol for
glucose control in critically ill patients. Journal of Critical
Care 2009;24:371–8.
Chan 2006 {published data only}
Chan ALF, Wang H-Y, Leung HWC. Incorporation
of a gentamicin dosage calculator into a computerized
prescriber-order-entry system. American Journal of Health-
System Pharmacy 2006;63(14):1344–5. [: 1079–2082]
Chiarelli 1990 {published data only}
Chiarelli F, Tumini S, Morgese G, Albisser AM. Controlled
study in diabetic children comparing insulin-dosage
adjustment by manual and computer algorithms. Diabetes
Care 1990;13(10):1080–4.
Cohen 2007 {published data only}
Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard
A-M, Rosenfeld RG, et al.Insulin growth factor-based dosing
of growth hormone therapy in children: a randomized,
controlled study. Journal of Clinical Endocrinology &
Metabolism 2007;92(7):2480–6. [: 0021–972X]
57Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Collins 2004 {published data only}
Collins CD, Pedersen CA, Schneider PJ, Miller AS,
Sierawski SJ, Roux RK. Effect on amphotericin B lipid
complex use of a clinical decision support system for
computerized prescriber order entry. American Journal
of Health-System Pharmacy 2004;61(13):1395–9. [:
1079–2082]
Cupissol 1996 {published data only}
Cupissol D, BrŠS J, Gestin-Boyer C, Nouguier-Soul J, Vian
L, Tep A, et al.Validation of a new interactive software
monitoring a controlled-flow infusion pump for cisplatin
dosage regimen adjustment. Bulletin du Cancer 1996;83(8):
664–76.
Demakis 2000 {published data only}
Demakis JG, Beauchamp C, Cull WL, Denwood R, Eisen
SA, Lofgren R, et al.Improving residents’ compliance
with standards of ambulatory care. Results from the VA
Cooperative Study on Computerized Reminders. JAMA
2000;284:1411–6.
Dillon 1989 {published data only}
Dillon KR, Dougherty SH, Casner P, Polly S. Individualized
pharmacokinetic versus standard dosing of amikacin:
a comparison of therapeutic outcomes. Journal of
Antimicrobial Chemotherapy 1989;24:581–9.
Donovan 2010 {published data only}
Donovan JL, Kanaan AO, Thomson MS, Rochon P, Lee
M, Gavendo L, et al.Effect of clinical decision support on
psychotropic medication prescribing in the long-term care
setting. Journal of the American Geriatrics Society 2010;58
(5):1005–7. [: 0002–8614]
Doran 2004 {published data only}
Doran CV, Hudson NH, Moorhead KT, Chase JG, Shaw
GM, Hann CE. Derivative weighted active insulin control
modelling and clinical trials for ICU patients. Medical
Engineering & Physics 2004; Vol. 26, issue 10:855–66. [:
1350–4533]
Dortch 2008 {published data only}
Dortch MJ, Mowery NT, Ozdas A, Dossett L, Cao H,
Collier B, et al.A computerized insulin infusion titration
protocol improves glucose control with less hypoglycemia
compared to a manual titration protocol in a trauma
intensive care unit. Journal of Parenteral and Enteral
Nutrition 2008;32(1):18–27. [: 0148–6071]
Evans 1998 {published data only}
Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver
LK, Orme JF, et al.A computer-assisted management
program for antibiotics and other antiinfective agents.
New England Journal of Medicine 1998;338(4):232–8. [:
0028–4793]
Evans 1998a {published data only}
Evans WE, Relling MV, Rodman JH, Crom WR, Boyett
JM, Pui CH. Conventional compared with individualized
chemotherapy for childhood acute lymphoblastic leukemia.
New England Journal of Medicine 1998;338(8):499–505. [:
0028–4793]
Evans 1999 {published data only}
Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation
of a computer-assisted antibiotic-dose monitor. Annals of
Pharmacotherapy 1999;33(10):1026–31. [: 1060–0280]
Faber 2006 {published data only}
Faber E, Pytlik R, Slaby J, Zapletalova J, Kozak T, Raida
L, et al.Individually determined dosing of filgrastim
after autologous peripheral stem cell transplantation
in patients with malignant lymphoma - results of a
prospective multicentre controlled trial. European Journal of
Haematology 2006;77(6):493–500. [: 0902–4441]
Feldstein 2006 {published data only}
Feldstein AC, Smith DH, Perrin N, Yang X, Rix M, Raebel
MA, et al.Improved therapeutic monitoring with several
interventions. A randomized trial. Archives of Internal
Medicine 2006;166:1848–54.
Fety 1998 {published data only}
Fety R, Rolland F, Barberi-Heyob M,Hardouin A, Campion
L, Conroy T, et al.Clinical impact of pharmacokinetically-
guided dose adaptation of 5-fluorouracil: results from
a multicentric randomized trial in patients with locally
advanced head and neck carcinomas. Clinical Cancer
Research 1998;4(9):2039–45. [: 1078–0432]
Field 2009 {published data only}
Field TS, Rochon P, Lee M, Baril JL, Gurwitz JH.
Computerized clinical decision support during medication
ordering for long-term care residents with renal
insuf ciency. Pharmacoepidemiology and Drug Safety
(PDS) 2009:S121–2. [: 1053–8569]
Field 2009a {published data only}
Field TS, Rochon P, Lee M, Gavendo L, Baril JL, Gurwitz
JH. Computerized clinical decision support during
medication ordering for long-term care residents with renal
insufficiency. Journal of the American Medical Informatics
Association 2009;16(4):480–5. [: 1067–5027]
Fihn 1994 {published data only}
Fihn SD, McDonell MB, Vermes D, Henikoff JG, Martin
DC, Callahan CM, et al.A computerized intervention to
improve timing of outpatient follow-up: a multicenter
randomized trial in patients treated with warfarin. Journal
of General Internal Medicine 1994;9(3):131–9.
Fitzmaurice 1996 {published data only}
Fitzmaurice DA, Hobbs FD, Murray ET, Bradley CP,
Holder R. Evaluation of computerized decision support for
oral anticoagulation management based in primary care.
British Journal of General Practice 1996;46(410):533–5. [:
0960–1643]
Fitzmaurice 1998 {published data only}
Fitzmaurice DA, Hobbs FD, Murray ET. Primary care
anticoagulant clinic management using computerized
decision support and near patient international normalized
ratio (INR) testing: routine data from a practice nurse-led
clinic. Family Practice 1998;15(2):144–6.
58Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Flanders 2009 {published data only}
Flanders SJ, Juneja R, Roudebush CP, Carroll J, Golas A,
Elias BL. Glycemic control and insulin safety: the impact of
computerized intravenous insulin dosing. American Journal
of Medical Quality 2009; Vol. 24, issue 6:489–97.
Fritsch 2009 {published data only}
Fritsch N, Nouette-Gaulain K, Bordes M, Semjen F,
Meymat Y, Cros A-M. Target-controlled inhalation
induction with sevoflurane in children: a prospective pilot
study. Paediatric Anaesthesia 2009;19(2):126–32.
Fukudo 2009 {published data only}
Fukudo M, Yano I, Shinsako K, Katsura T, Takada Y,
Uemoto S, et al.Prospective evaluation of the Bayesian
method for individualizing tacrolimus dose early after
living-donor liver transplantation. Journal of Clinical
Pharmacology 2009;49(7):789–97. [: 0091–2700]
Gamelin 2008 {published data only}
Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet
D, et al.Individual fluorouracil dose adjustment based on
pharmacokinetic follow-up compared with conventional
dosage: results of a multicenter randomized trial of patients
with metastatic colorectal cancer. Journal of Clinical
Oncology 2008;26(13):2099–105.
Ghazal-Aswad 1997 {published data only}
Ghazal-Aswad S, Highley M, Bailey N, Lind M, Siddiqui
N, Sinha DP, et al.A randomised phase III study to
compare the toxicity and efficacy of carboplatin given
by pharmacokinetically guided formula compared to
conventional dosing in epithelial ovarian cancer. Acta
Obstetrica et Gynecologica Scandinavica 1997;76:26.
Gopakumaran 2004 {published data only}
Gopakumaran B. “Intelligent dosing system”: a useful
computer program for diabetes management?. Diabetes
Technology and Therapeutics 2004; Vol. 6, issue 3:336–8.
[: 1520–9156]
Griffey 2012 {published data only}
Griffey R T, Lo H G, Burdick E, Keohane C, Bates D W.
Guided medication dosing for elderly emergency patients
using real-time, computerized decision support. Journal
of the American Medical Informatics Association 2012;19:
86–93.
Guarracino 2001 {published data only}
Guarracino F, De Cosmo D, Penzo D, Tedesco M, Bossi A,
Zussa C, et al.Automated protamine dose assay in heparin
reversal management after cardiopulmonary by pass.
Minerva Anestesiologica 2001;67(4):165–9. [: 0375–9393]
Guarracino 2003 {published data only}
Guarracino F, Penzo D, De Cosmo D, Vardanega A,
De Stefani R. Pharmacokinetic-based total intravenous
anaesthesia using remifentanil and propofol for surgical
myocardial revascularization. European Journal of
Anaesthesiology 2003;20(5):385–90. [: 0265–0215]
Hermayer 2007 {published data only}
Hermayer KL, Neal DE, Hushion TV, Irving MG, Arnold
PC, Kozlowski L, et al.Outcomes of a cardiothoracic
intensive care web-based online intravenous insulin
infusion calculator study at a Medical University Hospital.
Diabetes Technology & Therapeutics 2007;9(6):523–34. [:
1520–9156]
Hobbs 1996 {published data only}
Hobbs FD, Delaney BC, Carson A, Kenkre JE. A
prospective controlled trial of computerized decision
support for lipid management in primary care. Family
Practice 1996;13(2):133–7.
Hoffman 2004 {published data only}
Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely
A, Hartman ML, et al.Efficacy and tolerability of an
individualized dosing regimen for adult growth hormone
replacement therapy in comparison with fixed body
weight-based dosing. Journal of Clinical Endocrinology &
Metabolism 2004;89(7):3224–33. [: 0021–972X]
Horn 2002 {published data only}
Horn W, Popow C, Miksch S, Kirchner L, Seyfang A.
Development and evaluation of VIE-PNN, a knowledge-
based system for calculating the parenteral nutrition of
newborn infants. Artificial Intelligence in Medicine 2002;24
(3):217–28.
Hwang 2004 {published data only}
Hwang HG, Chang IC, Hung WF, Sung ML, Yen D. The
design and evaluation of clinical decision support systems in
the area of pharmacokinetics. Medical Informatics and the
Internet in Medicine 2004;29(3-4):239–51.
Jankovic 1999 {published data only}
Jankovic SM, Timotijevic I, Mihajlovic GS, Dukic-
Dejanovic S. Comparison of two approaches to amitriptyline
dose individualisation. European Journal of Drug Metabolism
& Pharmacokinetics 1999;24(2):163–8. [: 0398–7639]
Jannuzzi 2000 {published data only}
Jannuzzi G, Cian P, Fattore C, Gatti G, Bartoli A, Monaco
F, et al.A multicenter randomized controlled trial on the
clinical impact of therapeutic drug monitoring in patients
with newly diagnosed epilepsy. The Italian TDM Study
Group in Epilepsy. Epilepsia 2000;41(2):222–30. [:
0013–9580]
Jellinek 2005 {published data only}
Jellinek SP, Cohen V, Likourezos A, Goldman WM, Lashley
EL. Analyzing a health-system’s use of unfractionated
heparin to ensure optimal anticoagulation. Journal of
Pharmacy Technology 2005;21(2):69–78. [: 8755–1225]
Judge 2006 {published data only}
Judge J, Field T S, DeFlorio M, Laprino J, Auger J, Rochon
P, et al.Prescribers’ responses to alerts during medication
ordering in the long term care setting. Journal of the
American Medical Informatics Association 2006;13:385–90.
Jung 2009 {published data only}
Jung H, Land C, Nicolay C, De Schepper J, Blum WF,
Schonau E. Growth response to an individualized versus
fixed dose GH treatment in short children born small for
gestational age: the OPTIMA study. European Journal of
Endocrinology 2009; Vol. 160, issue 2:149–56.
59Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kazemi 2011 {published data only}
Kazemi A, Ellenius J, Pourasghar F, Tofighi S, Salehi A,
Amanati A, et al.The effect of computerized physician order
entry and decision support system on medication errors in
the neonatal ward: experiences from an Iranian teaching
hospital. Journal of Medical Systems 2011;35(1):25–37. [:
0148–5598]
Kirk 2005 {published data only}
Kirk RC, Li-Meng Goh D, Packia J, Min Kam H, Ong
BKC. Computer calculated dose in paediatric prescribing.
Drug Safety 2005;28(9):817–24. [: 0114–5916]
Koide 2000 {published data only}
Koide D, Ohe K, Ross-Degnan D, Kaihara S. Computerized
reminders to monitor liver function to improve the use of
etretinate. International Journal of Medical Informatics 2000;
57:11–9.
Kristrom 2009 {published data only}
Kristrom B, Aronson AS, Dahlgren J, Gustafsson J, Halldin
M, Ivarsson SA, et al.Growth hormone (GH) dosing during
catch-up growth guided by individual responsiveness
decreases growth response variability in prepubertal children
with GH deficiency or idiopathic short stature. Journal of
Clinical Endocrinology & Metabolism 2009;94(2):483–90.
[: 0021–972X]
Kroese 2005 {published data only}
Kroese WLG, Avery AJ, Savelyich BSP, Brown NS, Schers
H, Howard R, et al.Assessing the accuracy of a computerized
decision support system for digoxin dosing in primary care:
an observational study. Journal of Clinical Pharmacy &
Therapeutics 2005;30(3):279–83. [: 0269–4727]
la Cour Freiesleben 2009 {published data only}
la Cour Freiesleben N, Lossl K, Bogstad J, Bredkjaer HE,
Toft B, Rosendahl M, et al.Individual versus standard dose
of rFSH in a mild stimulation protocol for intrauterine
insemination: a randomized study. Human Reproduction
2009;24(10):2523–30.
Lester 2006 {published data only}
Lester WT, Grant RW, Barnett GO, Chueh HC.
Randomized controlled trial of an informatics-based
intervention to increase statin prescription for secondary
prevention of coronary disease. Journal of General Internal
Medicine 2006;21:22–9.
Ligtenberg 2006 {published data only}
Ligtenberg JJ, Meertens JH, Monteban-Kooistra WE,
Tulleken JE, Zijlstra JG. Multicentric, randomized,
controlled trial to evaluate blood glucose control by the
model predictive control algorithm versus routine glucose
management protocols in intensive care unit patients:
response to Plank et al. Diabetes Care 2006; Vol. 29, issue
8:1987–8.
Lillis 2003 {published data only}
Lillis K. Automated dosing. Computerized physician order
entry reduces risk of medication and dosing errors in
neonatal ICU.Health Management Technology 2003;24(11):
36–7. [: 1074–4770]
Liu 2006 {published data only}
Liu N, Chazot T, Genty A, Landais A, Restoux A, McGee
K, et al.Titration of propofol for anesthetic induction
and maintenance guided by the bispectral index: closed-
loop versus manual control. A prospective, randomized,
multicenter study. Anesthesiology 2006;104(4):686–95. [:
0003–3022]
Manotti 2001 maintenance {published data only}
Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori
AG. Effect of computer-aided management on the quality
of treatment in anticoagulated patients: a prospective,
randomized, multicenter trial of APROAT (Automated
PRogram for Oral Anticoagulant Treatment). Haematologica
2001;86(10):1060–70.
Mar Fernandez 1996 {published data only}
Fernandez de Gatta MD, Calvo MV, Hernandez JM,
Caballero D, San Miguel JF, Dominguez-Gil A. Cost-
effectiveness analysis of serum vancomycin concentration
monitoring in patients with hematologic malignancies.
Clinical Pharmacology & Therapeutics 1996;60(3):332–40.
[: 0009–9236]
Mar Fernandez 2009 {published data only}
Mar Fernandez de Gatta MD, Victoria Calvo M, Ardanuy
R, Dominguez-Gil A, Lanao JM, Moreno SR. Evaluation
of population pharmacokinetic models for amikacin
dosage individualization in critically ill patients. Journal
of Pharmacy & Pharmacology 2009;61(6):759–66. [:
0022–3573]
Matheny 2008 {published data only}
Matheny ME, Sequist TD, Seger AC, Fiskio JM, Sperling
M, Bugbee D, et al.A randomized trial of electronic clinical
reminders to improve medication laboratory monitoring.
Journal of the AmericanMedical Informatics Association 2008;
15:424–9.
Maurizi 2011 {published data only}
Maurizi AR, Lauria A, Maggi D, Palermo A, Fioriti E,
Manfrini S, et al.A novel insulin unit calculator for the
management of type 1 diabetes. Diabetes Technology &
Therapeutics 2011;13:425–8.
McCluggage 2010 {published data only}
McCluggage L, Lee K, Potter T, Dugger R, Pakyz A.
Implementation and evaluation of vancomycin nomogram
guidelines in a computerized prescriber-order-entry system.
American Journal of Health-System Pharmacy 2010;67(1):
70–5.
McCowan 2001 {published data only}
McCowan C, Neville RG, Ricketts IW,Warner FC, Hoskins
G, Thomas GE. Lessons from a randomized controlled trial
designed to evaluate computer decision support software to
improve the management of asthma. Medical Informatics
and the Internet in Medicine 2001;26:191–201.
McCoy 2008 {published data only}
McCoy AB, Peterson JF, Gadd CS, Danciu I, Waitman
LR. A system to improve medication safety in the setting
of acute kidney injury: initial provider response. Annual
Symposium Proceedings/AMIA Symposium 2008:1051.
60Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McCoy 2010 {published data only}
McCoy AB, Waitman LR, Gadd CS, Danciu I, Smith
JP, Lewis JB, et al.A computerized provider order entry
intervention for medication safety during acute kidney
injury: a quality improvement report. American Journal of
Kidney Diseases 2010;56(5):832–41.
McDonald 1976 {published data only}
McDonald CJ. Use of a computer to detect and respond to
clinical events: its effect on clinician behavior. Annals of
Internal Medicine 1976;84(2):162–7.
McDonald 1980 {published data only}
McDonald CJ, Wilson GA, McCabe GP, Jr. Physician
response to computer reminders. JAMA 1980;244(14):
1579–81.
McMichael 1993 {published data only}
McMichael J, Lieberman R, Doyle H, McCauley J, Fung J,
Starzl TE. An intelligent and cost-effective computer dosing
system for individualizing FK506 therapy in transplantation
and autoimmune disorders. Journal of Clinical Pharmacology
1993;33(7):599–605.
McMullin 1997 {published data only}
McMullin ST, Reichley RM, Kahn MG, Dunagan WC,
Bailey TC. Automated system for identifying potential
dosage problems at a large university hospital. American
Journal of Health-System Pharmacy 1997;54(5):545–9. [:
1079–2082]
McMullin 2004 {published data only}
McMullin ST, Lonergan TP, Rynearson CS, Doerr TD,
Veregge PA, Scanlan ES. Impact of an evidence-based
computerized decision support system on primary care
prescription costs. Annals of Family Medicine 2004; Vol. 2,
issue 5:494–8. [: 1544–1709]
McMullin 2005 {published data only}
McMullin ST, Lonergan TP, Rynearson CS. Twelve-month
drug cost savings related to use of an electronic prescribing
system with integrated decision support in primary care.
Journal of Managed Care Pharmacy 2005;11(4):322–32. [:
1083–4087]
Motykie 1999 {published data only}
Motykie GD, Mokhtee D, Zebala LP, Caprini JA, Kudrna
JC, Mungall DR. The use of a Bayesian forecasting model
in the management of warfarin therapy after total hip
arthroplasty. Journal of Arthroplasty 1999;14(8):988–93. [:
0883–5403]
Mullett 2001 {published data only}
Mullett CJ, Evans RS, Christenson JC, Dean JM.
Development and impact of a computerized pediatric
antiinfective decision support program. Pediatrics 2001;108
(4):E75.
Murchie 1989 {published data only}
Murchie CJ, Kenny GN. Comparison among manual,
computer-assisted, and closed-loop control of blood
pressure after cardiac surgery. Journal of Cardiothoracic
Anesthesia 1989;3(1):16–19.
Nash 2005 {published data only}
Nash IS, Rojas M, Hebert P, Marrone SR, Colgan C, Fisher
LA, et al.Reducing excessive medication administration in
hospitalized adults with renal dysfunction. American Journal
of Medical Quality 2005;20(2):64–9. [: 1062–8606]
Newby 2002 {published data only}
Newby LK, Harrington RA, Bhapkar MV, Van de Werf F,
Hochman JS, Granger CB, et al.An automated strategy for
bedside aPTT determination and unfractionated heparin
infusion adjustment in acute coronary syndromes: insights
from PARAGON A. Journal of Thrombosis & Thrombolysis
2002;14(1):33–42. [: 0929–5305]
Nieuwenhuyze 1995 {published data only}
Van den Nieuwenhuyzen MC, Engbers FH, Burm
AG, Vletter AA, van Kleef JW, Bovill JG. Computer-
controlled infusion of alfentanil versus patient-controlled
administration of morphine for postoperative analgesia: a
double-blind randomized trial. Anesthesia and Analgesia
1995;81(4):671–9.
Nightingale 2000 {published data only}
Nightingale PG, Adu D, Richards NT, Peters M.
Implementation of rules based computerised bedside
prescribing and administration: intervention study. BMJ
2000;320(7237):750–3.
Oppenheim 2002 {published data only}
Oppenheim MI, Vidal C, Velasco FT, Boyer AG, Cooper
MR, Hayes JG, et al.Impact of a computerized alert during
physician order entry on medication dosing in patients with
renal impairment. Proceedings/AMIA Annual Symposium
2002:577–81. [: 1531–605X]
Overhage 1997 {published data only}
Overhage JM, Tierney WM, Zhou XH, McDonald CJ.
A randomized trial of “corollary orders” to prevent errors
of omission. Journal of the American Medical Informatics
Association 1997;4:364–75.
Palen 2006 {published data only}
Palen TE, Raebel M, Lyons E, Magid DM. Evaluation
of laboratory monitoring alerts within a computerized
physician order entry system for medication orders.
American Journal of Managed Care 2006;12:389–95.
Pea 2002 {published data only}
Pea F, Bertolissi M, Di Silvestre A, Poz D, Giordano F,
Furlanut M. TDM coupled with Bayesian forecasting
should be considered an invaluable tool for optimizing
vancomycin daily exposure in unstable critically ill patients.
International Journal of Antimicrobial Agents 2002;20(5):
326–32. [: 0924–8579]
Peck 1973 {published data only}
Peck CC, Sheiner LB, Martin CM, Combs DT, Melmon
KL. Computer-assisted digoxin therapy. New England
Journal of Medicine 1973;289(9):441–6.
Peters 1996 {published data only}
Peters A, Kerner W. Analytical design and clinical
application of an intelligent control system for insulin
treatment [Analytisches Design und klinische Anwendung
61Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
eineslernfähigen Regelsystems für die Pharmakotherapie
mit Insulin]. Biomedizinische Technik 1996;41(1-2):2–13.
Peterson 1986 {published data only}
Peterson CM, Jovanovic L, Chanoch LH. Randomized trial
of computer-assisted insulin delivery in patients with type
I diabetes beginning pump therapy. American Journal of
Medicine 1986;81(1):69–72.
Peterson 2005 {published data only}
Peterson JF, Kuperman GJ, Shek C, Patel M, Avorn J, Bates
DW. Guided prescription of psychotropic medications for
geriatric inpatients. Archives of Internal Medicine 2005;165
(7):802–7. [: 0003–9926]
Peterson 2007 {published data only}
Peterson JF, Rosenbaum BP, Waitman LR, Habermann R,
Powers J, Harrell D, et al.Physicians’ response to guided
geriatric dosing: initial results from a randomized trial.
Studies in Health Technology & Informatics 2007;129(Pt 2):
1037–40. [: 0926–9630]
Phillips 2008 {published data only}
Phillips IE,Nelsen C, Peterson J, Sullivan TM,Waitman LR.
Improving aminoglycoside dosing through computerized
clinical decision support and pharmacy therapeutic
monitoring systems. AMIA 2008; Vol. Annual Symposium
Proceedings/AMIA Symposium.:1093.
Piazza 2009 {published data only}
Piazza G, Goldhaber SZ. Computerized decision support
for the cardiovascular clinician: applications for venous
thromboembolism prevention and beyond. Circulation
2009; Vol. 120, issue 12:1133–7. [: 0009–7322]
Poller 1993 {published data only}
Poller L, Wright D, Rowlands M. Prospective comparative
study of computer programs used for management of
warfarin. Journal of Clinical Pathology 1993;46(4):299-303.
Popovic-Todorovic 2003 {published data only}
Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsboll
S, Nielsen IK, Andersen AN. A prospective randomized
clinical trial comparing an individual dose of recombinant
FSH based on predictive factors versus a ’standard’ dose of
150 IU/day in ’standard’ patients undergoing IVF/ICSI
treatment. Human Reproduction 2003;18(11):2275–82. [:
0268–1161]
Proost 2003 {published data only}
Proost JH, Punt NC. Dose individualization in PharmDIS-
e+. International Journal of Clinical Pharmacology and
Therapeutics 2003;41(10):451–8. [: 0946–1965]
Roberts 2010 {published data only}
Roberts GW, Farmer CJ, Cheney PC, Govis SM, Belcher
TW, Walsh SA, et al.Clinical decision support implemented
with academic detailing improves prescribing of key
renally cleared drugs in the hospital setting. Journal of the
American Medical Informatics Association 2010; Vol. 17,
issue 3:308–12.
Rochon 2006 {published data only}
Rochon PA, Field TS, Bates DW, Lee M, Gavendo L,
Erramuspe-Mainard J, et al.Clinical application of a
computerized system for physician order entry with clinical
decision support to prevent adverse drug events in long-
term care. CMAJ 2006;174(1):52–4. [: 0820–3946]
Rood 2005 {published data only}
Rood E, Bosman RJ, van der Spoel JI, Taylor P, Zandstra
DF. Use of a computerized guideline for glucose regulation
in the intensive care unit improved both guideline adherence
and glucose regulation. Journal of the American Medical
Informatics Association 2005;12(2):172–80. [: 1067–5027]
Rothschild 2002 {published data only}
Rothschild JM, Lee TH, Bae T, Bates DW. Clinician use of
a palmtop drug reference guide. Journal of the American
Medical Informatics Association 2002; Vol. 9, issue 3:
223–9. [: 1067–5027]
Rothschild 2003 {published data only}
Rothschild JM, Keohane CA, Thompson S, Bates DW.
Intelligent intravenous infusion pumps to improve
medication administration safety. Annual Symposium
Proceedings/AMIA Symposium 2003:992.
Rothschild 2005 {published data only}
Rothschild JM, Keohane CA, Cook EF, Orav EJ, Burdick
E, Thompson S, et al.A controlled trial of smart infusion
pumps to improve medication safety in critically ill patients.
Critical Care Medicine 2005; Vol. 33, issue 3:533–40. [:
0090–3493]
Rotman 1996 {published data only}
Rotman BL, Sullivan AN, McDonald TW, Brown BW,
DeSmedt P, Goodnature D, et al.A randomized controlled
trial of a computer based physician workstation in an
outpatient setting: implementation barriers to outcome
evaluation. Journal of the American Medical Informatics
Association 1996;3(5):340–8.
Roumie 2005 {published data only}
Roumie CL, Elasy TA, Greevy R, Griffin MR, Liu X,
Stone WJ, et al.Improving blood pressure control through
provider education, provider alerts, and patient education: a
cluster randomized trial. Annals of Internal Medicine 2006;
145:165–75.
Ruiz 1993 {published data only}
Ruiz R, Borches D, Gonzalez A, Corral J. A new sodium-
nitroprusside-infusion controller for the regulation of
arterial blood pressure. Biomedical Instrumentation &
Technology 1993;27(3):244–51.
Ryff-de Leche 1992 {published data only}
Ryff-de Leche A, Engler H, Nutzi E, Berger M, Berger
W. Clinical application of two computerized diabetes
management systems: comparison with the log-book
method. Diabetes Research 1992;19(3):97–105.
Santana 2003 {published data only}
Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T,
Gajjar A, et al.A pilot study of protracted topotecan dosing
using a pharmacokinetically guided dosing approach in
children with solid tumors. Clinical Cancer Research 2003;9
(2):633–40. [: 1078–0432]
62Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Santana 2005 {published data only}
Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff
AM, Houghton PJ, et al.Improved response in high-risk
neuroblastoma with protracted topotecan administration
using a pharmacokinetically guided dosing approach.
Journal of Clinical Oncology 2005; Vol. 23, issue 18:
4039–47. [: 0732–183X]
Schneider 2005 {published data only}
Schneider BL, Gulseth MP, Cusick MA, Sisson DC,
Tomsche JJ. Computer program to assist pharmacy
management of an inpatient warfarin dosing service.
American Journal of Health-System Pharmacy 2005;62(22):
2393–6. [: 1079–2082]
Schrezenmeir 2002 {published data only}
Schrezenmeir J, Dirting K, Papazov P. Controlled
multicenter study on the effect of computer assistance in
intensive insulin therapy of type 1 diabetics. Computer
Methods & Programs in Biomedicine 2002;69(2):97–114. [:
0169–2607]
Shiach 2002 {published data only}
Shiach CR, Campbell B, Poller L, Keown M, Chauhan N.
Randomised cross-over study of near patient testing versus
hospital laboratory testing with computer assisted dosing
in a community anticoagulant clinic. British Journal of
Haematology 2002;117(Suppl 1):33.
Shieh 2006 {published data only}
Shieh J-S, Fu M, Huang S-J, Kao M-C. Comparison of
the applicability of rule-based and self-organizing fuzzy
logic controllers for sedation control of intracranial pressure
pattern in a neurosurgical intensive care unit. IEEE
Transactions on Biomedical Engineering 2006;53(8):1700–5.
[: 0018–9294]
Soper 2006 {published data only}
Soper J, Chan GTC, Skinner JR, Spinetto HD, Gentles
TL. Management of oral anticoagulation in a population of
children with cardiac disease using a computerised system
to support decision-making. Cardiology in the Young 2006;
16(3):256–60. [: 1047–9511]
Sparano 2006 {published data only}
Sparano JA. TAILORx: trial assigning individualized
options for treatment (Rx). Clinical Breast Cancer 2006;7
(4):347–50. [: 1526–8209]
Strack 1985 {published data only}
Strack T, Bergeler J, Beyer J, Hutten H. Computer assisted
conventional insulin therapy. Life Support Systems 1985;3
Suppl 1:568–72.
Tamblyn 2003 {published data only}
Tamblyn R, Huang A, Perreault R, Jacques A, Roy D,
Hanley J, et al.The medical office of the 21st century
(MOXXI): effectiveness of computerized decision-making
support in reducing inappropriate prescribing in primary
care. CMAJ 2003;169(6):549–56.
Tamblyn 2008 {published data only}
Tamblyn R, Huang A, Taylor L, Kawasumi Y, Bartlett G,
Grad R, et al.A randomized trial of the effectiveness of on-
demand versus computer-triggered drug decision support in
primary care. Journal of the American Medical Informatics
Association 2008;15(4):430–8. [: 1067–5027]
Tamblyn 2010 {published data only}
Tamblyn R, Reidel K, Huang A, Taylor L, Winslade N,
Bartlett G, et al.Increasing the detection and response to
adherence problems with cardiovascular medication in
primary care through computerized drug management
systems: a randomized controlled trial. Medical Decision
Making 2010;30(2):176–88.
Terrell 2009 {published data only}
Terrell KM, Perkins AJ, Dexter PR, Hui SL, Callahan
CM, Miller DK. Computerized decision support to reduce
potentially inappropriate prescribing to older emergency
department patients: a randomized, controlled trial. Journal
of the American Geriatrics Society 2009;57(8):1388–94.
Thomson 2011 {published data only}
Thomson BKA, MacRae JM, Barnieh L, Zhang J, MacKay
E, Manning MA, et al.Evaluation of an electronic warfarin
nomogram for anticoagulation of hemodialysis patients.
BMC Nephrology 2011;12:46.
Tierney 2005 {published data only}
Tierney WM, Overhage JM, Murray MD, Harris LE, Zhou
XH, Eckert GJ, et al.Can computer-generated evidence-
based care suggestions enhance evidence-based management
of asthma and chronic obstructive pulmonary disease? A
randomized, controlled trial. Health Services Research 2005;
40:477–97.
Tomek 2011 {published data only}
Tomek A, Mat’oka V, Kumstov T, Rmek M, Arbochov
I, T’ovkov K, et al.Warfarin loading dose guided by
pharmacogenetics is effective and safe in cardioembolic
stroke patients. Proceedings of the 20th European Stroke
Conference; 2011 May 24-27; Hamburg, Germany. 2011.
Traugott 2011 {published data only}
Traugott KA, Maxwell PR, Green K, Frei C, Lewis JS,
2nd. Effects of therapeutic drug monitoring criteria in
a computerized prescriber-order-entry system on the
appropriateness of vancomycin level orders. American
Journal of Health-System Pharmacy 2011;68(4):347–52.
Trivedi 2007 {published data only}
Trivedi MH, Daly EJ. Measurement-based care for
refractory depression: a clinical decision support model for
clinical research and practice. Drug & Alcohol Dependence
2007;88 Suppl 2:S61–71. [: 0376–8716]
Trivedi 2007a {published data only}
Trivedi MH, Rush AJ, Gaynes BN, Stewart JW, Wisniewski
SR,Warden D, et al.Maximizing the adequacy of medication
treatment in controlled trials and clinical practice: STAR
(*)D measurement-based care. Neuropsychopharmacology
2007;32(12):2479–89. [: 0893–133X]
van der Bol 2010 {published data only}
van der Bol JM, Mathijssen RHJ, Creemers G-JM, Planting
AST, Loos WJ, Wiemer EAC, et al.A CYP3A4 phenotype-
based dosing algorithm for individualized treatment of
63Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
irinotecan. Clinical Cancer Research 2010;16(2):736–42. [:
1078–0432]
van Leeuwen 2005 {published data only}
van Leeuwen Y, Rombouts EK, Kruithof CJ, Van Der Meer
FJM, Rosendaal FR. Comparison between two computer
algorithms in oral anticoagulant dosage: a double blind
randomised controlled trial. Journal of Thrombosis &
Haemostasis 2005; Vol. 3:1.
van Leeuwen 2007 {published data only}
van Leeuwen Y, Rombouts EK, Kruithof CJ, van der Meer
FJM, Rosendaal FR. Improved control of oral anticoagulant
dosing: a randomized controlled trial comparing two
computer algorithms. Journal of Thrombosis & Haemostasis
2007;5(8):1644–9. [: 1538–7933]
van Lent-Evers 1999 {published data only}
van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA,
Vinks AA. Impact of goal-oriented and model-based clinical
pharmacokinetic dosing of aminoglycosides on clinical
outcome: a cost-effectiveness analysis. Therapeutic Drug
Monitoring 1999;21(1):63–73. [: 0163–4356]
Van Wyk 2008 {published data only}
Van Wyk JT, Van Wijk MAM, Sturkenboom MCJM,
Mosseveld M, Moorman PW, van der Lei J. Electronic
alerts versus on-demand decision support to improve
dyslipidemia treatment: a cluster randomized controlled
trial. Circulation 2008; Vol. 117, issue 3:371–8. [:
0009–7322]
Verstappen 2007 {published data only}
Verstappen SMM, Jacobs JWG, van der Veen MJ, Heurkens
AHM, Schenk Y, ter Borg EJ, et al.Intensive treatment
with methotrexate in early rheumatoid arthritis: aiming
for remission. Computer Assisted Management in Early
Rheumatoid Arthritis (CAMERA, an open-label strategy
trial). Annals of the Rheumatic Diseases 2007;66(11):
1443–9. [: 0003–4967]
Verstappen 2010 {published data only}
Verstappen SMM, Bakker MF, Heurkens AHM, van der
Veen MJ, Kruize AA, Geurts MAW, et al.Adverse events
and factors associated with toxicity in patients with early
rheumatoid arthritis treated with methotrexate tight control
therapy: the CAMERA study. Annals of the Rheumatic
Diseases 2010; Vol. 69, issue 6:1044–8.
Wasmuth 2007 {published data only}
Wasmuth JC, Lambertz I, Voigt E, Vogel M, Hoffmann
C, Burger D, et al.Maintenance of indinavir by dose
adjustment in HIV-1-infected patients with indinavir-
related toxicity. European Journal of Clinical Pharmacology
2007;63(10):901–8.
Wasmuth 2007a {published data only}
Wasmuth JC, Rodermann E, Voigt E, Vogel M, Lauenroth-
Mai E, Jessen A, et al.Comparison of indinavir + ritonavir
600 + 100 mg vs. 400 + 100 mg BID combinations
in HIV1-infected patients guided by therapeutic drug
monitoring. European Journal of Medical Research 2007;12
(7):289–94. [: 0949–2321]
Whipple 1991 {published data only}
Whipple JK, Ausman RK, Franson T, Quebbeman EJ.
Effect of individualized pharmacokinetic dosing on patient
outcome. Critical Care Medicine 1991;19:1480–5.
White 1984 {published data only}
White KS, Lindsay A, Pryor TA, Brown WF, Walsh K.
Application of a computerized medical decision-making
process to the problem of digoxin intoxication. Journal of
the American College of Cardiology 1984;4(3):571–6.
Willcourt 1994 {published data only}
Willcourt RJ, Pager D, Wendel J, Hale RW. Induction of
labor with pulsatile oxytocin by a computer-controlled
pump. American Journal of Obstetrics and Gynecology 1994;
170(2):603–8.
Wilson 2002 {published data only}
Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson
D, Drbohlav N, et al.Dose-adjusted EPOCH chemotherapy
for untreated large B-cell lymphomas: a pharmacodynamic
approach with high efficacy. Blood 2002;99(8):2685–93. [:
0006–4971]
Yamamoto 2005 {published data only}
Yamamoto N, Tamura T, Murakami H, Shimoyama T,
Nokihara H, Ueda Y, et al.Randomized pharmacokinetic
and pharmacodynamic study of docetaxel: dosing based
on body-surface area compared with individualized dosing
based on cytochrome P450 activity estimated using a
urinary metabolite of exogenous cortisol. Journal of Clinical
Oncology 2005;23(6):1061–9. [: 0732–183X]
References to studies awaiting assessment
Anderson 2011 {published data only}
Anderson JL, Horne BD, Stevens SM, Woller SC,
Samuelson KM, Mansfield JW, et al.A randomized and
clinical effectiveness trial comparing two pharmacogenetic
algorithms and standard care for individualizing warfarin
dosing: CoumaGen-II. Proceedings of the American Heart
Association; 2011 Nov 12-16; Orlando, FL. 2011.
Anderson 2012 {published data only}
Anderson JL, Horne BD, Stevens SM, Woller SC,
Samuelson KM, Mansfield JW, et al.A randomized and
clinical effectiveness trial comparing two pharmacogenetic
algorithms and standard care for individualizing warfarin
dosing (CoumaGen-II). Circulation 2012;125(16):
1997–2005. [PUBMED: 22431865]
Caduff 2013 {published data only}
Caduff Good A, Nobel D, Krahenbuhl S, Geisen C, Henz
S. Randomised trial of a clinical dosing algorithm to start
anticoagulation with phenprocoumon. Swiss Medical Weekly
2013;143:w13709. [PUBMED: 23299853]
Dumont 2012 {published data only}
Dumont C, Bourguignon C. Effect of a computerized
insulin dose calculator on the process of glycemic control.
American Journal of Critical Care 2012;21(2):106–15.
[PUBMED: 22381987]
64Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Horibe 2012 {published data only}
Horibe M, Nair BG, Yurina G, Neradilek MB, Rozet I. A
novel computerized fading memory algorithm for glycemic
control in postoperative surgical patients. Anesthesia and
Analgesia 2012;115(3):580–7. [PUBMED: 22669346]
Jeanne 2012 {published data only}
Jeanne M, Clement C, De Jonckheere J, Logier R, Tavernier
B. Variations of the analgesia nociception index during
general anaesthesia for laparoscopic abdominal surgery.
Journal of Clinical Monitoring and Computing 2012;26(4):
289–94. [PUBMED: 22454275]
Joerger 2012 {published data only}
Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B,
Schellens JH, et al.Evaluation of a pharmacology-driven
dosing algorithm of 3-weekly paclitaxel using therapeutic
drug monitoring: a pharmacokinetic-pharmacodynamic
simulation study. Clinical Pharmacokinetics 2012;51(9):
607–17. [PUBMED: 22804749]
Kelly 2012 {published data only}
Kelly PJ, Kay-Lambkin FJ, Baker AL, Deane FP, Brooks AC,
Mitchell A, et al.Study protocol: a randomized controlled
trial of a computer-based depression and substance abuse
intervention for people attending residential substance abuse
treatment. BMC Public Health 2012;12:113. [PUBMED:
22325594]
Kim 2012 {published data only}
Kim S, Lee HW, Lee W, Um TH, Cho CR, Chun S, et
al.New allele-specific real-time PCR system for warfarin
dose genotyping equipped with an automatic interpretative
function that allows rapid, accurate, and user-friendly
reporting in clinical laboratories. Thrombosis Research 2012;
130(1):104–9. [PUBMED: 21911247]
Magee 2012 {published data only}
Magee MC. Improving IV insulin administration in a
community hospital. Journal of Visualized Experiments
2012;64:e3705. [PUBMED: 22710978]
Nieuwlaat 2011 {published data only}
Nieuwlaat R, Spyropoulos AC, Hubers L, Stehouwer A, Van
Spall HG, Eikelboom JW, et al.Randomized comparison of
the DAWN AC computer program and a simple manual
nomogram for quality of warfarin dosing. 23rd Congress of
the International Society on Thrombosis and Haemostasis.
2011; Vol. Proceedings of the 57th Annual SSC Meeting;
2011 Jul 23–28; Kyoto Japan;:302.
Nieuwlaat 2012 {published data only}
Nieuwlaat R, Hubers LM, Spyropoulos AC, Eikelboom JW,
Connolly BJ, Van Spall HG, et al.Randomised comparison
of a simple warfarin dosing algorithm versus a computerised
anticoagulation management system for control of warfarin
maintenance therapy. Thrombosis and Haemostasis 2012;
108(6):1228–35. [PUBMED: 23015161]
Overgaard 2010 {published data only}
Overgaard K, Corell P, Madsen P, Rasmussen RS.
Computer-aid improves oral anticoagulant therapy.
Proceedings of the 19th European Stroke Conference; 2010
May 25-28; Barcelona, Spain. 2010.
Pielmeier 2012 {published data only}
Pielmeier U, Rousing ML, Andreassen S, Nielsen BS,
Haure P. Decision support for optimized blood glucose
control and nutrition in a neurotrauma intensive care unit:
preliminary results of clinical advice and prediction accuracy
of the Glucosafe system. Journal of Clinical Monitoring and
Computing 2012;26(4):319–28. [PUBMED: 22581038]
Radhakrishnan 2012 {published data only}
Radhakrishnan A, Vido D, Tayur S, Akan M, Murali S.
Genotype guided therapeutic dosing of warfarin in geriatric
patients. Journal of the American College of Cardiology 2012;
59(13 Suppl 1):E1696.
Rasmussen 2012 {published data only}
Rasmussen RS, Corell P, Madsen P, Overgaard K. Effects of
computer-assisted oral anticoagulant therapy. Thrombosis
Journal 2012;10(1):17. [PUBMED: 22935243]
Spaniel 2012 {published data only}
Spaniel F, Hrdlicka J, Novak T, Kozeny J, Hoschl C, Mohr
P, et al.Effectiveness of the information technology-aided
program of relapse prevention in schizophrenia (ITAREPS):
a randomized, controlled, double-blind study. Journal
of Psychiatric Practice 2012;18(4):269–80. [PUBMED:
22805901]
Tamblyn 2012 {published data only}
Tamblyn R, Eguale T, Buckeridge DL, Huang A, Hanley
J, Reidel K, et al.The effectiveness of a new generation of
computerized drug alerts in reducing the risk of injury
from drug side effects: a cluster randomized trial. Journal
of the American Medical Informatics Association 2012;19(4):
635–43. [PUBMED: 22246963]
Whitehead 2012 {published data only}
Whitehead J, Thygesen H, Jaki T, Davies S, Halford S,
Turner H, et al.A novel phase I/IIa design for early phase
oncology studies and its application in the evaluation of
MK-0752 in pancreatic cancer. Statistics in Medicine 2012;
31(18):1931–43. [PUBMED: 22495759]
Wiltshire 2012 {published data only}
Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A
placebo- andmidazolam-controlled phase I single ascending-
dose study evaluating the safety, pharmacokinetics, and
pharmacodynamics of remimazolam (CNS 7056): Part
II. Population pharmacokinetic and pharmacodynamic
modeling and simulation. Anesthesia and Analgesia 2012;
115(2):284–96. [PUBMED: 22253270]
Additional references
Arditi 2012
Arditi C, Rège-Walther M, Wyatt JC, Durieux P,
Burnand B. Computer-generated reminders delivered on
paper to healthcare professionals; effects on professional
practice and health care outcomes. Cochrane Database
of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/
14651858.CD001175.pub3]
Baldwin 1995
Baldwin L. Calculating drug doses. British Medical Journal
1995;310(6988):1154.
65Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bates 2003
Bates DW, Kuperman GJ, Wang S, Gandhi T, Kittler A,
Volk L, et al.Ten commandments for effective clinical
decision support: making the practice of evidence-
based medicine a reality. Journal of the American Medical
Informatics Association 2003;10(6):523–30.
Brennan 1991
Brennan TA, Leape LL, Laird NM, Hebert L, Localio
AR, Lawthers AG, et al.Incidence of adverse events and
negligence in hospitalized patients. Results of the Harvard
Medical Practice Study I. New England Journal of Medicine
1991;324(6):370–6.
Chatellier 1998
Chatellier G, Colombet I, Degoulet P. Computer-adjusted
dosage of anticoagulant therapy improves the quality of
anticoagulation. Studies in Health Technology and Informatics
1998;52(Pt 2):819–23.
CLINICIP
CLINICIP Project. CLINICIP (Closed Loop Insulin
Infusion for Critically Ill Patients). www.clinicip.org
(accessed 25 September 2013).
Deeks 2011
Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing
data and undertaking meta-analyses. In: Higgins JPT,
Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 [updated March
2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Durieux 2005
Durieux P. Electronic medical alerts - so simple, so complex.
New England Journal of Medicine 2005;352(10):1034–6.
EPOC 2009
EPOC. Risk of bias - EPOC specific.
epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/
Risk%20of%20Bias%2005-01-2009.doc (accessed 25
September 2013).
EPOC 2012
EPOC. What study designs should be in-
cluded in an EPOC review and what should
they be called?. epocoslo.cochrane.org/
sites/epocoslo.cochrane.org/files/uploads/
What%20study%20designs%20should%20be%20included%20in%20an%20EPOC%20reviews%20and%20what%20should%20they%20be%20called.pdf
(accessed 25 September 2013).
Eslami 2009
Eslami S, Abu-Hanna A, de Jonge E, de Keizer NF. Tight
glycemic control and computerized decision-support
systems: a systematic review. Intensive Care Medicine 2009;
35(9):1505–17.
Fitzmaurice 1998a
Fitzmaurice DA, Hobbs FD, Delaney BC, Wilson S,
McManus R. Review of computerized decision support
systems for oral anticoagulation management. British
Journal of Haematology 1998;102(4):907–9.
Franke 2000
Franke L, Avery AJ, Groom L, Horsfield P. Is there a role
for computerized decision support for drug dosing in
general practice? A questionnaire survey. Journal of Clinical
Pharmacy and Therapeutics 2000;25(5):373–7.
Garcia-Alamino 2010
Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R,
Bankhead C, Fitzmaurice D, et al.Self-monitoring and self-
management of oral anticoagulation. Cochrane Database
of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/
14651858.CD003839.pub2]
Garg 2005
Garg AX, Adhikari NK, McDonald H, Rosas-Arellano M,
Devereaux PJ, Beyene J, et al.Effects of computerized clinical
decision support systems on practitioner performance and
patient outcomes: a systematic review. JAMA 2005;293
(10):1223–38.
Guyatt 2008
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,
Alonso-Coello P, et al.GRADE: an emerging consensus on
rating quality of evidence and strength of recommendations.
British Medical Journal 2008;336(7650):924–6.
Guyatt 2011
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J,
Helfand M, et al.GRADE guidelines: 7. Rating the quality
of evidence - inconsistency. Journal of Clinical Epidemiology
2011;64:1294–302.
Higgins 2011
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing
risk of bias in included studies. In: Higgins JPT, Green
S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0. [updated March 2011].
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Hozo 2005
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and
variance from the median, range, and the size of a sample.
BMC Medical Research Methodology 2005;5:13.
Ioannidis 2007
Ioannidis JP, Trikalinos TA. The appropriateness of
asymmetry tests for publication bias in meta-analyses: a
large survey. Canadian Medical Association Journal 2007;
176:1091–6.
Kawamoto 2005
Kawamoto K, Houlihan CA, Balas EA, Lobach DF.
Improving clinical practice using clinical decision support
systems: a systematic review of trials to identify features
critical to success. British Medical Journal 2005;330(7494):
765.
Kuperman 2003
Kuperman GJ, Gibson RF. Computer physician order entry:
bene ts, costs, and issues. Annals of Internal Medicine
2003;139(1):31–9.
66Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McDonald 1976a
McDonald CJ. Protocol-based computer reminders, the
quality of care and the non-perfectability of man. New
England Journal of Medicine 1976;295(24):1351–5.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred
reporting items for systematic reviews and meta-analyses:
the PRISMA statement. PLOS Medicine 2009;6:e1000097.
Mollon 2009
Mollon B, Chong J Jr, Holbrook AM, Sung M, Thabane L,
Foster G. Features predicting the success of computerized
decision support for prescribing: a systematic review of
randomized controlled trials. BMC Medical Informatics and
Decision Making 2009;9:11.
Moore 1984a
Moore RD, Smith CR, Lietman PS. Association of
aminoglycoside plasma levels with therapeutic outcome in
gram-negative pneumonia. American Journal of Medicine
1984;77(4):657–62. [: Moore 1984a]
Moore 1984b
Moore RD, Smith CR, Lietman PS. The association of
aminoglycoside plasma levels with mortality in patients
with gram-negative bacteremia. Journal of Infectious Diseases
1984;149(3):443–8. [: Moore 1984b]
Moore 1987
Moore RD, Lietman PS, Smith CR. Clinical response to
aminoglycoside therapy: importance of the ratio of peak
concentration to minimal inhibitory concentration. Journal
of Infectious Diseases 1987;155(1):93–9.
National Asthma 2002
National Asthma Education and Prevention Program.
Expert Panel Report: guidelines for the diagnosis and
management of asthma update on selected topics - 2002.
Journal of Allergy and Clinical Immunology 2002;110(5
Suppl):S141–219.
Nieuwlaat 2011a
Nieuwlaat R, Connolly SJ, Mackay JA, Weise-Kelly L,
Navarro T, Wilczynski N L, et al.Computerized clinical
decision support systems for therapeutic drug monitoring
and dosing: a decision-maker-researcher partnership
systematic review. Implementation Science 2011;6:90.
Pearson 2009
Pearson SA, Moxey A, Robertson J, Hains I, Williamson M,
Reeve J, et al.Do computerised clinical decision support
systems for prescribing change practice? A systematic review
of the literature (1990-2007). BMC Health Services Research
2009;9:154.
RevMan 2011
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.1. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012.
Robertson 2010
Robertson J, Walkom E, Pearson SA, Hains I, Williamsone
M, Newby D. The impact of pharmacy computerised
clinical decision support on prescribing, clinical and
patient outcomes: a systematic review of the literature.
International Journal of Pharmacy Practice 2010;2:69–87.
Rolfe 1995
Rolfe S, Harper NJ. Ability of hospital doctors to calculate
drug doses. British Medical Journal 1995;310(6988):
1173–4.
Shojania 2009
Shojania KG, Jennings A, Mayhew A, Ramsay CR, Eccles
MP, Grimshaw J. The effects of on-screen, point of care
computer reminders on processes and outcomes of care.
Cochrane Database of Systematic Reviews 2009, Issue 3.
[DOI: 10.1002/14651858.CD001096.pub2]
Ukoumunne 1999
Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA,
Burney PG, Donner A. Methods in health service research.
Evaluation of health interventions at area and organisation
level. British Medical Journal 1999;319:376–9.
Yourman 2008
Yourman L, Concato J, Agostini JV. Use of computer
decision support interventions to improve medication
prescribing in older adults: a systematic review. American
Journal of Geriatric Pharmacotherapy 2008;6(2):119–29.
References to other published versions of this review
Durieux 2008
Durieux P, Trinquart L, Colombet I, Nies J, Walton R,
Rajeswaran A, et al.Computerized advice on drug dosage
to improve prescribing practice. Cochrane Database
of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/
14651858.CD002894.pub2]
Walton 2001
Walton R T, Harvey E, Dovey S, Freemantle N.
Computerised advice on drug dosage to improve prescribing
practice. Cochrane Database of Systematic Reviews 2001,
Issue 1. [DOI: 10.1002/14651858.CD002894]
∗ Indicates the major publication for the study
67Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ageno 1998
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Episode of care
Power calculation: Not reported
Participants Profession: Mixed (physicians + nurses)
Level of training: Accredited/licensed
Clinical specialty: Other, anticoagulant clinic
Country: Canada (Ontario)
Centre: 1 general hospital (Hamilton General Hospital)
Location of care: Outpatient care
Participants: 101 outpatients on long-term oral anticoagulant therapy after mechanical
heart valve replacement
Interventions Clinical problem: Long-term warfarin therapy
Intervention: Prediction rules, computer-assisted group (n = 50) vs. control group (n =
51)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Proportion of doses adjustments (potential
unit of analysis error)
Serum concentrations and therapeutic range: None
Physiological parameters: None (percentage of days in range with an INR of 2.5-3.5
according to the Duxburry method (reported as time spent in days per 100 patient-days
of treatment), % of INRs > 5: reported, % of INRs < 2: reported, mean INR values: no
dispersion data, % of INRs in range (2.3-3.7): not included, % of days in range (2.5-3.
5): not included, % of days in range (2.3-3.7): not included)
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: None
Improvement: None
Notes - The author confirm that none of the participants was included in both studies Ageno
1998 and Ageno 2000
- Therapeutic INR range: “Warfarin is administered with a therapeutic INR range of 2.5
to 3.5, according to the 1995 American College of Chest Physicians recommendations”
Risk of bias
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Ageno 1998 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation not specified
Allocation concealment (selection bias) Unclear risk “Consecutive patients whowere discharged
from the Hamilton General Hospital (On-
tario, Canada) after mechanical heart valve
replacement were randomized to be con-
trolled by the computerized system or stan-
dardmanualmonitoring by trainedperson-
nel”. No further information provided
Baseline outcome measurements similar Low risk No baseline measure of outcome
Baseline characteristics similar Unclear risk Participant randomization. “The two
groups were similar with respect to age and
gender.” No further information provided
Providerswere 2physicians and3 registered
nurses, all with several years of experience
in the management of people on oral anti-
coagulants
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clearly specified in the paper
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Ageno 2000
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Other (dose, INR, participant)
Power calculation: Not reported
Participants Profession: Mixed (physicians + nurses)
Level of training: Accredited/licensed
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Ageno 2000 (Continued)
Clinical specialty: General/family practice
Country: Canada (Ontario)
Centre: 1 general hospital (Hamilton General Hospital)
Location of care: Inpatient care
Participants: 101 participants who required oral anticoagulation (heart valve replace-
ment, treatment of venous thromboembolism, atrial fibrillation, prophylaxis for deep
vein thrombosis, acute myocardial infarction and vascular surgery)
Interventions Clinical problem: Warfarin adjustment in hospitalized people
Intervention: Computer-based control of oral anticoagulation (n = 50 participants) vs.
standard manual dosing (n = 51 participants). The computerized induction treatment
module (DAWN AC INDUCTION) calculated the daily dosage of warfarin based on
algorithms that could be set at every centre according to the local clinical practice
Computer advice: Given in real time
CDSS integration in CPOE: Not reported
Starter: Not reported
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Proportion of doses adjustments (potential
unit of analysis error) (daily dose of warfarin: no dispersion data)
Serum concentrations and therapeutic range: None
Physiological parameters: None (% of INRs > 5: reported, mean INR values: no disper-
sion data, % of participants with at least 1 INR > upper limit of therapeutic range: not
included)
Time to achieve therapeutic control: None
Clinical events: Minor bleeding (major bleeding: not included)
Healthcare costs: None
Improvement: None
Notes - There were different indications for oral anticoagulation: “heart valve replacement (n:
74), treatment of venous thromboembolism (n:16), atrial fibrillation (n:5), prophylaxis
for deep vein thrombosis (n:4), acute myocardial infarction (n:1), and vascular surgery
(n:1)”
- The author confirm that none of the participants was included in both studies Ageno
1998 and Ageno 2000
- Therapeutic INR range: “Because of a higher risk of bleeding during the early days
of treatment due to the presence of pacing wires which are usually removed between
the fifth and seventh post operative day, the initial therapeutic INR for participants
following heart valve replacement ranges between 1.5 to 2.6. After the wires are removed,
the therapeutic INR is 2.5 to 3.5 for mechanical valves, and 2.0 to 3.0 for bioprosthetic
valves. For all other indications, the therapeutic INR ranges between 2.0 and 3.0. In the
algorithm set in the computer, we defined a low therapeutic regime for the first 5 days
of treatment for all the participants following heart valve replacement”
Risk of bias
Bias Authors’ judgement Support for judgement
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Ageno 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Random sequence generation not specified
Allocation concealment (selection bias) Unclear risk “Consecutive patients who were hospital-
ized at the Hamilton General Hospital
(Ontario, Canada) and who required oral
anticoagulation were randomized to con-
trol by the computerized system or stan-
dard manual dosing until the seventh day
of treatment or until discharge, whichever
happened first”. No further information
provided
Baseline outcome measurements similar Low risk No baseline measure of outcome
Baseline characteristics similar Low risk Participant randomization. “The two
groups were similar with respect to age (64.
6 manual group; 63.3 computer group),
whereas the proportion of males was higher
in the computer group (64%) than in the
manual group (53%) [...] The proportion
of participants following heart valve re-
placement was 78% in the computer group
and 69% in the manual group.[...] The
mean INRwas 2.09 in the computer group,
and 2.07 in the manual group”
Providers were trained nurses or physicians
(supposed to be the same providers at base-
line and during intervention)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clearly specified in the paper
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes included bleeding events. Mi-
nor and major bleeding events were not
clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
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Anderson 2007
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Done
Participants Profession: Mixed (physicians + pharmacists)
Level of training: Not reported
Clinical specialty: Not reported
Country: USA (Salt Lake City)
Centre: 1 general urban hospital and surgical centre (LDS Hospital, Intermountain’s
outstanding heart network in the Salt Lake Valley)
Location of care: Inpatient care
Participants: 206 participants being initiated on oral anticoagulation. 200 participants
analyzed
Interventions Clinical problem: Warfarin initiation
Intervention: Pharmacogenetic-guided dosing (n = 101) versus standard empirical dos-
ing (n = 99). Pharmacogenetic-arm dosing was determined with a regression equation
included CYP2C9 (*1, *2, *3) and VKORC1 (C1173T) genotypes, age, weight and sex.
Standard dosing followed the 10-mg warfarin nomogram of Kovacs et al.
Computer advice: Given in real time
CDSS integration in CPOE: Not reported
Starter: User-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: Dose adjustments per participant
Serum concentrations and therapeutic range: None
Physiological parameters: Time (%) within therapeutic range (% of out-of-range INRs:
not included, Number of INR measurements: not included, % participants reaching
therapeutic INR on days 5 and 8: not included)
Time to achieve therapeutic control: None (time to first supratherapeutic INR: not
included)
Clinical events:%participantswith adverse events (clinical plus INR≥ 4),%participants
with serious adverse events (clinical only)
Healthcare costs: None
Improvement: None
Notes - Therapeutic INR range: “Although the target INR range was 2 to 3, we prospectively
defined an out-of-range INR value, for purposes of end-point analysis and for clinical
dose adjustment, as 1.8 or 3.2 to allow for measurement error and to avoid problems
inherent in overcorrection”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization (in permuted blocks of 5)
to the pharmacogenetic or standard arm”
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Allocation concealment (selection bias) Low risk “The randomization arm assignment was
blinded to patients and clinicians/investi-
gators and known only to a designated re-
search assistant and pharmacist”
Baseline outcome measurements similar Low risk Not applicable (initiation of warfarin ther-
apy)
Baseline characteristics similar High risk “Clinical characteristics were balanced ex-
cept for older age and greater prevalence of
hypertension in pharmacogenetic patients.
” The results on primary endpoint were un-
changed by further adjustment for differ-
ences in age and hypertension
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent missing data
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective. “An indepen-
dentData and SafetyMonitoringCommit-
tee tracked unblinded safety data. A sepa-
rate independent Clinical Events Commit-
tee adjudicated key clinical adverse events
blinded to study arm”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were randomized. “The ran-
domization arm assignment was blinded
to patients and clinicians/investigators and
known only to a designated research assis-
tant and pharmacist”
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Anderson 2008
Methods
Participants
Interventions
Outcomes
Notes - Same study as Anderson 2007
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Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Other (blood sample, participant)
Power calculation: Not done “In this pilot study, the number of subjects needed to be
included was empirically based”
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Nephrology
Country: Norway (Oslo)
Centre: 1 university hospital
Location of care: Mixed (nephrology and standard clinical follow-up)
Participants: 40 adult kidney transplant recipients on CsA, prednisolone and mycophe-
nolate were included 2 weeks after transplantation (discharge from the surgical depart-
ment) and followed for at least 8 weeks (standard clinical follow-up)
Interventions Clinical problem: CsA in early post-transplant phase
Intervention: Computer dosing of CsA doses (n = 20 participants) vs. standard practice (n
=20participants). IndividualCsAdoseswere calculated by a populationpharmacokinetic
model and suggested to the physician
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Indirect intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Daily CsA dose
Serum concentrations and therapeutic range: None (% participants with a deviation
from the targeted blood concentration > 50% on at least 1 occasion: not included)
Physiological parameters: Glomerular filtration rate (renal function) (mL/min) (% of
blood concentrations within the therapeutic window for an individual: reported, 2-hour
plasma glucose (mmol/L): not included)
Time to achieve therapeutic control: None
Clinical events: Proportion of participants with cytomegalovirus infections
Healthcare costs: None
Improvement: Proportion of participants without biopsy-confirmed rejections
Notes “The attending physician specified individual therapeutic C2 windows based on clinical
evaluation of patient characteristics and risk factors. The standard protocol at our center
is 900-1100 µg/L for the first month of transplant, followed by 700-900 µg/L up to
month 3 in a normal risk patient; high-risk patients start with a therapeutic window of
1200-1600 µg/L followed by appropriate tapering”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation not specified
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Allocation concealment (selection bias) Unclear risk “A single center randomized prospective
trial in adult kidney transplant recipi-
ents on CsA-based immunosuppression
was performed.” No further information
provided
Baseline outcome measurements similar Low risk “There was no significant differences be-
tween the number of samples collected in
the 2 groups (P=0.12) or in the percentage
of C2 values obtained in each group (MAP-
BE: 82%, CONTR: 78%, P=0.39).” No
further information provided
Baseline characteristics similar Unclear risk Participant randomization. “There was no
relevant demographic differences between
groups”
Providers were physicians (supposed to be
the same providers at baseline and during
intervention)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “There was no significant differences be-
tween the number of samples collected in
the 2 groups (P=0.12)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
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Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Done. “Using a one-sided test at a 5% level of statistical significance,
the trial was designed to have an 85% statistical power to detect a difference of 0.5% in
change in A1C ( A1C) from baseline to end of trial between the CGMS and CGMS/
KADIS group, with an assumed SD of 0.6”
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: General/family practice, diabetes specialty
Country: Germany
Centre: 5 outpatient centres (3 general and 2 diabetes specialist practices)
Location of care: Outpatient care
Participants: 49 insulin-treated outpatients. 46 subjects completed the study (3 subjects
had incomplete first CGMS monitoring and were excluded)
Interventions Clinical problem: Insulin in people with diabetes
Intervention: CGMS + KADIS (n = 24 participants) vs. CGMS (n = 25 participants).
CGMS provides information about glycaemic control by glucose readings every 5 min
and was used as the source of glucose data. All participants were educated to use CGMS
monitors and the CGMS data were downloaded and transferred to the centre (Institute
of Diabetes) for analysis. Depending on the group to which the participant belonged,
physicians received eitherCGMSdata alone orCGMSdata plusKADISdecision support
report. KADIS is based on a mathematical model that describes the glucose/insulin
metabolism in type 1 diabetes in the form of a coupled differential equation
Computer advice: Not reported
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Not reported
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Insulin (IU/day)
Serum concentrations and therapeutic range: None
Physiological parameters: Mean sensor glucose (mmol/L), A1C (%) (duration of hypo-
glycaemic excursions (h/day): not included, duration of hyperglycaemic excursions (h/
day): not included, Bread Exchange Unit: not included)
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: None
Improvement: None
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “Patients with even random numbers, de-
rived from a random number table, were
assigned for the CGMS and patients with
uneven random numbers for the CGMS/
KADIS group”
Allocation concealment (selection bias) Unclear risk Random number table. No further infor-
mation provided
Baseline outcome measurements similar Low risk “Both study groups included type 1 and
type 2 diabetic subjects in equal propor-
tions. There were no significant differences
in age, sex, diabetes duration, BMI [body
mass index], or insulin application between
groups (Table 1)”
Baseline characteristics similar Low risk Participant randomization. “The two
groups were similar with respect to age (64.
6 manual group; 63.3 computer group),
whereas the proportion of males was higher
in the computer group (64%) than in the
manual group (53%) [...] The proportion
of participants following heart valve re-
placement was 78% in the computer group
and 69% in the manual group.[...] The
mean INRwas 2.09 in the computer group,
and 2.07 in the manual group”
Providers were trained nurses or physicians
(supposed to be the same providers at base-
line and during intervention)
Incomplete outcome data (attrition bias)
All outcomes
High risk “Of the 49 subjects found eligible, 46 (24 in
the CGMS and 22 in the CGMS/KADIS
group) completed the study. Three subjects
had incomplete first CGMS monitoring
(one in the CGMS and two in the CGMS/
KADIS group) and were excluded”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
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Other bias Low risk No evidence of other risk of biases
Begg 1989
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: Not reported
Country: New Zealand
Centre: 1 general hospital (Christchurch Hospital)
Location of care: Inpatient care
Participants: 50 hospital inpatients (ICU excluded)
Interventions Clinical problem: Aminoglycoside
Intervention: Pharmacokinetic model, computer-assisted group (n = 24) vs. control
group (n = 26)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: Aminoglycoside (mg/day)
Serum concentrations and therapeutic range: Aminoglycoside peak plasma concentra-
tion after 2 days (mg/L), % participants within drug therapeutic range (plasma peak
concentrations of 6-10 mg/L and trough concentrations of 1-2 mg/L at 2 days), % par-
ticipants with plasma peak concentrations of 6-10 mg/L at 2 days (peak concentration
criterion alone) (peak concentrations after 5 days: not included, through concentrations:
not included, number of dose alterations: not included)
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: Death, nephrotoxicity (increase in creatinine clearance)
Healthcare costs: None
Improvement: None
Notes “Patients in the intensive care unit were excluded, since they formed the basis of a similar
study with a different control group being conducted concurrently”
Hickling K, Begg E, Moore ML (1989): 32 adult patients in intensive care unit at
Christchurch Hospital (New Zealand) who required gentamicin or tobramycin therapy
for serious life threatening infections, other than those receiving haemodialysis for renal
acute failure
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer generated randomisation pro-
cedure”
Allocation concealment (selection bias) Low risk “Computer generated randomisation pro-
cedure”
Baseline outcome measurements similar Low risk No information provided
Baseline characteristics similar Low risk “There were no major differences between
the groups in their demographic features
(Table 1)”
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of participants randomized: 50
(24 in the computer-assisted group, 26 in
the control group)
Number of participants analyzed: 45 (“for
the remaining patients aminoglycoside
therapy was discontinued before analysis
of plasma concentration”). Peak concentra-
tions were available for 33 participants at 2
days, and 26 participants at 5 days. Trough
concentrations were available for 32 partic-
ipants at 2 days, and 26 participants at 5
days
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Blaha 2009
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
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Participants Profession: Mixed (physicians + nurses)
Level of training: Not reported
Clinical specialty: Surgical ICU
Country: Czech Republic (Prague)
Centre: 1 university hospital (Charles University and General University Hospital)
Location of care: Inpatient care
Participants: 120 adults admitted to the postoperative ICU after elective cardiac surgery
were randomly assigned into the Matias protocol based on the absolute glucose value (n
= 40), the Bath protocol based on the relative glucose change (n = 40), or the computer-
based model predictive control algorithm with variable sampling rate (eMPC) (n = 40)
Interventions Clinical problem: Insulin in critically ill people (cardiac surgery patients)
Intervention: Matias protocol based on the absolute glucose value (n = 40 participants)
versus computer-based model predictive control algorithm with variable sampling rate
(eMPC) (n = 40 participants). The eMPC is an enhanced version of themodel predictive
control algorithm (MPC), amodel of the glucoregulatory system.Glucose concentration,
insulin dosage, and carbohydrate content of enteral and parenteral input are the input
variables for the eMPC. The insulin infusion rate and the time of the next glucose sample
are the outputs. Group with the Bath protocol based on the relative glucose change (n =
40) was excluded since most of standard protocols use the absolute glucose value and this
protocol had not been used in the Charles University and General University Hospital
before the study
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None
Physiological parameters: % of time within the target range for blood glucose during the
study or the first 48 h (80-110 mg/dL or 4.4-6.1 mmol/L), mean blood glucose (mmol/
L)
Time to achieve therapeutic control: Time to target range (hours),mean sampling interval
(hours)
Clinical events: Proportion of participants with severe hypoglycaemic episodes (blood
glucose level < 2.3 mmol/L)
Healthcare costs: None
Improvement: None
Notes - “The target glucose range was 4.4 - 6.1mmol/l, which has been demonstrated to reduce
mortality and morbidity”. “severe hypoglycemic episodes (blood glucose <2.3 mmol/l)”
- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients;
www.clinicip.org), an integrated project funded by the European Community
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Random sequence generation not specified
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk No significant differences on blood glucose
at study start or number of participants
with history of diabetes (Table 1)
Baseline characteristics similar Low risk No significant differences on baseline char-
acteristics (Table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Because the duration of the ICU stay and
the total monitoring time differed among
patients, only data for up to 48 h were
used for the comparison of the protocols.
Forty-eight hours of ICU stay were accom-
plished in 109 of 120 patients included in
the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomes were objective. Hypogly-
caemic episodes are clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Burton 1991
Methods Design: RCT
Unit of allocation: House staff team (a random number table was used to determine
which of the house staff teams would be assigned to the intervention group. At the end
of each 4 months, during the study, intervention groups were changed to control and
vice versa to ensure equal allocation of participant types and infections to each group)
Unit of analysis: Participant (cluster was not taken into account in the analysis)
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Not reported
Country: USA (Dallas)
Centre: 1 Veterans Administration Medical Center (680-bed tertiary care - affiliated
81Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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institution)
Location of care: Inpatient care
Participants: 147 participants treated with aminoglycosides
Interventions Clinical problem: Aminoglycoside
Intervention: Dose advice based on Bayesian pharmacokinetic model (n = 72) vs. usual
care (n = 75)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: Beginning aminoglycoside dose (mg/day)
, Ending aminoglycoside dose (mg/day)
Serum concentrations and therapeutic range: Aminoglycoside peak serum concentration
(mg/L), toxic drug level (% participants within peak concentration > 4mg/L) (maximum
trough concentration: not included, % participants within trough concentrations ≥ 2
mg/L: not included)
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: Nephrotoxicity (rise in serum creatinine level of 0.5 mg/dL if the initial
value was ≤ 1.5 mg/dL or a 30% rise in the serum creatinine value), death
Healthcare costs: Length of stay
Improvement: % of participants cured (afebrile for 4 consecutive days and without: re-
currence of fever, leukocytosis, recurrence of infection, use of another effective antibiotic
within 48 hours of stopping aminoglycoside)
Notes “All initial and revised dosages in the intervention group were targeted to obtain peak
and trough serum concentrations within the recognized therapeutic range of 5 to 10 mg/
L for peak concentrations and less than 2 mg/L for through concentrations of gentam-
icin and tobramycin. The therapeutic range for amikacin was 20 to 30 mg/L for peak
concentrations and less than 5 mg/L for through serum concentrations”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random number table to determine
which 9 of the 17 house staff teams would
be assigned as control groups”
Allocation concealment (selection bias) Low risk “Random number table to determine
which 9 of the 17 house staff teams would
be assigned as control groups”
Baseline outcome measurements similar Low risk No information provided
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Baseline characteristics similar Low risk “As shown in Table II, there were no signif-
icant differences in any of the patient char-
acteristics between subjects in the control
versus the intervention group.” “In a sim-
ilar manner, there were no significant dif-
ferences in the clinical diagnosis between
patients in each group (Table I)”
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of participants randomized: 147
(72 in intervention group and 75 in the
control group)
Number of participants analyzed: 136 for
number of participants cured (68 in each
groups), 143 for toxic drug levels (70 in
intervention group and 73 in the control
group)
“Intervention patients were excluded from
the study if recommended dosing was not
implemented within 48 hours of the first
dose of aminoglycoside”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective. Nephrotoxicity
and % of participants cured were clearly
defined in the methods section
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Teams were randomized in 1 site. At the
end of each 4 months during the study, in-
tervention groups were changed to control
and vice versa
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of bias
Carter 1987
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Mixed (physicians + pharmacists)
Level of training: Not reported
Clinical specialty: Not reported
Country: USA
Centre: 1 Veterans Administration Medical Center
Location of care: Inpatient care
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Participants: 65 adult inpatients receiving warfarin sodium
Interventions Clinical problem: Initiation of warfarin therapy
Intervention: Pharmacokinetic concepts, analogue-computer program (n = 31) vs. em-
piric dosing (n = 34)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Indirect intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Warfarin stabilization dosage (mg/day)
(for the 39 participants who achieved stable prothrombin ratios before discharge)
Serum concentrations and therapeutic range: None
Physiological parameters: None
Time to achieve therapeutic control: Time to stabilization (for the 39 participants who
achieved stable prothrombin ratios before discharge)
Clinical events: None
Healthcare costs: None
Improvement: None
Notes “A prothrombin time (PT) ratio (patient PT divided by control PT) between 1,3 and 2,
5 was considered to be in therapeutic range”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patients were randomly assigned to
one of the three groups for warfarin dosage
prediction”. No further information pro-
vided
Allocation concealment (selection bias) Unclear risk “The patients were randomly assigned to
one of the three groups for warfarin dosage
prediction”. No further information pro-
vided
Baseline outcome measurements similar Low risk Not applicable (initiation of warfarin ther-
apy)
Baseline characteristics similar High risk Demographic data only available for the
subgroup of participants who achieved sta-
ble prothrombin ratios before discharge
(54/101 participants)
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of participants randomized: 101
Number of participants analyzed: 87 (31
in the analogue-computer group, 22 in the
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linear-regression group, 34 in the empiric-
dosing group)
“Fourteen randomized patients (3 analog
computer, 7 linear regression, 4 empiric
dosing) were removed from the study be-
cause they did not receive an initial war-
farin dosage of 10 mg for three days or be-
cause the drug was discontinued before day
5”
“33 patients were discharged before they
met the stated criteria for a stable PT [pro-
thrombin]”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Casner 1993
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not done
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: Not reported
Country: USA (El Paso, Texas)
Centre: 1 general hospital
Location of care: Inpatient care
Participants: 35 participants with diagnoses of asthma or obstructive pulmonary disease
Interventions Clinical problem: Theophylline maintenance for asthma
Intervention: Suggestion based on linear 1 compartment model (n = 17) vs. usual care
(n = 18)
Computer advice: Given in real time
CDSS integration in CPOE: Yes
Starter: User-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Not reported
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Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: Serum theophylline (mg/L) (at the 3rd
level (C3) after adjustment and prior to discontinuation of infusion)
Physiological parameters: None (PH and partial pressure of carbon dioxide (PCO2)
measurements: not included)
Time to achieve therapeutic control: None
Clinical events: Proportion of participants with theophylline toxicity (nausea, vomiting,
tremor, tachycardia and seizures)
Healthcare costs: Length of stay
Improvement: None
Notes “Physicians adjusting theophylline infusions were instructed to attain a therapeutic goal
of 15mg/L theophylline level and to base this empirically on the C1 and C2 levels that
had been obtained”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Each patient was randomized to one of
two groups as determined by a computer-
derived randomization list”
Allocation concealment (selection bias) Low risk “Each patient was randomized to one of
two groups as determined by a computer-
derived randomization list”
Baseline outcome measurements similar Low risk Not appropriate (theophylline mainte-
nance for asthma)
Baseline characteristics similar Low risk “There were no significant differences be-
tween the kinetic group in age or height,
although there was a significant difference
in actual body weight (85.5 versus 69.0
kg; p<0.05), but the ideal weights of both
groups was not significantly different (55.
7 versus 54.1 kg). Theophilline infusion
doses were based on ideal body weight”
Table 1: 54.7 versus 54.1 kg
Incomplete outcome data (attrition bias)
All outcomes
High risk “Twelve patients were withdrawn from
study because of incomplete data collection
(i.e., either C1, C2, or C3 was missing or
inadequate time interval between levels),
which left 35 patients for analysis”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective. Theophylline
toxicity was defined
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Chertow 2001
Methods Design: NRCT (alternating time series design with 4 consecutive 2-month period)
Unit of allocation: Participant
Unit of analysis: Episode of care
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: Other mixed
Country: USA (Boston, Massachusetts)
Centre: 1 urban tertiary care academic medical centre (Brigham and Women’s Hospital,
720 beds)
Location of care: Inpatient care
Participants: 17,828 inpatients with renal insufficiency
Interventions Clinical problem: Renal insufficiency
Intervention: CDSS periods (n = 7887 participants) vs. control periods (n = 9941 par-
ticipants)
Computer advice: Given in real time
CDSS integration in CPOE: Yes
Starter: System-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: Proportion of appropriate orders (potential
unit of analysis error)
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: Length of stay
Improvement: None
Notes “The BICS order entry application provides the physician with a range of possible dose
amounts for that medication (dose list) along with 1 dose that is highlighted as the
default or recommended dose amount.” “An expert panel [...] selected those medications
that were renally cleared and/or nephrotoxic” “To smooth dose recommendations, renal
insufficiency was divided into 3 categories: mild (estimated creatinine clearance, 50-80
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mL/min [0,84-1,34 mL/s]), moderate (estimated creatinine clearance, 16-49 mL/min
[0,27-0,82 mL/s]), and advanced (estimated creatinine clearance, d15 mL/min [d0,25
mL/s])” “A selection was considered appropriate if the dose amount or frequency interval
did not exceed the parameters set forth by the expert panel”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “The study periods consisted of 4 alternat-
ing 8-week blocks of intervention and con-
trol subperiods”
Allocation concealment (selection bias) High risk “The study periods consisted of 4 alternat-
ing 8-week blocks of intervention and con-
trol subperiods”
Baseline outcome measurements similar Low risk Not appropriate
Baseline characteristics similar Unclear risk Mean age of participants and sex “were not
significantly different across periods”. The
mean Diagnosis Related Group (DRG)
weight “was higher during control periods”
“The number of admissions and the hos-
pital census were higher during the control
periods”
Incomplete outcome data (attrition bias)
All outcomes
Low risk A log was kept of all instances
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Alternating 8-week blocks of intervention
and control subperiods
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Unclear risk “TheCockcroft-Gault formulamay overes-
timate renal function when the serum cre-
atinine is increasing, and underestimate re-
nal function when the serum creatinine is
decreasing”
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Claes 2005
Methods Design: RCT
Unit of allocation: GP practice
Unit of analysis: Participant (cluster was taken into account in statistical analysis)
Power calculation: Done
Participants Profession: Mixed (GP + pathologists)
Level of training: Accredited/licensed
Clinical specialty: General/family practice + laboratory medicine
Country: Belgium
Centre: 96 GPs regrouped in 66 GP practices, for whom the clinical laboratory of the
Medical Centre for GPs in Tessenderlo determined the INRs on venous blood
Location of care: Community-based care
Participants: 834 participants on oral anticoagulation were included (out of 936 partici-
pants eligible). 91 participants who underwent a surgical intervention with an interrup-
tion of the anticoagulation during the study period were excluded from the analysis
Interventions Clinical problem: Oral anticoagulation therapy at steady state (anticoagulation therapy
for at least 28 days)
Intervention: Multifaceted education and DAWN AC computer advice (n = 15 GP
practices, n = 201 participants) vs. multifaceted education (n = 17 GP practices, n =
170 participants). The Grol’s multifaceted education: summary of the guidelines printed
on the cover of a folder containing the anticoagulation files; information booklets on
anticoagulation for their patients; website with guidelines, study design, and general
information; newsletter sent every 2 months to inform the GPs on the study progress
and requested them to send the anticoagulation files for control
Computer advice:Not reported (the pathologist reviewed the computer-generated advice
and faxed it the same afternoon to the GP)
CDSS integration in CPOE: No (advice faxed)
Starter: User-initiated
Type of intervention: Indirect intervention (the pathologist reviewed the computer-
generated advice and faxed it to the GP)
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None (% of participants with treatment
changes: reported, median number of tests per participant and per month: reported)
Serum concentrations and therapeutic range: None
Physiological parameters: None (mean % of time in range (0.5 INT-units from target)
: reported, mean % of time in range (0.75 INT-units from target): not included, % of
participants with at least 1 INR > 5: reported, % of participants with at least 1 INR <
2: reported)
Time to achieve therapeutic control: None
Clinical events: Number of bleeding events (minor + major) per patient-years, number
of thromboembolic events per patient-years
Healthcare costs: See Claes 2006
Improvement: None
Notes - The practices were randomized into 4 groups: multifaceted education (group A), mul-
tifaceted education + feedback on the performance
of the practice (group B), multifaceted education + a CoaguChek device to determine
the INR on the spot using capillary blood (group C), multifaceted education + DAWN
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AC computer advice that generated a recommended dosing scheme and the time to next
visit (group D). Only groups A and D were retained for the review
- The target range were defined as within 0.5 INR-units and 0.75 INR-units from the
chosen target INR of 2.5 or 3.5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The 66 GP-practices were divided into
four different groups using a stratified
block randomization. Six different strata of
GP-practices were defined depending on
the number of anticoagulated patients (5
patients, 6-14 patients, 15 patients) and
the type of practice (single-handed GP or
group practice). These six strata (numbered
containers with cards) were divided blindly
over the four intervention groups by a uni-
versity staff member as follows: out of the
first container a card was drawn and placed
in box A, the next card in box B, C, D, A,
B, etc. The same procedure was followed
for the other five boxes”
Allocation concealment (selection bias) Low risk Unit of allocation: GP practice
Baseline outcome measurements similar Low risk “The 6 months retrospective analysis
showed that the patients of the practices as-
signed to groups A, B, C, and D were 55,
49, 46, and 44% of time within 0.5 INR-
units from target, respectively. There was
no significant difference among the four
groups in the per centwithin 0.5 INR-units
from target (P = 0.50) or within 0.75 INR-
units from target (P = 0.70)”
Baseline characteristics similar High risk Baseline characteristics were not reported
for GP practices, GPs or participants.
Number of participants per group were not
provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants per group were not
provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk GP practices were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Claes 2006
Methods Design: RCT
Unit of allocation: GP practice
Unit of analysis: Participant (cluster was taken into account in statistical analysis)
Power calculation: Done
Participants Profession: Mixed (GP + pathologists)
Level of training: Accredited/licensed
Clinical specialty: General/family practice + laboratory medicine
Country: Belgium
Centre: 96 GPs regrouped in 66 GP practices, for whom the clinical laboratory of the
Medical Centre for GPs in Tessenderlo determined the INRs on venous blood
Location of care: Community-based care
Participants: 834 participants on oral anticoagulation were included (out of 936 partici-
pants eligible). 91 participants who underwent a surgical intervention with an interrup-
tion of the anticoagulation during the study period were excluded from the analysis
Interventions Clinical problem: Oral anticoagulation therapy at steady state (anticoagulation therapy
for at least 28 days)
Intervention: Multifaceted education and DAWN AC computer advice (n = 15 GP
practices, n = 201 participants) vs. multifaceted education (n = 17 GP practices, n =
170 participants). The Grol’s multifaceted education: summary of the guidelines printed
on the cover of a folder containing the anticoagulation files; information booklets on
anticoagulation for their participants; website with guidelines, study design, and general
information; newsletter sent every 2 months to inform the GPs on the study progress
and request them to send the anticoagulation files for checking
Computer advice: Not reported (The pathologist reviewed the computer-generated ad-
vice and faxed it the same afternoon to the GP)
CDSS integration in CPOE: No (advice faxed)
Starter: User-initiated
Type of intervention: Indirect intervention (the pathologist reviewed the computer-
generated advice and faxed it to the GP)
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: See Claes 2005
Serum concentrations and therapeutic range: See Claes 2005
Physiological parameters: See Claes 2005
Time to achieve therapeutic control: See Claes 2005
Clinical events: See Claes 2005
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Healthcare costs: None ((monthly cost per participant (in EUR): reported, incremental
cost-effectiveness ratio (ICER): reported)
Improvement: See Claes 2005
Notes - This is a cost-effectiveness analysis conducted as a part of the Belgian Improvement
Study on Oral Anticoagulation Therapy (BISOAT) study reported by Claes et al. (see
Claes 2005)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The 66 GP-practices were divided into
four different groups using a stratified
block randomization. Six different strata of
GP-practices were defined depending on
the number of anticoagulated patients (5
patients, 6-14 patients, 15 patients) and
the type of practice (single-handed GP or
group practice). These six strata (numbered
containers with cards) were divided blindly
over the four intervention groups by a uni-
versity staff member as follows: out of the
first container a card was drawn and placed
in box A, the next card in box B, C, D, A,
B, etc. The same procedure was followed
for the other five boxes”
Allocation concealment (selection bias) Low risk Unit of allocation: GP practice
Baseline outcome measurements similar Low risk “The 6 months retrospective analysis
showed that the patients of the practices as-
signed to groups A, B, C, and D were 55,
49, 46, and 44% of time within 0.5 INR-
units from target, respectively. There was
no significant difference among the four
groups in the per centwithin 0.5 INR-units
from target (P = 0.50) or within 0.75 INR-
units from target (P = 0.70)”
Baseline characteristics similar High risk Baseline characteristics were not reported
for GP practices, GPs or participants.
Number of participants per group were not
provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants per group were not
provided
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk GP practices were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Cordingley 2009
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Nurses
Level of training: Not reported
Clinical specialty: ICU
Country: UK (London), Belgium (Leuven)
Centre: 1 large specialist heart and lung hospital affiliated with the university and NHS
Foundation Trust (Royal Brompton Hospital (RBH)), 1 university hospital (University
Hospital Gasthuisberg (KUL))
Location of care: Inpatient care
Participants: 34 critically ill patients admitted to ICU with hyperglycaemia (glucose >
120 mg/dL)
Interventions Clinical problem: Insulin in critically ill patients with hyperglycaemia
Intervention: eMPCalgorithm (n=16participants) vs. standard care (n =18participants)
. The eMPC algorithm calculates the time of the next glucose sample and the optimum
insulin infusion rate expected to achieve the target glucose concentration
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None
Physiological parameters: % of time in target glucose range (hyperglycaemia index (area
of the glucose-time concentration curve above 110 mg/dL (6.1 mmol/L) divided by the
time of the study): not included (data differed between text, table 3, table 4 and table 5
and the author had not replied by January 2012), blood glucose: not included (sample
mean), time-weighted mean glucose concentration (mg/dL) (area under the glucose-
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time curve for each participant divided by the elapsed time): not included)
Time to achieve therapeutic control: Time to establish glucose control (Ttarget ) (time
from study entry until the plasma glucose concentration was in the target range of 80-
110 mg/dL (4.4-6.1 mmol/L)) (minutes), mean sampling interval (hours)
Clinical events: Proportion of participants with plasma glucose concentrations < 60 mg/
dL, proportion of participants with plasma glucose concentrations < 40 mg/dL
Healthcare costs: None
Improvement: None
Notes - “At KULnursing staff (each taking care of 2 patients) aimed tomaintain plasma glucose
in the range 80-110 mg/dL (4.4-6.1 mmol/L) using a paper-based guideline that allows
intuitive decisions to be taken. At RBH, nurses (each taking care of 1 patient) used a
written dynamic insulin infusion protocol targeting a plasma glucose concentration of
72-108 mg/dL (4-6 mmol/L)”
- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients;
www.clinicip.org), an integrated project funded by the European Community
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients entered into the trial were ran-
domized [...]”.No further informationpro-
vided
Allocation concealment (selection bias) Unclear risk “Patients entered into the trial were ran-
domized [...]”.No further informationpro-
vided
Baseline outcome measurements similar Low risk “Glucose concentration at study entry was
similar in both groups (Table 3)”
Baseline characteristics similar Low risk No significant differences on main charac-
teristics (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 18 participants vs 16 participants. No ap-
parent missing data
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
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Other bias High risk An erratum had been published because
there were some inconsistencies in the text
and tables; we found other inconsistencies
in tables, full text, and abstract; the author
was contacted (had not replied by January
2012).
Destache 1990
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Done
Participants Profession: Mixed (physicians + clinical pharmacists)
Level of training: Mixed
Clinical specialty: Internal medicine, surgery ICU
Country: USA (Omaha, Nebraska)
Centre: 1 tertiary care facility (Saint Joseph Hospital)
Location of care: Inpatient care
Participants: 145 participants treated with aminoglycosides for infection
Interventions Clinical problem: Aminoglycoside
Intervention: Participants whose doctors accepted recommendations based on a 1 com-
partment Bayesian pharmacokinetic model (n = 75) vs. those of doctors who did not (n
= 70)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Indirect intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Number of doses adjustments (potential
unit of analysis error) (number of serum aminoglycoside concentrations drawn/partici-
pant: not included)
Serum concentrations and therapeutic range: proportion of participants with first peak
aminoglycoside serum concentrations “adequate” 0.5 h after infusion
Physiological parameters: None
Time to achieve therapeutic control: None (time for elevated temperature to decrease to
< 99.8 °F (37.7 °C): not included, time for elevated heart rate to decrease to < 90 beats/
min: not included, time for respiratory rate to decrease to < 24/min: not included)
Clinical events: Death, nephrotoxicity (≥ 0.5 mg/dL rise in serum creatinine)
Healthcare costs: Length of hospital stay (h), direct cost per participant (USD)
Improvement: None
Notes “First peak concentrations were categorized as ”adequate“ (>=5.0 mcg/ml and >=20.0
mcg/ml for amikacin [an aminoglycoside]), ”low“ (<5.0 mcg/ml and <20.0 mcg/ml for
amikacin), or not drawn”
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“The target trough therapeutic ranges are concentrations of <2.0 mcg/ml for gentamicin
and tobramycin and 5-10 mcg/ml for amikacin”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization assignments were deter-
mined by a table of random numbers”
Allocation concealment (selection bias) Low risk “Assignments were individually placed in
sealed envelopes”
Baseline outcome measurements similar Low risk Not appropriate
Baseline characteristics similar Low risk No significant differences except for weight
(table 3)
Incomplete outcome data (attrition bias)
All outcomes
High risk Many participants excluded from analysis:
20 of the 90 participants from the control
group (monitored by other clinical phar-
macists), 35 of the 110 participants from
the computer advice group (recommenda-
tions were not always followed)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective. Nephrotoxicity
was clearly defined in the methods section
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Fitzmaurice 2000
Methods Design: RCT
Unit of allocation: Primary care practice and participant (2 control populations: partic-
ipants individually randomized as controls in the intervention practices and all partici-
pants in the control practices, which allow an estimate of the Hawthorn effect)
Unit of analysis: Participant, INR (cluster was taken into account in statistical analysis)
Power calculation: Done
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Participants Profession: Mixed (physicians + nurses)
Level of training: Not reported
Clinical specialty: General/family practice
Country: UK (Birmingham)
Centre: 12 practices
Location of care: Community-based care
Participants: 224 outpatients with cardiovascular disease
Interventions Clinical problem: Warfarin adjustment for long-term therapy
Intervention: CDSS group (n = 122) vs. routine care (n = 102)
Computer advice: Given in real time
CDSS integration in CPOE: Not reported
Starter: User-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None
Physiological parameters: Proportion of INR measurements within therapeutic range
(unit of analysis error)
Time to achieve therapeutic control: None
Clinical events: Death, number of haemorrhagic events (epistaxis) per patient-years,
number of thrombotic events per patient-years
Healthcare costs: None
Improvement: None
Notes There were 2 levels of randomization. Practices were randomly tagged as intervention
or control practices. Then, in intervention practices, participants were individually ran-
domized to intervention or control. We did not analyze ’control practices’ because of a
potential unit of analysis error
“Dosing recommendations made by theCDSSwere based on the current INR in relation
to individual therapeutic range, based on the British Society of Haematology guidelines,
with the 2 main ranges being 2.0 to 3.0 and 3.0 to 4.5”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Practices were randomly selected by means
of random numbers from a list of 21 prac-
tices that had expressed interest in the study
Allocation concealment (selection bias) Low risk Practices were randomly selected by means
of random numbers from a list of 21 prac-
tices that had expressed interest in the study
Baseline outcome measurements similar Low risk Not appropriate
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Baseline characteristics similar Low risk No apparent differences (table 2)
Incomplete outcome data (attrition bias)
All outcomes
High risk 224 participants were recruited. 40 par-
ticipants discontinued the study before
12 months, including 11 participants ran-
domized to intervention who returned to
hospital care
Only participants with 3 or more INR re-
sults (n = 202) were included in the analy-
sis of proportion of time spent in the target
INR range
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Mainoutcomeswere objective.Monitoring
for haemorrhagic and thrombotic events is
not clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Practices were randomized and participants
individually randomized as controls in the
intervention practices (intrapractice con-
trols) and all participants in the control
practices (interpractice controls)
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Gonzalez 1989
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not done
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: Not reported
Country: USA (Virginia, Richmond)
Centre: 1 emergency department (Medical College of Virginia)
Location of care: Inpatient care
Participants: 82 participants with asthma treated with aminophylline
Interventions Clinical problem: Theophylline
Intervention: Bayesian 1 compartment pharmacokinetic model (n = 37) vs. population-
based guidelines (n = 30)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: System-initiated
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Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: Theophylline loading dose (mg/kg), theo-
phylline maintenance dose (mg/kg/h)
Serum concentrations and therapeutic range: Theophylline concentration (4 hours post
load) (mg/L) (theophylline concentration at 1 and 2 hours post load: not included)
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: Proportion of participants with adverse reactions (including nausea and
vomiting)
Healthcare costs: None
Improvement: None
Notes “Patients in group 1 received an IV bolus of aminophylline to achieve a serum theo-
phylline concentration of 10 to 20 mg/L”
“Patients in group 2 received and IV aminophylline bolus followed by a maintenance
infusion to achieve a serum theophylline concentration of 15 mg/L”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A random-numbers table was used to pre-
assign82patients to either group1or group
2”
Allocation concealment (selection bias) Low risk “A random-numbers table was used to pre-
assign82patients to either group1or group
2”
Baseline outcome measurements similar Low risk Not appropriate
Baseline characteristics similar Unclear risk No apparent differences on patient demo-
graphics (table 2). No further information
provided
Incomplete outcome data (attrition bias)
All outcomes
High risk “Fifteen patients were excluded because
of protocol violations (three left the ED
against medical advice; 12 had insufficient
blood level data)”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Main outcomes were objective. Adverse
events are not clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
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Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Hickling 1989
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Not reported
Level of training: Not reported
Clinical specialty: Other (intensive care)
Country: New Zealand
Centre: 1 general hospital (Christchurch Hospital)
Location of care: Inpatient care
Participants: 32 ICUpatientswho required aminoglycoside therapy for serious life threat-
ening infections
Interventions Clinical problem: aminoglycoside (gentamicin or tobramycin)
Intervention: Pharmacokinetic model, computer-assisted group (n = 15) vs. control
group (n = 17)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: Aminoglycoside mean peak concentration
at 48-72 h, % participants within drug therapeutic range after 2 days (peak plasma
concentrations 6-10 mg/L measured 1 h after the start of the infusion, and peak trough
concentrations 1-2 mg/L within 30 min of the next dose), % participants achieving
peak plasma concentrations at 48-72 h > 6 mg/L (peak concentration criterion alone)
(proportion of participants achieving peak plasma concentrations at 48-72 h > 5 mg/L:
not included, proportion of participants achieving peak plasma concentrations at 48-72
h > 7 mg/L: not included)
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: None
Improvement: None
Notes “The program was designed to predict the dose and dose interval required to achieve any
desired peak and trough concentration. For the purpose of the study the specific target
concentrations were a peak of 8 mg/l and a trough of 1.5 mg/l”
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was carried out by com-
puter using a random number generator”
Allocation concealment (selection bias) Low risk “Randomisation was carried out by com-
puter using a random number generator”
Baseline outcome measurements similar Low risk Not appropriate
Baseline characteristics similar High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 4 participants (out of 32) were excluded be-
cause a dose change was made on clinical
grounds before the 4th dose of aminogly-
coside
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Hovorka 2007
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: Other (Department of Cardiovascular Surgery)
Country: Czech Republic (Prague)
Centre: 1 university hospital (Charles University and General University Hospital)
Location of care: Inpatient care
Participants: 60 adults admitted for major elective cardiac surgery
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Interventions Clinical problem: Insulin in critically ill patients (cardiac surgery patients)
Intervention: Laptop-based algorithm eMPC (n = 30 participants) vs. standard protocol
treatment (n =30participants). The eMPC is an enhanced versionof themodel predictive
control algorithm (MPC), amodel of the glucoregulatory system.Glucose concentration,
insulin dosage, and carbohydrate content of enteral and parenteral input are the input
variables for the eMPC. The insulin infusion rate and the time of the next glucose sample
are the outputs
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Total Insulin dose (insulin units/24 h)
Serum concentrations and therapeutic range: None
Physiological parameters: % of time within the target range for blood glucose in the
first 24 h (80-110 mg/dL or 4.4-6.1 mmol/L), blood glucose levels at ICU (mmol/L)
(blood glucose levels at operating theatre: not included, time (h) above the target range
for blood glucose in the first 24 h (>110 mg/dL): not included, time (h) under the target
range for blood glucose in the first 24 h (>110 mg/dL): not included)
Time to achieve therapeutic control: Mean sampling interval (hours)
Clinical events: Proportion of participants with hypoglycaemic episodes (blood glucose
level < 2.9 mmol/L)
Healthcare costs: None
Improvement: None
Notes - “The target range for blood glucose levels, as defined by the study protocol, was 4.4-6.1
mmol/liter, which has reduced mortality and morbidity in post-cardiac surgery patients.
” “Severe hypoglycemia was defined as blood glucose less than 2.9 mmol/liter”
- The authors were contacted and confirmed that none of the participants from Kremen
2007 was included in Hovorka 2007
- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients;
www.clinicip.org), an integrated project funded by the European Community
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation not specified
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk No significant differences on blood glucose
at study start or number of participants
treated with diabetes before study start (ta-
ble 1)
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Baseline characteristics similar Low risk No significant differences on baseline char-
acteristics (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of glucose values used for cal-
culation varied in each hour (figure 2) but
the blood glucose was measured in 1- to 4-
h intervals as requested by each algorithm
during surgery and postoperatively over 24
h
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomes were objective. Hypogly-
caemic episodes are clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Hurley 1986
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Other (emergency)
Country: Australia (Victoria)
Centre: 1 community hospital (Preston and Northcote Community Hospital (PANCH)
)
Location of care: Inpatient care
Participants: 91 participants admitted to hospital with asthma
Interventions Clinical problem: Theophylline
Intervention: Doctors given estimate of theophylline clearance based on 1 compartment
linear pharmacokinetic model (n = 48) vs. usual care based on theophylline levels (n =
43). Computer gave advice on dose each day based on estimates of theophylline clearance
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: System-initiated
Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
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Outcomes Dose of drug administered to the participant: Initial and maintenance daily dose of
theophylline (mg/day)
Serum concentrations and therapeutic range: serum concentration at day 2 (µg/mL),
proportions of participants with serum trough concentrations in the therapeutic range,
proportions of participants with serum concentrations in the toxic range
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: Death, length of stay
Improvement: None
Notes “Ideally theophylline serum concentrations should be within a relatively narrow thera-
peutic range of 10 to 20 µg/ml”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Baseline outcome measurements similar Low risk Not appropriate
Baseline characteristics similar Low risk No apparent differences (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 96 participants enrolled, 91 participants
analyzed (1 participant because of intoler-
ance to aminophylline, 1 because of lack of
cooperation, 3 because of previous enrol-
ment in the trial)
Loading doses were available for 72 partic-
ipants, infusion rate at day 1 for 91 par-
ticipants, infusion rate at day 2 for 74 par-
ticipants. Missing values were equally dis-
tributed and unlikely to overturn the study
results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
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Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Jowett 2009
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: INR
Power calculation: Done
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Not reported
Country: Europe, Israel, Australia
Centre: 32 centres in 13 countries (Europe: 29, Israel: 2, Australia: 1)
Location of care: Outpatient care
Participants: 13,219 anticoagulation patients randomized at each centre into manual-
dosed or computer-assistant dosed arm (DAWN AC or PARMA 5). 13,052 participants
analyzed (167 participants without INR results): 2631 for the DAWN AC study and
10,421 for the PARMA 5 study
Interventions Clinical problem: Oral anticoagulation (warfarin, nicoumalone (acenocoumarol), phen-
procoumon)
Intervention: Computer-assisted dosage program (PARMA5 (n = 5290 participants)
) versus manual dosage (n = 5131 participants). Computer-assisted dosage program
(DAWN AC (n = 1315 participants)) versus Manual dosage (n = 1316 participants).
Recruitment was restricted to new patients initiated oral anticoagulation. 2 subroutines:
induction and steady-state monitoring; the aim of the dosage algorithm was to maintain
the INR value as close as possible to the mean target INR and to provide the next
appointment date
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: System-initiated
Type of intervention: Not reported
Calculated dose given as a recommendation: No
Outcomes Dose of drug administered to the participant: See Poller 2008 PARMA 5 and Poller
2009 DAWN AC
Serum concentrations and therapeutic range: See Poller 2008 PARMA 5 and Poller 2009
DAWN AC
Physiological parameters: See Poller 2008 PARMA 5 and Poller 2009 DAWN AC
Time to achieve therapeutic control: See Poller 2008 PARMA 5 and Poller 2009 DAWN
AC
Clinical events: See Poller 2008 PARMA 5 and Poller 2009 DAWN AC
Healthcare costs: None (total cost per participant (Euros, base 2006) for all INR visits
during the time period of the study (4.5 years) (dosing cost (staff time and the software
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for computer dosing), clinical event cost): reported)
Improvement: See Poller 2008 PARMA 5 and Poller 2009 DAWN AC
Notes - This is a cost-effectiveness analysis conducted as a part of the European Action on
Anticoagulation’s (EEA) randomized multicentre study of computer-assisted oral anti-
coagulant dosage vs. manual dosing reported by Poller et al (see Poller 2008 PARMA 5
and Poller 2009 DAWN AC)
- Costs were available for 28/32 clinics. There was no distinct results for PARMA 5 and
DAWN AC systems
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar Low risk No apparent differences on baseline char-
acteristics of the 13,052 participants (see
table 1 of Poller 2008 PARMA 5 and Poller
2009 DAWN AC)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Both cost and outcome data were available
for 6218/6447 inmanual-dosed group and
6366/6605 in computer-assisted dosage
group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomeswere objective. Events were
adjudicated by a committee
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
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Kremen 2007
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: Other (Department of Cardiovascular Surgery ICU)
Country: Czech Republic (Prague)
Centre: 1 university hospital (Charles University and General University Hospital)
Location of care: Inpatient care
Participants: 20 adults who underwent a planned-cardiac surgery (coronary artery bypass
or valve replacement) with glycaemia higher than 6.7 mmol/L at the time of admission
to ICU
Interventions Clinical problem: Insulin in critically ill patients (cardiac surgery patients) with hyper-
glycaemia
Intervention: Laptop-based algorithm MPC (n = 10 participants) vs. routine blood
glucose management protocol (n = 10 participants). The MPC is a model representing
the glucoregulatory system. Glucose concentration, insulin dosage, and carbohydrate
intake are the input variables for the MPC. The insulin infusion rate is the output
parameter and was adjusted hourly as suggested by the algorithm
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: Total Insulin dose (insulin units/48 h)
Serum concentrations and therapeutic range: None
Physiological parameters: Mean blood glucose (mmol/L) (Time (h) within the target
range for blood glucose in the first 24 h (80-110 mg/dL or 4.4-6.1 mmol/L): reported,
duration of hyperglycaemia (> 8.3 mmol/L) (h): not included)
Time to achieve therapeutic control: Time to establish glucose control (Ttarget ) (time
from study entry until the plasma glucose concentration was in the target range of 80-
110 mg/dL (4.4-6.1 mmol/L)) (min), time to target range (hours)
Clinical events: Proportion of participants with hypoglycaemic episodes (blood glucose
level < 2.9 mmol/L)
Healthcare costs: None
Improvement: None
Notes - “The target range for blood glucose levels, as defined by the study protocol, was 4.4-6.1
mmol/liter, which has reduced mortality and morbidity in post-cardiac surgery patients.
” “Severe hypoglycemia was defined as blood glucose less than 2.9 mmol/liter”
- The authors were contacted and confirmed that none of the participants from Kremen
2007 was included in Hovorka 2007
- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients;
www.clinicip.org), an integrated project funded by the European Community
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation not specified
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk No significant differences on blood glucose
at study start (table 2)
Baseline characteristics similar High risk 5 men/5 women in MPC group, 9 men/1
women in standard group (table 2)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The blood glucose was measured in 1- to 2-
h intervals as requested by each algorithm
during surgery and postoperatively over 48
h
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomes were objective. Hypogly-
caemic episodes are clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Unclear risk Pilot study. Outcomes were not defined in
the methods section
Other bias Unclear risk Pilot study with 10 participants in each
groups. Article in Czech language. Authors
were contacted but had not replied by
February 2012
Le Meur 2007
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Done
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Nephrology
Country: France
Centre: 11 centres
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Location of care: Inpatient care
Participants: 137 renal allograft recipients receiving basiliximab, CsA, MMF and corti-
costeroids. 130 participants analyzed
Interventions Clinical problem: MMF dosing in renal transplant patients
Intervention: Concentration-controlled (CC) regimen (n = 65 participants) vs. fixed-
dose (FD) MMF (n = 65 participants). In the CC group, MMF dose adjustments were
calculated by a computer program to reach an MPA AUC target of 40 mg.h/L and were
proposed to the physician. In the FD group, MMF dose adjustments were based on
clinical experience
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None (MMF dose: not included (fixed
dose in control group))
Serum concentrations and therapeutic range: None (serum creatinine level (µmol/L):
not included)
Physiological parameters: None (%participants within therapeutic range at day 14 (MPA
AUC > 30 mg.h/L): reported)
Time to achieve therapeutic control: None
Clinical events: Death, proportion of participants with cytomegalovirus infections, pro-
portion of participants with adverse events (anaemia, leukopenia, gastrointestinal adverse
effects, infections)
Healthcare costs: None
Improvement: Proportion of participants without treatment failure (a composite of
death, graft loss, acute rejection and MMF discontinuation), proportion of participants
without biopsy-confirmed rejections
Notes Primary outcome: Treatment failure (a composite of death, graft loss, acute rejection and
MMF discontinuation)
“In the CC group, MMF dose adjustments were calculated by a computer program
(available at www.chu-limoges.fr/stp/stpacces.htm, June 21, 2007) to reach an MPA
AUC target of 40 mg.h /L. The minimum dose change was 250 mg twice a day. Each
dose adjustment of at least 250 mg twice a day that was able to result in an AUC closer
to 40 mg.h /L was proposed by the program to the physician”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Within the first 3 days posttransplant, pa-
tients were randomized by an interactive
voice response system administered by a
private company; randomization was bal-
ancedwithin centers in blocks of 4 patients,
and patients were enrolled and assigned to
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one of the two groups by physicians at each
center”
Allocation concealment (selection bias) Low risk “Within the first 3 days posttransplant, pa-
tients were randomized by an interactive
voice response system administered by a
private company; randomization was bal-
ancedwithin centers in blocks of 4 patients,
and patients were enrolled and assigned to
one of the two groups by physicians at each
center”
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar High risk “The sex ratio differed between groups in
that there were a larger percentage of males
in the CC-treated group (Table 1)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “There were seven withdrawals (CC, n =
5; FD, n = 2) due to death, primary non
functioning graft or because MMF was
not administered.” In most of tables, only
percentages are reported and according to
the first decimal of percentages, there were
missing data in the denominator. However,
missing valueswere unlikely to overturn the
study results
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Acute rejection was diagnosed by renal
biopsy except in patients with contraindi-
cations and were graded according to the
Banff classification, in which case diagnosis
was based on clinical and laboratory crite-
ria (in particular, any unexplained increase
in serum creatinine).” No committee re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
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Le Meur 2007 extract
Methods
Participants
Interventions
Outcomes
Notes Text extracted from original article Le Meur 2007
Leehey 1993
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Mixed (physicians + pharmacists)
Level of training: Not reported
Clinical specialty: Not applicable
Country: USA (Hines, Illinois)
Centre: 1 Veterans Affairs Hospital
Location of care: Inpatient care
Participants: 324 participants receiving aminoglycosides for suspected or confirmed in-
fection were enrolled and randomly assigned to 1 of 3 groups: usual physician-directed
dosing (group 1), pharmacist-assisted dosing (group 2), or pharmacist-directed dosing
(group 3). 81 participants were dropped from the study because they received < 72 h of
therapy, leaving 243 study participants (73 in group 1, 90 in group 2, 80 in group 3)
Interventions Clinical problem: Aminoglycoside in participants with suspected or confirmed infection
Intervention: Pharmacist-directed dosing (group 3, n = 80) vs. usual physician-directed
dosing (group 1, n = 73). Participants randomized to group 1 (customary dosing) had no
intervention from study personnel other than the placement of an order in the hospital
chart for the determination of serum creatinine levels post-therapy. In participants ran-
domized to group 3 (pharmacist-directed dosing), all orders for aminoglycoside dosing
were written by a pharmacist (with countersignature by 1 of the 2 study physicians) spe-
cially trained in the Bayesian dosing methods used in the study). Group 2 (pharmacist-
assisted dosing) was excluded: dosing and monitoring recommendations were written
by a pharmacist in the progress note section of the hospital chart, and the physicians
caring for the participant were notified of these suggestions (the pharmacist served as a
consultant)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Indirect intervention
Calculated dose given as a recommendation: Yes
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Outcomes Dose of drug administered to the participant: Mean total aminoglycoside doses (mg)
(duration of therapy: not included)
Serum concentrations and therapeutic range: Mean peak serum aminoglycoside levels
(µg/mL) (mean serum trough concentrations (µg/mL): reported)
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: Need for dialysis, nephrotoxicity
Healthcare costs: None
Improvement: Proportion of participants with response to treatment
Notes Nephrotoxicity was defined as a ≥ 100% increase in serum creatinine concentration
with at least a 44 µmol/L (0.5 mg/dL) increment in this value
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk Not appropriate
Baseline characteristics similar High risk Sex gender not reported. There were dif-
ferences on use of contrast media and the
presence of lung disease
Incomplete outcome data (attrition bias)
All outcomes
Low risk 81 participants were dropped from the
study because they received < 72 h of ther-
apy, leaving 243 study participants (73 in
group 1, 90 in group 2, 80 in group 3).
Incomplete data were unlikely to overturn
the study results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Study data were reviewed by one of the
authors who was blinded as to group as-
signment”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
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Lesourd 2002
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: Obstetrics and gynaecology
Country: France (Toulouse, Rouen, Paris)
Centre: 3 centres (private and university teaching hospitals)
Location of care: Outpatient care
Participants: 164 women undergoing ovarian stimulation to treat infertility
Interventions Clinical problem: Ovarian stimulation by gonadotropins
Intervention: CDSS group (n = 82) vs. control group (n = 82)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Number of follicle-stimulating hormone
units administered
Serum concentrations and therapeutic range: None
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: None (cancelled cycles of ovarian stimulation: not included)
Healthcare costs: None
Improvement: Proportionof participantswith clinical pregnancies (ongoing pregnancies:
not included, mean number of follicles ≥ 18 mm: not included)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar High risk Participants in the group with the decision
by software were younger than in the group
with the decision by clinicians (31.7 ± 4.5
years versus 33.1 ± 4.2 years, P value < 0.
05 (table 2))
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomes (pregnancies) are objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Unclear risk Few results reported (1 sentence in the re-
sults). Not enough information to evaluate
the bias of the study
Manotti 2001
Methods Design: NRCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Done
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Not reported
Country: Italy
Centre: 5 anticoagulant clinics, all federated with the FCSA (Italian Federation of Anti-
coagulation Clinics)
Location of care: Outpatient care
Participants: 335 participants on oral anticoagulants
Interventions Clinical problem: initiation of oral anticoagulant therapy (warfarin and acenocoumarol)
Intervention: Computer-aided dosing (n = 145) vs. manual dosing (n = 190)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: System-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None (maintenance dose (mg/week): not
included (number of appointments, available only for warfarin))
Serum concentrations and therapeutic range: None
Physiological parameters: None (% of participants reaching a stable state of anticoagu-
lation (3 INR measurements within therapeutic range): reported)
Time to achieve therapeutic control: None
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Clinical events: None
Healthcare costs: None
Improvement: None
Notes “The use of only two separate therapeutic ranges was suggested:
Low Intensity = INR 2.0 to 3.0; target value 2.5. People with deep venous thrombosis/
pulmonary embolism, atrial fibrillation, heart valve disease, biological valve prosthesis.
High Intensity = INR 3.0 to 4.5 ; target value 3.5. People with a mechanical heart valve
prosthesis, coronary or other arterial disease”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized into two arms.
” No further information provided
Allocation concealment (selection bias) Unclear risk “Patients were randomized into two arms.
” No further information provided
Baseline outcome measurements similar Low risk Not applicable (initiation of oral anticoag-
ulant therapy)
Baseline characteristics similar Low risk No apparent differences (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data were provided with patient-years. No
details for follow-up
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
115Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mihajlovic 2003
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Not reported
Level of training: Not reported
Clinical specialty: Psychiatry
Country: Serbia
Centre: 1 psychiatric clinic of a clinical hospital centre (Clinical Hospital Center Kragu-
jevac)
Location of care: Not reported
Participants: 60 participants with major depressive disorder (according to ICD-10)
Interventions Clinical problem: Amitriptyline in the treatment of major depressive episode
Intervention: Computer-aided dosing of amitriptyline (n = 30 participants) vs. usual
dose regimen (n = 30 participants). The individualization of amitriptyline dose was cal-
culated using the modified Bayesian method (on the basis of therapeutic steady-state
concentration of 80 ng/mL, participant’s sex, weight, age, creatinine plasma concentra-
tion, albumin plasma concentration and volume of the liquid on the ’third space’)
Computer advice: Not reported
CDSS integration in CPOE: Not reported
Starter: Not reported
Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: Drug daily doses of amitriptyline + nor-
triptyline at day 14 (mg) (at day 28, day 42, day 56: not included)
Serum concentrations and therapeutic range: None
Physiological parameters: Steady-state plasma concentration of amitriptyline + nortripty-
line at J14 (during the treatment course) (at day 28, day 42, day 56: not included)
Time to achieve therapeutic control: None
Clinical events: Proportion of participants with adverse effects of amitriptyline per days
of research at day 14 (at day 28, day 42, day 56: not included)
Healthcare costs: None
Improvement: Hamilton Depression Rating scale scores at day 28 (at day 14, day 42,
day 56: not included, Clinical Global Impression scale: not included)
Notes Among the 60 participants included in the study, 15 were also included in Jankovic 1999
(excluded study)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random table, in blocks of 10”
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Allocation concealment (selection bias) Unclear risk “Random table, in blocks of 10”. No fur-
ther information provided
Baseline outcome measurements similar Low risk Not appropriate
Baseline characteristics similar Low risk “In general, the demographic characteris-
tics of the patients were similar in the ex-
perimental and control groups (table 1)”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated. Denominator not reported in
tables
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Main outcomes were objective. Hamilton
scale is an hetero-questionnaire
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias High risk Selection bias/opportunistic series:
- Mihajlovic 2003: 60 participants admit-
ted during 1997
- Mihajlovic 2010: Safety analysis of the
study reported by Mihajlovic 2003
All 15 participants from the Jankovic study
were included in theMihajlovic study (con-
firmed by the author S. Jankovic)
Mihajlovic 2010
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Not reported
Level of training: Not reported
Clinical specialty: Psychiatry
Country: Serbia
Centre: 1 psychiatric clinic of a clinical hospital centre (Clinical Hospital Center Kragu-
jevac)
Location of care: Not reported
Participants: 60 participants with major depressive disorder (according to ICD-10)
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Interventions Clinical problem: Amitriptyline in the treatment of major depressive episode
Intervention: Computer-aided dosing of amitriptyline (n = 30 participants) vs. usual
dose regimen (n = 30 participants). The individualization of amitriptyline dose was cal-
culated using the modified Bayesian method (on the basis of therapeutic steady-state
concentration of 80 ng/mL, participant’s sex, weight, age creatinine plasma concentra-
tion, albumin plasma concentration and volume of the liquid on the ’third space’)
Computer advice: Not reported
CDSS integration in CPOE: Not reported
Starter: Not reported
Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: See Mihajlovic 2003
Serum concentrations and therapeutic range: See Mihajlovic 2003
Physiological parameters: See Mihajlovic 2003
Time to achieve therapeutic control: See Mihajlovic 2003
Clinical events: None
Healthcare costs: See Mihajlovic 2003
Improvement: See Mihajlovic 2003
Notes This is a safety analysis conducted as a part of the randomized multicentre study of
computer-aided dosing of amitriptyline vs. usual dose regimen reported by Mihajlovic
et al. (see Mihajlovic 2003)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random table, in blocks of 10”
Allocation concealment (selection bias) Unclear risk “Random table, in blocks of 10”. No fur-
ther information provided
Baseline outcome measurements similar Low risk Not appropriate
Baseline characteristics similar Unclear risk “In general, the demographic characteris-
tics of the patients were similar in the ex-
perimental and control groups”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated. Denominator not reported in
tables
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Main outcomes were objective. Clinical
Global Impression Scale is an hetero-ques-
tionnaire
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were randomized
Selective reporting (reporting bias) Unclear risk All relevant outcomes were reported in the
results section
Other bias Unclear risk Selection bias/Opportunistic series:
- Mihajlovic 2003: 60 participants admit-
ted during 1997
- Mihajlovic 2010: Safety analysis of the
study reported by Mihajlovic 2003
All 15 participants from the Jankovic study
were included in theMihajlovic study (con-
firmed by the author S. Jankovic)
Mitra 2005
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant, dose of treatment
Power calculation: Not done
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: Rehabilitation
Country: USA
Centre: 1 free-standing, 288-bed, academic rehabilitation centre
Location of care: Inpatient care
Participants: 280 hospitalized rehabilitation patients who were prescribed warfarin for
anticoagulation
Interventions Clinical problem:Warfarin (Coumadin) to maintain hospitalized rehabilitation patients
within a therapeutic INR (2.0-3.0)
Intervention: Computer-aided dosing of warfarin (n = 14 participants) vs. physician
dosing (n = 16 participants). The computer-generated program (DAWN AC) gave in-
structions to the physicians for warfarin dosing and for timing and frequency of blood
draws
Computer advice: Given in real time
CDSS integration in CPOE: Not reported
Starter: Not reported
Type of intervention: Not reported
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None
Physiological parameters: None (time spent in days per 100 patient-days of treatment:
reported)
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Time to achieve therapeutic control: None
Clinical events: Proportion of participants with thromboembolism (pulmonary em-
bolism, deep vein thrombosis) (number of blood draws: not included)
Healthcare costs: Length of stay (days)
Improvement: None
Notes “The goal of both groups was to maintain patients within a target INR of 2.0 - 3.0”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects were randomized using a random
number table into one of twogroups: group
P (physician dosing) or group C (computer
dosing)”
Allocation concealment (selection bias) Unclear risk “Subjects were randomized using a random
number table into one of twogroups: group
P (physician dosing) or group C (computer
dosing).” No further information provided
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar High risk “A larger percentage of patients in group C
had a history of atrial fibrillation (28% vs.
6%), and group P had a larger proportion
of patients with a history of DVT [deep
vein thrombosis] (50% vs. 7%)”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “The total number of data points (INR val-
ues) was 1014, excluding 36 days during
which the INR score could not be imputed.
” The original group of 32 patients was re-
duced to 30 through loss of data sheets. It
is unclear if missing values could overturn
the study results
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Pulmonary embolism, deep vein thrombo-
sis: No committee reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
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Other bias Low risk No evidence of other risk of biases
Mungall 1994
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Done
Participants Profession: Mixed physicians + pharmacists)
Level of training: Not reported
Clinical specialty: Other (coronary care unit)
Country: USA (Michigan)
Centre: 2medical centres (McLarenRegionalMedical Center,MidlandRegionalMedical
Center)
Location of care: Inpatient care
Participants: 51 participants needing anticoagulation with heparin after myocardial in-
farction
Interventions Clinical problem: Heparin adjustment
Intervention: Bayesian computer-generated starting doses (n = 25) vs. doctors using
nomogram (n = 26)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Indirect intervention (dosage determined by pharmacy using)
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: mean heparin dose (units/h)
Serum concentrations and therapeutic range: None
Physiological parameters: None (activated partial thromboplastin time ratio (compared
with baseline activated partial thromboplastin time before heparin therapy): not in-
cluded, number of activated partial thromboplastin time measurements per day of ther-
apy: not included)
Time to achieve therapeutic control: None
Clinical events: Proportion of participants with clinical adverse events (recurrent chest
pain, recurrent chest pain and readministration of thromboplastin, development of con-
gestive heart failure, thrombotic stroke, arterial embolization, pulmonary embolus, tran-
sient ischaemic attack), proportion of participants with bleeding events
Healthcare costs: None
Improvement: None
Notes - The therapeutic range was 1.2-2.5 times the participant’s baseline activated partial
thromboplastin time
Risk of bias
Bias Authors’ judgement Support for judgement
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Mungall 1994 (Continued)
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar Low risk No significant differences on main charac-
teristics (table II)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Mean length of stay was 8 days. Accord-
ing to denominator in tables, there were no
missing data
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomes were objective. Bleeding
and clinical events are clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Pachler 2008
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported (non-inferiority trial but no margin addressed)
Participants Profession: Nurses
Level of training: Not reported
Clinical specialty: ICU
Country: Austria (Graz)
Centre: 1 x 9-bed medical ICU in a tertiary teaching hospital
Location of care: Inpatient care
Participants: 50 mechanically ventilated medical ICU patients
Interventions Clinical problem: Insulin in critically ill patients with hyperglycaemia
Intervention: Laptop-based algorithm eMPC (n = 25 participants) vs. routine nurse-
based protocol (n = 25 participants). The eMPC is an enhanced version of the MPC,
a model of the glucoregulatory system. Glucose concentration, insulin dosage and car-
bohydrate content of enteral and parenteral input are the input variables for the eMPC.
The insulin infusion rate and the time of the next glucose sample are the outputs
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Pachler 2008 (Continued)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Insulin (IU/h) (change of insulin rate
(number of times in 72 h): reported, carbohydrate administration (g/h): not included)
Serum concentrations and therapeutic range: None
Physiological parameters: Hyperglycaemia index (mmol/L) (blood glucose (mmol/L):
not included (unit of analysis error))
Time to achieve therapeutic control: Mean sampling interval (hours)
Clinical events: Proportion of participants with hypoglycaemic episodes (blood glucose
levels lower than 2.2 mM)
Healthcare costs: None
Improvement: None
Notes - Hyperglycaemic index was used as primary endpoint for the assessment of glucose
control. The hyperglycaemic index developed by Vogelzang et al. is defined as the AUC
above the upper limit of normal (glucose level 6.1 mmol/L, modified from the original
6.0 mmol/L) divided by the total length of stay (time in study)
- Non-inferiority trial analyzed like superiority trial
- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients;
www.clinicip.org), an integrated project funded by the European Community
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants fulfilling the inclusion crite-
rion were randomly assigned using seri-
ally numbered, sealed envelopes to either
the intervention group (BG control by the
eMPC) or the control group (routine BG
management protocol)
Allocation concealment (selection bias) Low risk Participants fulfilling the inclusion crite-
rion were randomly assigned using seri-
ally numbered, sealed envelopes to either
the intervention group (BG control by the
eMPC) or the control group (routine BG
management protocol)
Baseline outcome measurements similar Low risk No significant differences on blood glucose
at study start or number of participants
treated with insulin before study start (ta-
ble 1)
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Pachler 2008 (Continued)
Baseline characteristics similar Low risk No significant differences on baseline char-
acteristics (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated. Denominator not reported in
tables. The treatment was discontinued
ahead of schedule in 2 participants of the
control group and in 5 participants as-
signed to the eMPC group. It is not clear if
these participants were excluded from anal-
ysis
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomes were objective. Hypogly-
caemic episodes are clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Plank 2006
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant, time under treatment
Power calculation: Not reported
Participants Profession: Not reported
Level of training: Not reported
Clinical specialty: ICU
Country: Europe (Austria, Czech Republic, UK)
Centre: 3 ICUs across Europe (Graz, Prague, London)
Location of care: Inpatient care
Participants: 60 participants undergoing cardiac surgery with postsurgery hypergly-
caemia (glucose > 120 mg/dL)
Interventions Clinical problem: Insulin in critically ill patients with hyperglycaemia
Intervention: Laptop-based algorithm MPC (n = 30 participants) vs. routine blood
glucosemanagement protocol (n =30participants). TheMPC is amodel representing the
glucoregulatory system. Glucose concentration, insulin dosage and carbohydrate intake
are the input variables for the MPC. The insulin infusion rate is the output parameter
and was adjusted hourly as suggested by the algorithm
Computer advice: Given in real time
CDSS integration in CPOE: No
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Plank 2006 (Continued)
Starter: User-initiated
Type of intervention: Indirect intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Insulin dosages used for the first 24 h
(insulin units/24 h)
Serum concentrations and therapeutic range: None
Physiological parameters: % of time within the target range for blood glucose in the first
24 h (80-110 mg/dL or 4.4-6.1 mmol/L), mean glucose levels (mg/dL) (% of time above
the target range for blood glucose in the first 24 h (> 110 mg/dL): not included, % of
time between 54 and 79 mg/dL for blood glucose in the first 24 h (2.9 to < 4.4 mmol/
L): not included)
Time to achieve therapeutic control: Mean sampling interval (h)
Clinical events: Proportion of participants with hypoglycaemic episodes (blood glucose
level < 54 mg/dL or < 3 mmol/L)
Healthcare costs: None
Improvement: None
Notes - “The target range for blood glucose levels, as defined by the study protocol, was 80-110
mg/dl (4.4-6.1mmol/l), which has beendemonstrated to reducemortality andmorbidity
in postcardiac surgery patients. The MPC algorithm and the routine care management
protocol in Graz are aiming for exactly the same target range, while in Prague a slightly
higher level for the upper limit (81-117mg/dl [4.5-6.5mmol/l]) and in London a slightly
lower level for the lower limit (72-108 mg/dl [46 mmol/l]) is implemented in the routine
glucose protocol. Likewise, small differences in the definition of hypoglycemia can be
found among the routinemanagement protocols (London: 54mg/dl [3.0mmol/l], Graz:
60 mg/dl [3.3 mmol/l], and Prague: 63 mg/dl [3.5 mmol/l]). For the study protocol,
blood glucose levels 54 mg/dl (3.0 mmol/l) were defined as hypoglycemic events”
- The author was contacted and confirmed that the algorithm gave advice to the ICU
personnel (nurses and physicians), who input the glucose values and changed the infusion
rate
- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients;
www.clinicip.org), an integrated project funded by the European Community
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “60 patients were randomized by individ-
ual centers in blocks of 10”
Allocation concealment (selection bias) Unclear risk “60 patients were randomized by individ-
ual centers in blocks of 10”. No further in-
formation provided
Baseline outcome measurements similar Unclear risk Blood glucose at entry was reported by
ICU (Graz, Prague, London) but not across
study groups (table 1)
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Plank 2006 (Continued)
Baseline characteristics similar High risk Baseline characteristics of participants were
reported by ICU (Graz, Prague, London)
but not across study groups (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated. Denominator not reported in
tables
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomes were objective. Hypogly-
caemic episodes are clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Poller 1998 pop1
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Episode of care
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Not applicable
Country: Europe (Manchester (UK), London (UK), Oslo (Norway), Esbjerg (Denmark)
, Gaia (Portugal))
Centre: 5 centres
Location of care: Outpatient care
Participants: 79 inpatients needing anticoagulant therapy (stabilized patients)
Interventions Clinical problem: Warfarin therapy maintenance
Intervention: Computer-generated-dose group (n = 39) or traditional-dose group (n =
40)
Computer advice: Not reported
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Not reported
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None (proportion of doses adjustments:
unknown denominator)
Serum concentrations and therapeutic range: None
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Poller 1998 pop1 (Continued)
Physiological parameters: Proportion of time spent within target (INR)
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: None
Improvement: None
Notes The proportion of time within target INR range was determined according to the
Rosendaal method
“The program has two main modules - the induction module for starting warfarin
therapy over the first 4 days to reach a dose within 1 mg of eventual maintenance dose,
and the maintenance module (version 4 only was used) for finely tuning the dose to the
therapeutic range and sustaining it”
“The INR target ranges were decided by the individual centre, based on one of: the
guidelines on oral anticoagulation of the British Society of Haematology, the Leuven
Group, and the ACCP Consensus. Three different ranges of INR resulted; 2.0-3.0, 3.0-
4.5, and 2.5-3.5”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was done according to
computer-generated order at each centre”
Allocation concealment (selection bias) Low risk “Randomisation was done according to
computer-generated order at each centre”
Baseline outcome measurements similar Low risk Not appropriate (warfarin therapy mainte-
nance)
Baseline characteristics similar High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 285 randomized, 254 analyzed (16 ex-
cluded vs. 15)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
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Poller 1998 pop2
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Episode of care
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Not applicable
Country: Europe (Manchester (UK), London (UK),Oslo (Norway), Esbjerg (Denmark)
, Gaia (Portugal))
Centre: 5 centres
Location of care: Outpatient care
Participants: 175 outpatients needing anticoagulant therapy (in the stabilization period)
Interventions Clinical problem: Warfarin therapy stabilization
Intervention: Computer-generated-dose group (n = 83) or traditional-dose group (n =
92)
Computer advice: Not reported
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Not reported
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None (proportion of doses adjustments:
unknown denominator)
Serum concentrations and therapeutic range: None
Physiological parameters: Proportion of time spent within target (INR)
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: None
Improvement: None
Notes The proportion of time within target INR range was determined according to the
Rosendaal method
“The program has two main modules - the induction module for starting warfarin
therapy over the first 4 days to reach a dose within 1 mg of eventual maintenance dose,
and the maintenance module (version 4 only was used) for finely tuning the dose to the
therapeutic range and sustaining it”
“The INR target ranges were decided by the individual centre, based on one of: the
guidelines on oral anticoagulation of the British Society of Haematology, the Leuven
Group, and the ACCP Consensus. Three different ranges of INR resulted; 2.0-3.0, 3.0-
4.5, and 2.5-3.5”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was done according to
computer-generated order at each centre”
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Poller 1998 pop2 (Continued)
Allocation concealment (selection bias) Low risk “Randomisation was done according to
computer-generated order at each centre”
Baseline outcome measurements similar Low risk Not appropriate (Warfarin therapy main-
tenance)
Baseline characteristics similar High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 285 randomized, 254 analyzed (16 ex-
cluded versus 15)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Poller 2002
Methods
Participants
Interventions
Outcomes
Notes - Same data as Poller 1998 pop1; Poller 1998 pop2
Poller 2003
Methods
Participants
Interventions
Outcomes
Notes - Abstract corresponding to the Protocol of the study published in 2008 (Poller 2008)
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Poller 2008
Methods
Participants
Interventions
Outcomes
Notes - Clinical endpoint report from the European Action on Anticoagulation (EAA), which gave the combined results
using 2 currently marked computer-assisted dosage programs (DAWN AC and PARMA 5). The subgroup analyses
were included (Poller 2009 DAWN AC, Poller 2008 PARMA 5)
Poller 2008 PARMA 5
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: INR
Power calculation: Done
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Not reported
Country: Europe, Israel, Australia
Centre: 32 centres in 13 countries (Europe: 29, Israel: 2, Australia: 1)
Location of care: Outpatient care
Participants: 13,219 anticoagulation patients randomized at each centre into manual-
dosed or computer-assistant dosed arm (DAWN AC or PARMA 5). 13,052 participants
analyzed (167 participants without INR results): 2631 for the DAWN AC study and
10,421 for the PARMA 5 study
Interventions Clinical problem: Oral anticoagulation (warfarin, nicoumalone (acenocoumarol), phen-
procoumon)
Intervention: Computer-assisted dosage program (PARMA5 (n = 5290 participants))
versusmanual dosage (n = 5131 participants). Recruitment was restricted to new patients
initiated oral anticoagulation. 2 subroutines: induction and steady state monitoring; the
aim of the dosage algorithm was to maintain the INR value as close as possible to the
mean target INR and to provide the next appointment date
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: System-initiated
Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None
Physiological parameters: Time in target INR range (INR: not included)
Time to achieve therapeutic control: None
Clinical events: Death, number of bleeding events (major + minor) (events per 100
patient-years), number of thrombotic events (events per 100 patient-years) (number of
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Poller 2008 PARMA 5 (Continued)
events (minor bleeding events, major bleeding events, thrombotic events, deaths): not
included)
Healthcare costs: None
Improvement: None
Notes - Time in target INR range = proportion of time for which participants were maintained
within the locally decided target INR ranges
- This report is a subgroup analysis of the previous clinical endpoint report from the
European Action on Anticoagulation (EAA) (Poller 2008b), which gave the combined
results using 2 currently marked computer-assisted dosage programs (DAWN AC and
PARMA 5 ) (Poller 2009 DAWN AC, Poller 2008 PARMA 5)
- There were some incoherences between the number of events adjudicated in Poller
2008b (table 2) and the sum of number of events in Poller 2008 PARMA 5 (table II)
and in Poller 2009 DAWN AC (table 2). The author confirmed the numbers in Poller
2008b and Poller 2008 PARMA 5 and corrected those in Poller 2009 DAWN AC
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar Low risk No apparent differences on baseline char-
acteristics of the 10,421 participants (table
1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 44/5175 in manual-dosed group and 87/
5377 in computer-assisted dosage group
did not receive allocated intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomeswere objective. Events were
adjudicated by a committee
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
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Poller 2009 DAWN AC
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: INR
Power calculation: Done
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Not reported
Country: Europe, Israel, Australia
Centre: 32 centres in 13 countries (Europe: 29, Israel: 2, Australia: 1)
Location of care: Outpatient care
Participants: 13,219 anticoagulation patients randomized at each centre into manual-
dosed or computer-assistant dosed arm (DAWN AC or PARMA 5). 13,052 participants
analyzed (167 participants without INR results): 2631 for the DAWN AC study and
10,421 for the PARMA 5 study
Interventions Clinical problem: Oral anticoagulation (warfarin, nicoumalone (acenocoumarol), phen-
procoumon)
Intervention: Computer-assisted dosage program (DAWN AC (n = 1315 participants))
versusmanual dosage (n = 1316 participants). Recruitment was restricted to new patients
initiated oral anticoagulation. 2 modules: induction and maintenance; the time to the
next test was set by the program using a table of variables
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: System-initiated
Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None
Physiological parameters: Time in target INR range (INR: not included)
Time to achieve therapeutic control: None
Clinical events: Death, number of bleeding events (major + minor) (events per 100
patient-years), number of thrombotic events (events per 100 patient-years) (number of
events (minor bleeding events, major bleeding events, thrombotic events, deaths): not
included)
Healthcare costs: None
Improvement: None
Notes - Time in target INR range = proportion of time for which participants were maintained
within the locally decided target INR ranges
- This report is a subgroup analysis of the previous clinical endpoint report from the
European Action on Anticoagulation (EAA) (Poller 2008b), which gave the combined
results using 2 currently marked computer-assisted dosage programs (DAWN AC and
PARMA 5 ) (Poller 2009 DAWN AC, Poller 2008 PARMA 5)
- There were some incoherences between the number of events adjudicated in Poller
2008b (table 2) and the sum of number of events in Poller 2008 PARMA 5 (table II)
and in Poller 2009 DAWN AC (table 2). The author confirmed the numbers in Poller
2008b and Poller 2008 PARMA 5 and corrected those in Poller 2009 DAWN AC
132Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Poller 2009 DAWN AC (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar Low risk No apparent differences on baseline char-
acteristics of the 2631 participants (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12/1328 in manual-dosed group and 24/
1339 in computer-assisted dosage group
were excluded because no INR results were
reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomeswere objective. Events were
adjudicated by a committee
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Poller 2009 erratum
Methods
Participants
Interventions
Outcomes
Notes - Erratum from original article Poller 2009 DAWN AC
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Rodman 1984
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not done
Participants Profession: Not reported
Level of training: Not reported
Clinical specialty: Not reported
Country: USA
Centre: 1 medical centre (University of Southern California Medical Center)
Location of care: Inpatient care
Participants: 20 participants admitted to medical ICU or coronary care unit needing
lignocaine therapy
Interventions Clinical problem: Lidocaine therapy
Intervention: Advice on initial therapy using individualized linear 2 compartment phar-
macokinetic model (n = 9) vs. usual care (n = 11)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Not reported
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: mean first hour infusion rate (µg/kg/min)
, mean final infusion rate (µg/kg/min), mean overall infusion rate
Serum concentrations and therapeutic range: serum concentrations (lidocaine)
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: proportion of participants with adverse reactions (monitoring of rhythm,
intermittent hard-copy rhythm strips, serial electrocardiographs, daily measurements of
electrolyte and cardiac enzyme levels, liver function tests)
Healthcare costs: None
Improvement: None
Notes Objective: “To achieve and maintain plasma concentrations in the approximate middle
of the usual therapeutic range of 1.5 to 5.0 µg/mL”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Low risk Sealed envelope
Baseline outcome measurements similar Low risk Not appropriate
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Rodman 1984 (Continued)
Baseline characteristics similar High risk There were 6/9 men in the computer-as-
sisted therapy group and 11//11 in the con-
ventional lidocaine therapy group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Unclear risk Outcomes were not defined in themethods
section
Other bias Unclear risk Only 20 participants were included
Rousseau 2010
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Done
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Nephrology
Country: France
Centre: 11 centres
Location of care: Inpatient care
Participants: 137 renal allograft recipients receiving basiliximab, CsA, MMF and corti-
costeroids. 130 participants analyzed
Interventions Clinical problem: MMF dosing in renal transplant patients
Intervention: Concentration-controlled (CC) regimen (n = 65 participants) vs. fixed-
dose (FD) MMF (n = 65 participants). In the CC group, MMF dose adjustments were
calculated by a computer program to reach an MPA AUC target of 40 mg.h/L and were
proposed to the physician. In the FD group, MMF dose adjustments were based on
clinical experience
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
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Rousseau 2010 (Continued)
Outcomes Dose of drug administered to the participant: See Le Meur 2007
Serum concentrations and therapeutic range: See Le Meur 2007
Physiological parameters: See Le Meur 2007
Time to achieve therapeutic control: See Le Meur 2007
Clinical events: See Le Meur 2007
Healthcare costs: Cost per participant during the first year of transplantation based
on diagnosis-related groups reimbursements (EUR, base 2007) (hospital stays, drugs,
biological tests and medical transportation)
Improvement: See Le Meur 2007
Notes This is a cost-effectiveness analysis conducted as a part of the APOMYGRE randomized
multicentre study of concentration-controlled dosing regimen of MMF vs. fixed-dose
reported by Le Meur et al. (see Le Meur 2007)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Within the first 3 days posttransplant, pa-
tients were randomized by an interactive
voice response system administered by a
private company; randomization was bal-
ancedwithin centers in blocks of 4 patients,
and patients were enrolled and assigned to
one of the two groups by physicians at each
center”
Allocation concealment (selection bias) Low risk “Within the first 3 days posttransplant, pa-
tients were randomized by an interactive
voice response system administered by a
private company; randomization was bal-
ancedwithin centers in blocks of 4 patients,
and patients were enrolled and assigned to
one of the two groups by physicians at each
center”
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar High risk “The sex ratio differed between groups in
that there were a larger percentage of males
in the CC-treated group (table 1)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “There were seven withdrawals (CC, n =
5; FD, n = 2) due to death, primary non
functioning graft or because MMFwas not
administered.” In most of tables, only per-
centages were reported and according to
the first decimal of percentages, there were
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Rousseau 2010 (Continued)
missing data in the denominator. However,
missing valueswere unlikely to overturn the
study results
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Acute rejection was diagnosed by renal
biopsy except in patients with contraindi-
cations and were graded according to the
Banff classification, in which case diagnosis
was based on clinical and laboratory crite-
ria (in particular, any unexplained increase
in serum creatinine).” No committee re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Saager 2008
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Done
Participants Profession: Mixed (trained healthcare professionals)
Level of training: Not reported
Clinical specialty: Not reported
Country: USA
Centre: 1 large academic medical centre
Location of care: Inpatient care
Participants: 40 participants with diabetes mellitus scheduled for cardiac surgery (car-
diothoracic ICU)
Interventions Clinical problem: Insulin in people with diabetes undergoing cardiac surgery
Intervention: Computer-guided glucose management system (n = 20 participants) vs.
standard paper-based insulin protocol (n = 20 participants). The computer system (En-
doTool Glucose Management System (MD Scienti c)) used the previous 4 dose re-
sponses to recommend the insulin dose, glucose determination frequency, and a 50%
dextrose dose (when appropriate) for hypoglycaemia
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: System-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
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Saager 2008 (Continued)
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None
Physiological parameters: Mean blood glucose (mg/dL) in ICU (available in operating
room: not included, time in blood glucose range in operating room: reported, time in
blood glucose range in ICU: reported)
Time to achieve therapeutic control: None
Clinical events: Proportion of participants with side effects (hypoglycaemia: < 60 mg/
dL at any time) in ICU (available in operating room: not included)
Healthcare costs: None
Improvement: None
Notes “The standard paper-based ICU insulin protocol was developed at this institution with
the goal of targeting blood sugar concentrations between 90 and 150 mg/dL”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Baseline outcome measurements similar Low risk No significant differences on baseline char-
acteristics (table 1)
Baseline characteristics similar Low risk No significant differences on blood glucose
(table 1)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
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Sato 2011
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant, blood glucose measurements
Power calculation: Done
Participants Profession: Anaesthesiologists
Level of training: Not reported
Clinical specialty: Other (anaesthesiology/cardiology)
Country: Canada (Montreal)
Centre: 1 university hospital (Royal Victoria Hospital, McGill University HealthCentre)
Location of care: Inpatient care
Participants: 42 participants without diabetes undergoing elective cardiac surgery were
randomized. 36 participants were analyzed. All studies were conducted by 6 anaesthesiol-
ogists, each anaesthesiologist was assigned to 3 manual and 3 GINCS studies in random
order
Interventions Clinical problem: Glucose and insulin administration in cardiac surgical patients
Intervention: GIN Computer Software (GINCS) (n = 18) versus manual control group
(n = 18). The computer program uses an algorithm based on the original clamp equation
(DeFronzo et al.) andmodified for its use during cardiac surgery requiring extracorporeal
circulation. It takes account of the characteristic of glucose dynamics during cardiac
surgery andCPB, including plasma glucose fluctuation, alterations in glucose utilization,
transfusion of blood products, and rewarming of the patients
Computer advice: Given in real time
CDSS integration in CPOE: Not reported
Starter: Not reported
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: mean amount of insulin infused (IU)
(mean amount of glucose administered (g): reported)
Serum concentrations and therapeutic range: None
Physiological parameters: Mean blood glucose (mmol/L), % of participants with all
measurements within the target range for blood glucose (4-6 mmol/L) (% of time within
the target range for blood glucose (4-6 mmol/L) (unit of analysis error): reported, %
of time below the target range for blood glucose (4-6 mmol/L) (unit of analysis error):
not included, % of time above the target range for blood glucose (4-6 mmol/L) (unit of
analysis error): not included, time (min) within the target range for blood glucose (4-6
mmol/L): not included, time (min) below the target range for blood glucose (4-6 mmol/
L): not included, time (min) above the target range for blood glucose (4-6 mmol/L): not
included)
Time to achieve therapeutic control: Mean sampling interval (min)
Clinical events: Proportion of participants with hypoglycaemic episodes (blood glucose
level < 2.9 mmol/L)
Healthcare costs: None
Improvement: None
Notes “Target glycemia was defined as BG [blood glucose] between 4.0 to 6.0 mmol/L. Hyper-
glycemia was defined as BG 7.0 mmol/L. Hypoglycemia was defined as a BG 2.9 mmol/
L. Time within, above and below target range was calculated by assuming the linearity
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of BG level over time”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Consenting patients were allocated ac-
cording to a computer-generated random-
ization schedule into the computer-assisted
ormanual group (Planprocedure, SAS soft-
ware, SAS Institute, Cary, NC)”
Allocation concealment (selection bias) Low risk “Consenting patients were allocated ac-
cording to a computer-generated random-
ization schedule into the computer-assisted
ormanual group (Planprocedure, SAS soft-
ware, SAS Institute, Cary, NC)”
Baseline outcome measurements similar Low risk No significant differences on preoperative
blood glucose (table 1)
Baseline characteristics similar Low risk No significant differences on participants
demographic (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The blood glucose was measured in short
intervals as requested by each algorithm be-
fore, during and after cardiopulmonary by-
pass (over maximum 320 min)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Main outcomes were objective. Hypogly-
caemic episodes were clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
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Terrell 2010
Methods Design: RCT
Unit of allocation: Provider
Unit of analysis:Medication, participant visit (cluster was taken into account in statistical
analysis)
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Mixed
Clinical specialty: Emergency
Country: USA
Centre: 1 urban public hospital
Location of care: Inpatient care
Participants: 42 emergency medicine faculty and resident physicians randomized (intern
physicians excluded). Subjects were adults with renal insufficiency who were being dis-
charged home from the emergency department. 6015 participant visits with prescription
initially written for a targeted medication. Among the 2783 visits in which creatinine
level was estimated, 113 (4%) participant visits (corresponded to 119 prescriptions) re-
sulted in prescription of at least 1 medication that required dosage adjustment (3232
participant visits excluded because of insufficient information in the electronic medical
record to estimate the creatinine clearance)
Interventions Clinical problem: 10 high-use medications that require adjustments for renal impair-
ment (amoxicillin, amoxicillin/clavulanate, cephalexin, ciprofloxacin, colchicine, hy-
drochlorothiazide, levofloxacin, lisinopril, ranitinide, trimethoprim/sulfamethoxazole)
Intervention: Computerized decision support (21 physicians) vs. control group (21
physicians). Decision support was provided when an intervention physician prescribed
a targeted medication to a person whose creatinine level was below the threshold for
dosage adjustment for that particular medication. The physician could either accept or
reject the decision support’s recommendation.
Computer advice: Given in real time
CDSS integration in CPOE: Yes
Starter: System-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None (% excessively dosed prescriptions:
reported, % visits with excessively dosed prescriptions: not included)
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: None
Improvement: None
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “A biostatistician randomly assigned physi-
cians in blocks of 2, stratified by stage of
training (i.e., faculty status and by year of
residency training) into the intervention or
control group”
Allocation concealment (selection bias) Low risk “A biostatistician randomly assigned physi-
cians in blocks of 2, stratified by stage of
training (i.e., faculty status and by year of
residency training) into the intervention or
control group”
Baseline outcome measurements similar Low risk Not stated
Baseline characteristics similar Low risk “There were no important differences in
the characteristics of intervention and con-
trol physicians or the 2 groups of patients
who received their care” (table 1)
Incomplete outcome data (attrition bias)
All outcomes
High risk 46% of participant visits excluded because
of insufficient data to estimate creatinine
clearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Physicians were randomized but the study
was carried out in a single site and included
a small sample of residents and academic
emergency physicians
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Unclear risk 46% participant visits were excluded, only
prescription that required dosage adjust-
ment were analyzed and there was no ad-
justment for within-patient correlation
“Providers in the intervention group ini-
tially prescribed targetedmedications more
often than control physicians did and con-
sequently had substantially more opportu-
nities to adjust dosing”
142Computerized advice on drug dosage to improve prescribing practice (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Theil 1993 fentanyl
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: Other (anaesthesia)
Country: USA (Durham, North Carolina)
Centre: 1 University Medical Center (Duke University Medical Center)
Location of care: Inpatient care
Participants: 24 participants undergoing cardiac surgery with continuous infusion of IV
anaesthetics
Interventions Clinical problem: Fentanyl
Intervention: Computer-controlled pump using pharmacokinetic model to achieve tar-
get serum level (n = 12) vs. infusion controlled by doctor (n = 12)
Computer advice: Given in real time
CDSS integration in CPOE: Yes
Starter: System-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: None (fentanyl loading dose (µg/kg):
reported, fentanyl maintenance infusion dose during cardiopulmonary bypass (µg/kg):
reported, fentanyl total dose (µg/kg): reported,mean number of infusion changes during
cardiopulmonary bypass (potential unit of error analysis): reported)
Serum concentrations and therapeutic range:None (mean plasma fentanyl concentration
during cardiopulmonary bypass (ng/mL): reported)
Physiological parameters: None (haemodynamic values: not included)
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: None
Improvement: None
Notes “The primary objective for all patients was to maintain heart rate (HR) and mean arterial
pressure (MAP) within 20% of baseline values. If possible, hemodynamic control was
achieved by altering only the anesthetic infusions. Hypertension (MAP>20% baseline)
and tachycardia (HR>20%) were initially treated by incremental increases in fentanyl
or midazolam.[...] Hypotension (MAP>20%) prior to and during cardiopulmonary by-
pass (CPB) was treated by intravenous volume expansion, and a decrease in anesthetic
delivery”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
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Allocation concealment (selection bias) Unclear risk No details
Baseline outcome measurements similar Low risk Not applicable (people undergoing cardiac
surgery)
Baseline characteristics similar Low risk No significant differences on participants
demographic (table 3)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were reported for all participants in-
cluded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were randomized but blinded
(“Both systems were attached to each pa-
tient by an independent operator”)
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Theil 1993 midazolam
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Physicians
Level of training: Not reported
Clinical specialty: Other (anaesthesia)
Country: USA (Durham, North Carolina)
Centre: 1 University Medical Center (Duke University Medical Center)
Location of care: Inpatient care
Participants: 24 participants undergoing cardiac surgery with continuous infusion of IV
anaesthetics
Interventions Clinical problem: Midazolam
Intervention: Computer-controlled pump using pharmacokinetic model to achieve tar-
get serum level (n = 12) vs. infusion controlled by doctor (n = 12)
Computer advice: Given in real time
CDSS integration in CPOE: Yes
Starter: System-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Not reported
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Outcomes Dose of drug administered to the participant: None (midazolam loading dose (µg/kg)
: reported, midazolam maintenance infusion dose during cardiopulmonary bypass (µg/
kg): reported,midazolam total dose (µg/kg): reported, mean number of infusion changes
during cardiopulmonary bypass (potential unit of error analysis): reported)
Serum concentrations and therapeutic range: None (mean plasma midazolam concen-
tration during cardiopulmonary bypass (ng/mL): reported)
Physiological parameters: None (haemodynamic values: not included)
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: None
Improvement: None
Notes “The primary objective for all patients was to maintain heart rate (HR) and mean arterial
pressure (MAP) within 20% of baseline values. If possible, hemodynamic control was
achieved by altering only the anesthetic infusions. Hypertension (MAP>20% baseline)
and tachycardia (HR>20%) were initially treated by incremental increases in fentanyl
or midazolam.[...] Hypotension (MAP>20%) prior to and during cardiopulmonary by-
pass (CPB) was treated by intravenous volume expansion, and a decrease in anesthetic
delivery”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Baseline outcome measurements similar Low risk Not applicable (people undergoing cardiac
surgery)
Baseline characteristics similar Low risk No significant differences on participants
demographic (table 3)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were reported for all participants in-
cluded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were randomized but blinded
(“both systems were attached to each pa-
tient by an independent operator”)
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
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Other bias Low risk No evidence of other risk of biases
Vadher 1997
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Mixed (physicians + nurses)
Level of training: In training
Clinical specialty: Not reported
Country: UK (London)
Centre: 1 district general hospital (Whittington Hospital)
Location of care: Mixed
Participants: 148 inpatients requiring start of warfarin therapy
Interventions Clinical problem: Warfarin therapy initiation
Intervention: CDSS group (n = 72 ) vs. control group (n = 76)
Computer advice: Not reported
CDSS integration in CPOE: No
Starter: Not reported
Type of intervention: Not reported
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None
Physiological parameters: None (time spent in days per 100 patient-days of treatment:
reported)
Time to achieve therapeutic control: Median time to reach therapeutic prothrombin
ratio (days), median to reach stable dose (days)
Clinical events: Thromboembolism, haemorrhage, death
Healthcare costs: None
Improvement: None
Notes “We developed an initiation regimen aiming for a therapeutic range of international
normalised ratio of 2 to 3”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “We used simple randomization with a ta-
ble of random numbers to assign the pa-
tients to management by doctors aided by
the decision support system (intervention
group) or to management by doctors alone
(control group)”
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Allocation concealment (selection bias) Unclear risk “We used simple randomization with a ta-
ble of random numbers to assign the pa-
tients to management by doctors aided by
the decision support system (intervention
group) or to management by doctors alone
(control group).” No further information
provided
Baseline outcome measurements similar Low risk Not appropriate (warfarin therapy initia-
tion)
Baseline characteristics similar Low risk No apparent differences on baseline char-
acteristics (table 1)
Incomplete outcome data (attrition bias)
All outcomes
High risk 64/76 participants in the control group
were followed up as outpatients and 53/72
in the intervention group. There was no
description of missing data
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Vadher 1997 pop1
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant, participant time
Power calculation: Not reported
Participants Profession: Mixed (physicians + nurses)
Level of training: Mixed
Clinical specialty: Other (cardiology)
Country: UK (London)
Centre: 1 district general hospital (Whittington Hospital)
Location of care: Outpatient care
Participants: Participants who had been initiated on warfarin therapy as inpatients and
followed in the outpatient clinic. Most of these participants required anticoagulation for
deep vein thrombosis, pulmonary embolus or atrial fibrillation
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Interventions Clinical problem: Warfarin long-term therapy (therapeutic range 2-3)
Intervention: CDSS group (n = 37) vs. control group (n = 44)
Computer advice: Given in real time
CDSS integration in CPOE: Not reported
Starter: User-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Maintenance dose (mg/day)
Serum concentrations and therapeutic range: None
Physiological parameters: None (time spent in days per 100 patient-days of treatment:
reported)
Time to achieve therapeutic control: None
Clinical events: Thromboembolism, haemorrhage
Healthcare costs: None
Improvement: None
Notes The therapeutic range of INR was 2-3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Simple randomization using random
number tables was used”
Allocation concealment (selection bias) Unclear risk “Simple randomization using random
number tables was used.” No further infor-
mation provided
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar Low risk No apparent differences on baseline char-
acteristics (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
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Other bias High risk - The nurse-practitioners used the com-
puter-decision support system and were
compared to the clinician group of 3 ju-
nior doctors undergoing general profes-
sional training in general medicine
- The was a risk of contamination due to lo-
gistical problems (“it was difficult to shield
the clinicians from theCDSS suggestions”)
Vadher 1997 pop2
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant, participant time
Power calculation: Not reported
Concealment of allocation: Not reported
Participants Profession: Mixed (physicians + nurses)
Level of training: Mixed
Clinical specialty: Other (cardiology)
Location of care: Outpatient care
Country: UK (London)
Centre: 1 district general hospital (Whittington Hospital)
Participants: Participants who had been on warfarin for more than 1 year. Most of
the participants required anticoagulation for heart valve disease, valve replacement or
recurrent thromboembolism
Interventions Clinical problem: Warfarin long term (therapeutic range 3-4.5)
Intervention: CDSS group (n = 50) vs. control group (n = 46)
Computer advice: Given in real time
CDSS integration in CPOE: Not reported
Starter: User-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Maintenance dose (mg/day)
Serum concentrations and therapeutic range: None
Physiological parameters: None (time spent in days per 100 patient-days of treatment:
reported)
Time to achieve therapeutic control: None
Clinical events: Thromboembolism, haemorrhage
Healthcare costs: None
Improvement: None
Notes The therapeutic range of INR was 3-4.5
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Simple randomization using random
number tables was used”
Allocation concealment (selection bias) Unclear risk “Simple randomization using random
number tables was used.” No further infor-
mation provided
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar Low risk No apparent differences on baseline char-
acteristics (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias High risk - The nurse-practitioners used the com-
puter-decision support system and were
compared to the clinician group of 3 ju-
nior doctors undergoing general profes-
sional training in general medicine
- The was a risk of contamination due to lo-
gistical problems (“it was difficult to shield
the clinicians from theCDSS suggestions”)
Verner 1992
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not done
Participants Profession: Physicians
Level of training: Accredited/licensed
Clinical specialty: Internal medicine
Country: Israel (Tel Hashomer)
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Centre: A 1400 bed regional teaching hospital (Sheba Medical Center)
Location of care: Inpatient care
Participants: 25 participants needing aminophylline therapy for acute asthma
Interventions Clinical problem: Theophylline
Intervention: Computer suggested dose based on individualized pharmacokinetic model
to doctor (n = 10) vs. usual care (n = 15)
Computer advice: Not reported
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Not reported
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: Loading dose of theophylline (mg)
Serum concentrations and therapeutic range: Serum theophylline concentration 20min-
utes after completion of loading dose infusion (µg/mL) (% of time spent in therapeutic
range (serum theophylline concentrations in 10-20 µg/mL): reported)
Physiological parameters: None
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: Mean hospitalization time (days)
Improvement: None
Notes “The computer program was used to estimate the predicted admission serum theo-
phylline concentration, and the partial loading dose needed to achieve the target con-
centration which was set at 16 g/ml”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Randomization was based on the final
digit in the patient’s identification card
number (odds versus even)”
Allocation concealment (selection bias) High risk Odd versus even identification card num-
ber
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar High risk There were significant differences between
the groups (age, asthma/chronic obstruc-
tive lung disease and associated medical
conditions)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were reported for all participants in-
cluded
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
Wexler 2010
Methods Design: RCT
Unit of allocation: Provider (physicians team)
Unit of analysis: Participant (cluster was not taken into account in statistical analysis)
Power calculation: Done
Participants Profession: Physicians
Level of training: In training
Clinical specialty: Internal medicine
Country: USA (Boston)
Centre: 1 tertiary care medical centre (Massachusetts General Hospital Diabetes Center)
Location of care: Inpatient care
Participants: 144 insulin-treated people with type 2 diabetes enrolled. 128 participants
analyzed
Interventions Clinical problem: Insulin in general medical inpatients with type 2 diabetes
Intervention: Electronic basal-bolus insulin order template (n = 65 participants) vs.
usual insulin ordering (n = 63 participants). The total daily dose of insulin required
for the participant (basal (long-acting) and prandial (short-acting)) was calculated by
multiplying the weight of the participant by 0.5 units/kg. A button to use insulin-dose
calculator was available
Computer advice: Given in real time
CDSS integration in CPOE: Yes
Starter: System-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: Basal insulin dose (units)
Serum concentrations and therapeutic range: None
Physiological parameters: Mean blood glucose (mg/dL)
Time to achieve therapeutic control: None
Clinical events: Proportion of participants with hypoglycaemia (< 60 mg/dL at any time)
(severe hypoglycaemia (<40mg/dL at any time): not included, prolongedhyperglycaemia
(3 consecutive glucose values > 240 mg/dL): not included)
Healthcare costs: Length of stay (days)
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Improvement: None
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Using a computerized coin toss, we ran-
domly assigned seven teams of providers
(42 internalmedicine residents) working in
general medical acute care units to have the
option to use the order template (interven-
tion group) or to use usual insulin ordering
(control group)”
Allocation concealment (selection bias) Low risk “Using a computerized coin toss, we ran-
domly assigned seven teams of providers
(42 internalmedicine residents) working in
general medical acute care units to have the
option to use the order template (interven-
tion group) or to use usual insulin ordering
(control group)”
Baseline outcome measurements similar Unclear risk It is unclear if the mean blood glucose val-
ues given at the beginning of the results
were baseline data or results with all ran-
domized participants (186 ± 56 mg/dL in
intervention participants versus 206 ± 61
mg/dL in control participants (P value = 0.
004))
Baseline characteristics similar Low risk There was no significant differences on par-
ticipants demographic or primary diagno-
sis (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 144 insulin-treated people with type 2 dia-
betes were admitted, 16 participants whose
point-of-care glucose values were between
60 and 180mg/dL were excluded (non-tar-
get population)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Teamof providers were randomized but the
study was carried out in a single site
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Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
White 1987
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not done
Participants Profession: Mixed (physicians + pharmacists)
Level of training: Accredited/licensed
Clinical specialty: Other (anticoagulant clinic)
Country: USA (California)
Centre: 2 university hospitals (Veterans Administration Medical Center, Davis Medical
Center)
Location of care: Inpatient care
Participants: 75 participants requiring anticoagulation with warfarin
Interventions Clinical problem: Warfarin initiation
Intervention: Initial dose suggested by Bayesian computer pharmacokinetic and phar-
macodynamic model (n = 39) vs. usual care (n = 36)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Not reported
Calculated dose given as a recommendation: Yes
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None (participant with supratherapeutic
prothrombin ratio (PR) at any time: not included)
Physiological parameters: Days on warfarin PR therapeutic
Time to achieve therapeutic control: Time to reach a therapeutic PR, time to reach a
therapeutic dose
Clinical events: Proportion of participants with a bleeding complication, death
Healthcare costs: Length of stay
Improvement: None
Notes The therapeutic range was defined as PR = 1.8 ± 0.4, or, using a generalized formula,
PR±(0.22)*(PR)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Random sequence generation not specified
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk Not applicable
Baseline characteristics similar Low risk There was no significant differences on de-
mographic and clinical characteristics of
participants (table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were 4/36 participants in the physi-
cian-dosed group and 3/39 in the com-
puter-dosed group which data could not be
analyzed. Incomplete data were unlikely to
overturn the study results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Low risk All relevant outcomes were reported in the
results section
Other bias Low risk No evidence of other risk of biases
White 1991
Methods Design: RCT
Unit of allocation: Participant
Unit of analysis: Participant
Power calculation: Not reported
Participants Profession: Nurses
Level of training: Mixed
Clinical specialty: Not reported
Country: USA (California)
Centre: 1 university hospital (Davis Medical Center)
Location of care: Outpatient care
Participants: 50 participants needing anticoagulation with warfarin (long-term oral ther-
apy)
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Interventions Clinical problem: Long-term warfarin adjustment
Intervention: Maintenance dose suggested by Bayesian computer pharmacokinetic
model (n = 24) vs. usual care (n = 26)
Computer advice: Given in real time
CDSS integration in CPOE: No
Starter: User-initiated
Type of intervention: Direct intervention
Calculated dose given as a recommendation: Not reported
Outcomes Dose of drug administered to the participant: None
Serum concentrations and therapeutic range: None
Physiological parameters: None (proportion of participants within target (final pro-
thrombin time): reported)
Time to achieve therapeutic control: None
Clinical events: None
Healthcare costs: None
Improvement: None
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation not specified
Allocation concealment (selection bias) Unclear risk No information provided
Baseline outcome measurements similar Low risk “There were no significant differences be-
tween the groups with respect to age, gen-
der, target prothrombin times, percentage
of patients initially below the target, per-
centage of patients initially above the tar-
get, or the mean of the absolute value of
the differences between initial prothrom-
bin times and the corresponding target pro-
thrombin times (Table 1)”
Baseline characteristics similar Low risk “There were no significant differences be-
tween the groups with respect to age, gen-
der, target prothrombin times, percentage
of patients initially below the target, per-
centage of patients initially above the tar-
get, or the mean of the absolute value of
the differences between initial prothrom-
bin times and the corresponding target pro-
thrombin times (Table 1)”
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White 1991 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/26 participants in the nurse-specialist
group and 1/24 participant in the com-
puter group did not return for follow-up.
Incomplete data were unlikely to overturn
the study results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were objective
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were randomized
Selective reporting (reporting bias) Unclear risk Outcomes were not described in the meth-
ods section
Other bias Low risk No evidence of other risk of biases
CDSS: clinical decision support system; CGMS: continuous glucose monitoring system; CPOE: computer physician order entry; CsA:
cyclosporine A; eMPC: Enhanced software Model Predictive Control; GP: general practitioner; ICU: intensive care unit; INR:
international normalized ratio; IU: international unit; IV: intravenous; KADIS: KArlsburg Diabetes Management System; MMF:
mycophenolate mofetil; MPA: mycophenolic acid (MPA); NRCT: non-randomized controlled trial; RCT: randomized controlled
trial.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbrecht 1982 - Not computerized drug dosage (computer controlled pump not under physician control)
Absalom 2003 - Not computerized drug dosage (automatic control of the propofol infusion using closed-loop system)
Albisser 2007 - Not computerized drug dosage (prediction of future glycaemia and future risks of hypoglycaemia and
hyperglycaemia)
Alvis 1985 - Design
Barletta 2009 - Design (before and after study without control group)
Barras 2008 -Not computerized drugdosage (trial comparing individualized dosing of enoxaparin based on participa
nt weight and renal function to conventional dosing)
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(Continued)
Barras 2010 -Not computerized drug dosage (dose calculated from an equation including the weight of the participa
nt)
Bartal 2003 - Not computerized drug dosage (utility of pharmacokinetic monitoring of aminoglycoside levels in
the context of once-daily treatment (primary endpoint: renal toxicity))
Berg 2009 - Not computerized drug dosage (individually tailored treatment duration)
Burger 2003 - Not computerized drug dosage (t able with therapeutic drug monitoring rules depending on the
concentration ratio method (standardized pharmacokinetic curve))
Bury 2005 - Not computerized drug dosage
Caraballo 2008 - Not computerized drug dosage (alerts)
Carter 1987a - Not computerized drug dosage
Cavalcanti 2009 - Design ( the target range for blood glucose was different according to the interventions or the
conventional treatment)
Chan 2006 - Design (before and after study without control group)
Chiarelli 1990 - Participa nt aid not under physician control
Cohen 2007 -Not computerized drugdosage (trial comparing growth hormone dosingusing a prespecified algorithm
to conventional growth hormone dose)
Collins 2004 - Not computerized drug dosage (alerts)
Cupissol 1996 - Not computerized drug dosage (control of the cisplatin infusion using automatic pump)
Demakis 2000 - Not computerized drug dosage (reminder to standard of care)
Dillon 1989 - Design (some participa nts in the standardized dosing arm crossed-over to pharmacokinetic dosing
arm)
Donovan 2010 - Not computerized drug dosage (alerts)
Doran 2004 - Design (cohort with 4 participa nts)
Dortch 2008 - Design (retrospective study)
Evans 1998 - Design (before and after study without control group)
Evans 1998a - Not computerized drug dosage (no recommendation to the healthcare professional: chemotherapy
protocol)
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(Continued)
Evans 1999 - Design (before and after study without control group)
Faber 2006 - Not computerized drug dosage (individualize d dosing concerned the day of administration)
Feldstein 2006 - Not computerized drug dosage (alert for prescribing laboratory monitoring test)
Fety 1998 - Not computerized drug dosage (no recommendation to the healthcare professional: chemotherapy
protocol)
Field 2009 - The dose advice was not individualized (maximal suggested dose)
Field 2009a - The dose advice was not individualized (maximal suggested dose)
Fihn 1994 - Absence of relevant data for primary outcome
Fitzmaurice 1996 - Absence of relevant data for primary outcome
Fitzmaurice 1998 - Design
Flanders 2009 - Design (before and after study without control group)
Fritsch 2009 - Not computerized drug dosage (target-controlled inhalation induction)
Fukudo 2009 - Design (control group without random or quasi-random allocation)
Gamelin 2008 - Not computerized drug dosage (table with dose-adjustment algorithm according to plasma concen-
tration)
Ghazal-Aswad 1997 - Conference publication (contact author failed due to erroneous email)
Gopakumaran 2004 - Discussion
Griffey 2012 - The dose advice was not individualized (most commonly used dose)
Guarracino 2001 - Not computerized drug dosage (evaluation of automated protamine dose assay)
Guarracino 2003 - Design (n ot a comparative study)
Hermayer 2007 - Design (before and after study without control group)
Hobbs 1996 - Absence of relevant data for primary outcome
Hoffman 2004 - Not computerized drug dosage (dose adjustment based on the occurrence of adverse events)
Horn 2002 - Design
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(Continued)
Hwang 2004 - Design
Jankovic 1999 - The 15 participa nts from the Jankovic study were included in theMihajlovic study (60 participa nts)
Jannuzzi 2000 - Not computerized drug dosage (dosage based on serum drug level monitoring)
Jellinek 2005 - Not computerized drug dosage (decision support algorithm)
Judge 2006 - Not computerized drug dosage (alerts)
Jung 2009 - Not computerized drug dosage (no individualized dose recomme nded to the healthcare professional:
protocol for adjustment of growth hormone dosage)
Kazemi 2011 - Design (before and after study without control group)
Kirk 2005 - Design (cohort study)
Koide 2000 - Design (before after study)
Kristrom 2009 - The dose advice was not individualized (dose selection within an interval using a predicted response)
Kroese 2005 - Design (n ot a comparative study)
la Cour Freiesleben 2009 - Not computerized drug dosage (paper nomogram)
Lester 2006 - Not computerized drug dosage (email with low-density lipopr o tein therapeutic goal)
Ligtenberg 2006 - Not a study but a comment on Plank 2006
Lillis 2003 - Design (case history)
Liu 2006 - Not computerized drug dosage (closed-loop system)
Manotti 2001 maintenance - Absence of relevant data for primary outcome
Mar Fernandez 1996 - Not computerized drug dosage (no recommendation to the healthcare professional: pharmacokinetic
model used for drug monitoring)
Mar Fernandez 2009 - Not computerized drug dosage (predictive performance of population models)
Matheny 2008 - Not computerized drug dosage (reminders for annual intervals for laboratory monitoring)
Maurizi 2011 - Participa nt aid not under physician control (advice delivered directly to the participa nt: self monitor
glucose)
McCluggage 2010 - Design (historical control group)
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(Continued)
McCowan 2001 - Not computerized drug dosage (software that implements guidelines during consultations)
McCoy 2008 - Not computerized drug dosage (alerts)
McCoy 2010 - Not computerized drug dosage (alerts)
McDonald 1976 - Not computerized drug dosage (reminders)
McDonald 1980 - Not computerized drug dosage (dose prescribing rather than drug dosage)
McMichael 1993 - Absence of relevant data for primary outcome (n o professional behaviour change or participa nt
outcomes)
McMullin 1997 - Design (n ot a comparative study)
McMullin 2004 - Not computerized drug dosage (list of prescriptions most appreciate)
McMullin 2005 - Not computerized drug dosage (list of prescriptions most appreciate)
Motykie 1999 - Design (historical control group)
Mullett 2001 - Design (before and after study without control group)
Murchie 1989 - Absence of relevant data for primary outcome
Nash 2005 - Not computerized drug dosage (thresholds)
Newby 2002 - Not computerized drug dosage (automated adjustment)
Nieuwenhuyze 1995 - Participa nt aid not under physician control
Nightingale 2000 - Not computerized drug dosage (dose prescribing rather than drug dosage)
Oppenheim 2002 - Design ( not a comparative study)
Overhage 1997 - The dose advice was not individualized (’ response orders’ )
Palen 2006 - Not computerized drug dosage (alert for prescribing laboratory monitoring test)
Pea 2002 - Absence of relevant data for primary outcome
Peck 1973 - Absence of relevant data for primary outcome
Peters 1996 - Participa nt aid not under physician control
Peterson 1986 - Participa nt aid not under physician control
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(Continued)
Peterson 2005 - Not computerized drug dosage (screen showing the most commo nly used dose)
Peterson 2007 - Not computerized drug dosage (screen showing a default dose and minimum/maximum dose)
Phillips 2008 - Design (n ot a comparative study)
Piazza 2009 - Not computerized drug dosage (alerts)
Poller 1993 - Absence of relevant data for primary outcome
Popovic-Todorovic 2003 - Not computerized drug dosage (rules without calculation)
Proost 2003 - Discussion (p resentation of the project PharmDIS-e+)
Roberts 2010 - Design (before and after study without control group)
Rochon 2006 - Discussion
Rood 2005 - Absence of relevant data for primary outcome
Rothschild 2002 - Absence of relevant data for primary outcome (survey)
Rothschild 2003 - Not computerized drug dosage (feedback)
Rothschild 2005 - Not computerized drug dosage (smart infusion pumps providing decision support feedback)
Rotman 1996 - Not computerized drug dosage
Roumie 2005 - Not computerized drug dosage (alert with guidelines or goal blood pressure)
Ruiz 1993 - Not computerized drug dosage (closed-loop system)
Ryff-de Leche 1992 - Not computerized drug dosage (infusion not under physician control)
Santana 2003 - Not computerized drug dosage (treatment plan in 2 cohorts)
Santana 2005 - Design (n ot a comparative study)
Schneider 2005 - Not computerized drug dosage (organizational computer program)
Schrezenmeir 2002 - Participa nt aid not under physician control (advice delivered directly to the participa nt)
Shiach 2002 - Not computerized drug dosage (comparison of 2 systems of prothrombin time measurement)
Shieh 2006 - Not computerized drug dosage (comparison of 2 protocols for drug controller)
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(Continued)
Soper 2006 - Design (historical control group)
Sparano 2006 - Not computerized drug dosage (trial comparing 2 therapies)
Strack 1985 - Design
Tamblyn 2003 - Not computer drug dosage
Tamblyn 2008 - Not computerized drug dosage (adherence calculation)
Tamblyn 2010 - Not computerized drug dosage (adherence calculation)
Terrell 2009 - Not computerized drug dosage (recommendation on substitute therapies)
Thomson 2011 - Design (before and after study without control group)
Tierney 2005 - Not computerized drug dosage (reminders)
Tomek 2011 - Conference publication (the author was contacted by January 201 2 but the message could not be
delivered because the recipient ad d ress was rejected ) )
Traugott 2011 - Design (before and after study without control group)
Trivedi 2007 - Design (discussion)
Trivedi 2007a - Not computerized drug dosage (decision support tool without calculation)
van der Bol 2010 - Not computerized drug dosage (dose calculated from an equation)
van Leeuwen 2005 - Abstract corresponding to the study published in 2007 (excluded study: van Leeuwen 2007)
van Leeuwen 2007 - Design (n o control group: comparison of 2 computer algorithms)
van Lent-Evers 1999 - Design (historical control group)
Van Wyk 2008 - Not computerized drug dosage (screening and treatment of dyslipidaemia)
Verstappen 2007 - Not computerized drug dosage (CAMERA study: comparison of 2 strategies of management in early
rheumatoid arthritis)
Verstappen 2010 - Not computerized drug dosage (CAMERA study: comparison of 2 strategies of management in early
rheumatoid arthritis)
Wasmuth 2007 - Design (cohort study)
Wasmuth 2007a - Not computerized drug dosage (trial comparing 2 doses of treatment)
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(Continued)
Whipple 1991 - Not computerized drug dosage (the clinical pharmacist calculated the dose and interval of aminogly-
coside concentration)
White 1984 - Absence of relevant data for primary outcome
Willcourt 1994 - Participa nt aid not under physician control
Wilson 2002 - Design (cohort study)
Yamamoto 2005 - Not computerized drug dosage (dose calculated from an equation)
Characteristics of studies awaiting assessment [ordered by study ID]
Anderson 2011
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Anderson 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Caduff 2013
Methods
Participants
Interventions
Outcomes
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Caduff 2013 (Continued)
Notes Not yet assessed
Dumont 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Horibe 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Jeanne 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Joerger 2012
Methods
Participants
Interventions
Outcomes
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Joerger 2012 (Continued)
Notes Not yet assessed
Kelly 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Kim 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Magee 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Nieuwlaat 2011
Methods
Participants
Interventions
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Nieuwlaat 2011 (Continued)
Outcomes
Notes Not yet assessed
Nieuwlaat 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Overgaard 2010
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Pielmeier 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
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Radhakrishnan 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Rasmussen 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Spaniel 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Tamblyn 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
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Whitehead 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
Wiltshire 2012
Methods
Participants
Interventions
Outcomes
Notes Not yet assessed
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D A T A A N D A N A L Y S E S
Comparison 1. Serum concentrations and therapeutic range
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serum concentrations (mg/L) -
part A (SMD > 0 in favour of
the intervention)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Aminoglycoside
antibiotics: peak concentration
4 372 Std. Mean Difference (IV, Random, 95% CI) 0.79 [0.46, 1.13]
1.2 Theophylline 4 201 Std. Mean Difference (IV, Random, 95% CI) 0.41 [-0.20, 1.02]
1.3 Lidocaine 1 20 Std. Mean Difference (IV, Random, 95% CI) 1.32 [0.33, 2.32]
2 Serum concentrations (ng/L) -
part B (SMD < 0 in favour of
the intervention)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Midazolam 1 24 Std. Mean Difference (IV, Random, 95% CI) -1.43 [-2.34, -0.51]
2.2 Fentanyl 1 24 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.53, 1.08]
2.3 Antidepressants: steady-
state plasma concentration
1 60 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-1.20, -0.16]
3 Proportion of participants
within therapeutic range
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Aminoglycoside
antibiotics: % of participants
with peak concentrations
adequate after 2 days
2 72 Risk Ratio (M-H, Random, 95% CI) 4.44 [1.94, 10.13]
3.2 Anti-rejection drugs 1 125 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.38, 1.32]
4 Proportion of participants with
toxic drug levels
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Theophylline 2 109 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.25, 1.13]
Comparison 2. Physiological parameters
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral anticoagulants: % time in
target INR range
6 13581 Mean Difference (IV, Random, 95% CI) 3.68 [0.90, 6.45]
2 Insulin: % time in target glucose
range
4 234 Mean Difference (IV, Random, 95% CI) 22.18 [9.94, 34.43]
3 Insulin: mean blood glucose
(mg/dL)
9 520 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-1.03, -0.42]
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Comparison 3. Time to achieve therapeutic control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to achieve therapeutic
range
5 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Oral anticoagulants:
time to achieve therapeutic
prothrombin ratio (days)
2 223 Mean Difference (IV, Random, 95% CI) -0.58 [-1.84, 0.69]
1.2 Insulin: time to achieve
therapeutic control (h)
3 134 Mean Difference (IV, Random, 95% CI) 0.53 [-1.22, 2.27]
2 Time to stabilization 3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Oral anticoagulants: time
to stabilization (days)
3 255 Std. Mean Difference (IV, Random, 95% CI) -0.56 [-1.07, -0.04]
Comparison 4. Clinical improvement
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Aminoglycoside antibiotics 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Number of participants
cured
2 271 Risk Ratio (M-H, Random, 95% CI) 1.12 [1.02, 1.22]
2 Anti-rejection drugs 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 No biopsy-confirmed
rejections
2 170 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [1.00, 1.32]
Comparison 5. Clinical adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 10 14046 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.80, 1.45]
1.1 Oral anticoagulants 5 13499 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.78, 1.51]
1.2 Aminoglycoside
antibiotics
3 326 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.14, 3.10]
1.3 Theophylline 1 91 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.01, 3.64]
1.4 Cyclosporine 1 130 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.06, 15.65]
2 Anticoagulants: events 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Bleeding 6 552 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.30, 1.41]
2.2 Thromboembolism 4 355 Risk Ratio (M-H, Random, 95% CI) 3.25 [0.66, 16.03]
3 Anticoagulants: event rates 4 Rate Ratio (Random, 95% CI) Subtotals only
3.1 Bleeding 4 18902 Rate Ratio (Random, 95% CI) 0.81 [0.60, 1.08]
3.2 Thromboembolism 4 18902 Rate Ratio (Random, 95% CI) 0.68 [0.49, 0.94]
4 Insulin 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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4.1 Hypoglycaemia (< 60 mg/
dL)
7 378 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.35, 1.48]
4.2 Severe hypoglycaemia (<
40 mg/dL)
4 292 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.11, 4.31]
5 Aminoglycoside antibiotics 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Nephrotoxicity 4 493 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.42, 1.06]
6 Anti-rejection drugs 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Cytomegalovirus
infections
2 170 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.58, 1.40]
Comparison 6. Healthcare resources
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Length of stay (days) 9 18507 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-0.33, 0.02]
1.1 Oral anticoagulants 2 105 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-1.10, 0.86]
1.2 Insulin 1 128 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.17, 0.53]
1.3 Theophylline 3 151 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.56, 0.16]
1.4 Aminoglycoside
antibiotics
2 295 Std. Mean Difference (IV, Random, 95% CI) -0.35 [-0.58, -0.12]
1.5 Anti-rejection drugs 1 17828 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.07, -0.01]
WH A T ’ S N E W
Last assessed as up-to-date: 12 December 2012.
Date Event Description
6 November 2013 New citation required but conclusions have not
changed
A new search for studies was conducted January 2012.
12 December 2012 New search has been performed Search strategies were significantly revised and
databases searched from 1996 to January 2012
C O N T R I B U T I O N S O F A U T H O R S
PD, IC, LT and FG prepared the protocol. All authors applied the inclusion criteria, assessed the quality and extracted the data for
the included studies. FG and LT conducted the quantitative analyses and qualitative analyses. FG and EC drafted the manuscript with
input from all authors. RW conducted the initial review and provided comments on the revised manuscript.
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D E C L A R A T I O N S O F I N T E R E S T
None.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Drug Therapy, Computer-Assisted; ∗Physician’s Practice Patterns; Medication Errors [prevention & control]; Randomized Controlled
Trials as Topic
MeSH check words
Humans
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